



(51) International Patent Classification:

A01N 37/52 (2006.01) *C07D 265/30* (2006.01)
A01N 43/40 (2006.01) *C07D 211/12* (2006.01)
A01N 43/84 (2006.01) *A01P 3/00* (2006.01)
C07C 257/12 (2006.01)

(21) International Application Number:

PCT/IB2017/056277

(22) International Filing Date:

11 October 2017 (11.10.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

201611035246 14 October 2016 (14.10.2016) IN

(71) Applicant: **PI INDUSTRIES LTD** [IN/IN]; 5th Floor,
Vipul Square, B Block, Sushant Lok, Phase -1, Gurgaon
122009 (IN).

(72) **Inventors:** **NAIK, Maruti N.**; Bunder Road 6th cross,
Hanuman Nagar, Bhatkal, Karnataka 581320 (IN). **MA-
HAJAN, Vishal Ashok**; A-102, Neco Skypark, Vishal
Nagar, Pimple Nilakh, Pune 411008 (IN). **WALUNJ,
Gulab Eknath**; Khanderaywadi, Post Pimpalgaon Depa,
Taluka, Sangamner, District: Ahmednagar, Maharashtra
422605 (IN). **KALE, Manoj Ganpat**; 15/3, New Bhag-
wan Nagar, Jalgaon, Maharashtra 425002 (IN). **JHALA,
Vikram Singh**; Village Losing ka dhana, Post Losing,
Tehsil Badgaon, District Udaipur, Rajasthan 313011 (IN).
MANJUNATHA, Sulur G; E-714, Golden Magic, Brigade
Gardenia, J P Nagar 7th Phase, Bangalore 560078 (IN).
VENKATESHA, Hagalavadi M; #8, 2nd Main Road,
Byraveshwaranagar, Nagarbhavi Road, Bangalore 560072
(IN). **AUTKAR, Santosh Shridhar**; Post: Vyala; Taluka:
Balapur; Dist.: Akola, Maharashtra 444302 (IN). **GARG,
Ruchi**; 38/47 C-1-K, Tulsipur, Mehmoorganj, Varanasi, Ut-
tar Pradesh 221010 (IN). **SAMANTA, Jatim**; c/o Hari Pa-
da Samanta, Village Hintamunipur, Post, Durbachati, Po-
lice station Pathar Pratima, South 24 Parganas, West Ben-
gal 743347 (IN). **KLAUSENER, Alexander G. M.**; Schiff-
gesweg 18, 50259 Pulheim (DE). **POSCHARNY, Kon-
stantin**; Mendelssohnstrasse 25, 40233 Düsseldorf (DE).

(74) **Agent:** **GARG, Vidisha** et al.; Anand and Anand Adv-
ocates, B-41, Nizamuddin East, New Delhi 110013 (IN).

(81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

(54) **Title:** 4-AMINO SUBSTITUTED PHENYLAMIDINE DERIVATIVES AND THEIR USE TO PROTECT CROPS BY
FIGHTING UNDESIRE PHYTOPATHOGENIC MICOORGANISMS



(57) **Abstract:** This invention relates to 4-substituted phenylamine derivatives of the general formula (I), wherein R^1 to R^8 and A have the meanings as defined in description. The invention further relates to methods for their preparation and use of said compounds to fight undesired phytopathogenic microorganisms, and agents for said purpose, comprising said phenylamine derivatives, all according to the invention. This invention further relates to a method for fighting undesired phytopathogenic microorganisms by application of said 4-substituted phenylamine derivatives of general formula (I) to such undesired microorganisms and/or to their habitat, according to the invention.

4-AMINO SUBSTITUTED PHENYLAMIDINE DERIVATIVES AND THEIR USE TO PROTECT CROPS BY FIGHTING UNDESIRE PHOTOPATHOGENIC MICOORGANISMS

FIELD OF THE INVENTION

5

The present invention relates to compounds intended to protect crops by fighting undesired phytopathogenic microorganisms. More precisely, the subject of the present invention relates to 4-substituted phenylamine derivatives used to protect crops by fighting undesired phytopathogenic microorganisms.

10

BACKGROUND OF THE INVENTION

The control of damages to crops caused by phytopathogenic microorganisms is extremely important in achieving high crop efficiency. For instance, plant disease damage to ornamental, vegetable, field, cereal, and fruit crops can cause significant reduction in productivity and thereby result in increased costs to the consumer. Many products are commercially available to control such damages. The need continues for new compounds which are more effective, less costly, less toxic, environmentally safer and/or have different modes of action. Certain phenylamine derivatives are disclosed in literature as microbicidally active ingredients in pesticides. For example, WO2000046184, WO2003093224, WO2003024219, WO2005089547 and WO2005120234 discloses the use of phenylamine derivatives especially phenylamide, either alone or as part of composition, as fungicides. Certain phenyl benzamides compound, method of producing such compounds and their use for controlling undesired microorganisms is disclosed in WO2004005242.

US4173637 discloses phenylurea compounds and compositions containing these compounds as insecticides. JP08291146 discloses N-substitued phenylsulfonamide compounds having excellent herbicidal activity, especially paddy field herbicides. WO2008110314 discloses Fluoroalkyl phenylamides as fungicidal compounds, method of their preparation and a method for protecting seeds from unwanted microorganisms using such compounds. One other PCT publication WO2011095462 discloses phenylamine derivatives including carboxamides, process for preparing them and insecticidal, acaricidal, nematocidal or molluscicidal compositions comprising these derivatives.

The effectiveness of the phenylamine derivatives described in the prior art is good, but leaves something to be desired in various cases. Therefore, it is always of high interest in agriculture to use novel pesticidal compounds in order to avoid and/or control the development of microorganisms such

as fungal or bacterial pathogens or pests being resistant to known active ingredients. It is therefore of high interest to use novel compounds being more active than those already known, with the aim of decreasing the amounts of active compound to be used, whilst at the same time maintaining an effectiveness at least equivalent to the already known compounds.


5

We have now found a new family of compounds which possess the above mentioned effects or advantages. A new family of compounds namely, 4-substituted phenylamine derivatives wherein the phenyl ring is substituted according to the invention thus allowing an unexpected and significantly higher activity against undesired microorganisms such as fungal or bacterial pathogens or pests.

10

SUMMARY OF THE INVENTION

This present invention relates to 4-substituted phenylamine derivatives of the general formula (I)



(I)


15

wherein the definition of the substituents is defined in foregoing detailed description.

DETAILED DESCRIPTION OF THE INVENTION

20

Accordingly, the present invention relates to compounds of general formula (I)



(I)

25 wherein

R¹ is selected from the group consisting of hydrogen, CN, SRⁿ, S(O)_nRⁿ, ORⁿ, C₁₋₁₂-alkyl, C₁₋₁₂-alkoxy, C₁₋₁₂-alkylthio, C₂₋₁₂-alkenyl, C₂₋₁₂-alkynyl, C₁₋₁₂-haloalkyl, C₂₋₁₂-haloalkenyl, C₂₋₁₂-haloalkynyl, C₃₋₈-cycloalkyl, C₄₋₈-cycloalkenyl, C₅₋₈-cycloalkynyl; where in the cyclic ring system one

or more carbon atoms may be replaced by heteroatoms selected from the group consisting of N, O, and S(O)_n;

R² and R³ are independently selected from the group consisting of hydrogen, CN, S(O)_nR'', OR', (C=O)-R'', C₁₋₁₂-alkyl, C₂₋₁₂-alkenyl, C₂₋₁₂-alkynyl, C₁₋₁₂-haloalkyl, C₂₋₁₂-haloalkenyl, C₂₋₁₂-haloalkynyl, C₃₋₈-cycloalkyl, C₄₋₈-cycloalkenyl, C₅₋₈-cycloalkynyl, C₅₋₁₈-aryl, C₇₋₁₉-aralkyl, C₇₋₁₉-alkaryl; where in the cyclic ring system one or more carbon atoms may be replaced by heteroatoms selected from the group consisting of N, O, and S(O)_n;

R¹ and R², R² and R³ or R¹ and R³ together with the atoms to which they are attached or together with further atoms selected from the group consisting of C, N, O, S and optionally including 1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O)_m and SiR'₂ may form a four to seven membered ring, which for its part may be substituted by one or more X, R', OR', SR', NR'₂, SiR'₃, COOR', CN, and CONR'₂; and wherein all of the groups of R¹, R², and R³ may optionally be substituted by one or more groups selected from the group consisting of X, R', OR', SR', NR'₂, SiR'₃, COOR', CN, and CONR'₂;

R⁴, R⁵, R⁶ and R⁷ are independently selected from the group consisting of hydrogen, X, CN, SCN, SF₅, S(O)_nR'', SiR'₃, OR'', NR'R'', (C=O)-R'', CR'=NR'', C₁₋₁₂-alkyl, C₂₋₁₂-alkenyl, C₂₋₁₂-alkynyl, C₁₋₁₂-haloalkyl, C₂₋₁₂-haloalkenyl, C₂₋₁₂-haloalkynyl, C₁₋₁₂-haloalkoxy, C₁₋₁₂-haloalkylthio, C₃₋₈-cycloalkyl, C₄₋₈-cycloalkenyl, C₅₋₈-cycloalkynyl, C₃₋₈-cycloalkyloxy, C₃₋₈-cycloalkylthio, C₅₋₁₈-aryl, C₇₋₁₉-aralkyl, C₇₋₁₉-alkaryl; where in the cyclic ring system one or more carbon atoms may be replaced by heteroatoms selected from the group consisting of N, O, and S(O)_n; and all of the groups mentioned above may optionally be substituted by one or more groups selected from the group consisting of X, R', OR', SR', NR'₂, SiR'₃, COOR', CN, and CONR'₂; or

wherein R⁴ and R⁷ or R⁵ and R⁶ together with the atom to which they are attached or together with further atoms selected from the group consisting of C, N, O, S and optionally including 1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O)_m and SiR'₂ may form a four to seven membered ring, which for its part may be substituted by one or more X, R', OR', SR', NR'₂, SiR'₃, COOR', CN, and CONR'₂; and wherein all of the groups of R⁴, R⁵, R⁶ and R⁷ may optionally be substituted by one or more groups selected from the group consisting of X, R', OR', SR', NR'₂, SiR'₃, COOR', CN, and CONR'₂;

R⁸ is selected from the group consisting of hydrogen, CN, SCN, S(O)_nR'', SiR'₃, NR'R'', (C=O)-R'', CR'=NR'', C₁₋₁₂-alkyl, C₂₋₁₂-alkenyl, C₂₋₁₂-alkynyl, C₁₋₁₂-haloalkyl, C₂₋₁₂-haloalkenyl, C₂₋₁₂-haloalkynyl, C₃₋₈-cycloalkyl, C₄₋₈-cycloalkenyl, C₅₋₈-cycloalkynyl, C₅₋₁₈-aryl, C₇₋₁₉-aralkyl, C₇₋₁₉-alkaryl; where in the cyclic ring system one or more carbon atoms may be replaced by heteroatoms selected from the

group consisting of N, O, and S(O)_n; and all of the groups mentioned above may be substituted by one or more groups selected from the group consisting of X, R', OR', SR', NR'₂, SiR'₃, COOR', CN, and CONR'₂; wherein

- 5 A is selected from the group consisting of fused or non-fused C₆₋₁₈-aryl, C₅₋₁₈-heteroaryl, wherein one or more carbon atoms are replaced by heteroatoms selected from N, O, S and optionally including 1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O)_m and SiR'₂ optionally substituted by one or more groups of R⁹; wherein

- R⁹ is selected from the group consisting of hydrogen, X, CN, SCN, SF₅, R'', OR'', NO₂, NR''₂, SiR'₃,
 10 (C=O)-R'', S(O)_nR'', OS(O)_nR'', OSiR'₃, NR'S(O)_nR'', C₁₋₈-alkyl-S(O)_nR'', C₁₋₈-alkyl-(C=O)-R'',
 CR'=NR'', S(O)_nC₅₋₁₈-aryl, S(O)_nC₇₋₁₉-aralkyl, S(O)_nC₇₋₁₉-alkaryl, C₁₋₁₂-alkyl, C₂₋₁₂-alkenyl, C₂₋₁₂-alkynyl, C₁₋₁₂-haloalkyl, C₂₋₁₂-haloalkenyl, C₂₋₁₂-haloalkynyl, C₁₋₁₂-alkoxy, C₁₋₁₂-alkylthio, C₁₋₁₂-haloalkoxy, C₁₋₁₂-haloalkylthio, C₃₋₁₂-cycloalkyl, C₄₋₈-cycloalkenyl, C₅₋₈-cycloalkynyl, C₃₋₈-cycloalkyloxy, C₃₋₈-cycloalkylthio, C₇₋₁₉-aralkyl, C₇₋₁₉-alkaryl; bicyclic C₅₋₁₂-alkyl, C₇₋₁₂-alkenyl;
 15 where in the cyclic ring system one or more carbon atoms may be replaced by heteroatoms selected from the group consisting of N, O, and S(O)_n; and all of the groups mentioned above may be substituted by one or more groups selected from the group consisting of X, R', OR', SR', NR'₂, SiR'₃, COOR', CN, and CONR'₂; or two R⁹ together with the atoms to which they attached may form a ring, which may be substituted;

- 20 and wherein all of the groups of R⁸, R⁹ and R¹⁰ may optionally be substituted by one or more groups selected from the group consisting of X, R', OR', SR', NR'₂, SiR'₃, COOR', CN, and CONR'₂;

wherein

X represents halogen;

wherein


- 25 R' represents hydrogen, straight chain or branched chain C₁₋₁₂-alkyl or cyclic C₃₋₁₀-alkyl which are optionally substituted by one or more X;

- R'' represents hydrogen; NR'₂, OR', straight chain or branched chain C₁₋₁₂-alkyl, C₁₋₁₂-haloalkyl, cyclic C₃₋₈-alkyl which are optionally substituted by one or more groups selected from the group consisting
 30 of X, R', OR', SR', NR'₂, SiR'₃, COOR', CN, and CONR'₂, C₅₋₁₈-aryl which is optionally substituted by one or more R';

wherein

m and n represent integers wherein n=0, 1 or 2; and m = 1 or 2.

- 35 According to one other embodiment, compounds of general formula (Ib) further can be described as



wherein

R^x and R^y are independently selected from the group consisting of hydrogen, hydroxy, CN, NO₂, COOR', S(O)_nR'', OR', (C=O)-R'', C₁-C₁₂-alkyl, C₂₋₁₂-alkenyl, C₂₋₁₂-alkynyl, C₃₋₈-cycloalkyl, C₄₋₈-cycloalkenyl, C₅₋₈-cycloalkynyl, C₅₋₁₈-aryl, C₇₋₁₉-aralkyl, C₇₋₁₉-alkaryl; where in the cyclic ring system one or more carbon atoms may be replaced by heteroatoms selected from the group consisting of N, O, and S(O)_n; or

R^x and R^y together with the atom to which they are attached or together with further atoms selected from the group consisting of C, N, O, S and optionally including 1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O)_m and SiR'₂, may form a three to seven membered ring, which for its part may be substituted by one or more X, R', OR', SR', NR'₂, SiR'₂, COOR', CN, and CONR'₂;

and wherein all other substituents R^4 to R^9 are as defined in first embodiment.

In one another embodiment preferred substitution, R^1 of compound of general formula (I) are of hydrogen, C₁₋₁₂-alkyl, C₁₋₁₂-alkoxy, C₁₋₁₂-alkylthio, C₁₋₁₂-haloalkyl, C₃₋₈-cycloalkyl;

In one another embodiment more preferred substitution, R^1 of compound of general formula (I) is of hydrogen, C₁₋₆-alkyl;

In one another embodiment preferred substitution, R^2 and R^3 of compound of general formula (I) are C₁₋₁₂-alkyl, C₂₋₆-alkenyl, C₂₋₁₂-alkynyl, C₁₋₁₂-alkoxy, C₁₋₁₂-alkylthio, C₁₋₁₂-haloalkyl, C₃₋₈-cycloalkyl;

In one another embodiment R^1 and R^2 , R^2 and R^3 or R^1 and R^3 together with the atoms to which they are attached or together with further atoms selected from the group consisting of C, N, O, S and optionally including 1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O)_m and SiR'₂ may form a four to seven membered ring, which for its part may be substituted by one or more X, R', OR', SR' and CN;

In one another embodiment preferred ring formation structures with the substitutions R^1 and R^2 , R^2 and R^3 or R^1 and R^3 together with the atoms to which they are attached are azetidine, pyrrolidine, imidazolidine, oxazolidine, piperidine, morpholine, thiomorpholine, piperazine, 1-methylpiperazine,

1-methylpyrrolidine, 1-methylpiperidine, 3-methyl-1,3-thiazinane;

In one another embodiment preferred substitution, R^4 and R^5 of compound of general formula (I) are of X, CN, $S(O)_nR''$, $NR'R''$, $(C=O)-R''$, $CR'=NR''$, C_{1-12} -alkyl, C_{2-6} -alkenyl, C_{2-6} -alkynyl, C_{1-12} -haloalkyl, C_{1-12} -haloalkylthio, C_{3-8} -cycloalkyl, C_{3-8} -cycloalkylthio.

10

In one another embodiment preferred substitution, R^6 and R^7 of compound of general formula (I) are of hydrogen, X, CN, $S(O)_nR''$, $NR'R''$, $(C=O)-R''$, $CR'=NR''$, C_{1-12} -alkyl, C_{2-6} -alkenyl, C_{2-6} -alkynyl, C_{1-12} -haloalkyl, C_{1-12} -haloalkylthio, C_{3-8} -cycloalkyl, C_{3-8} -cycloalkylthio.

In one another embodiment preferred substitution, R^8 on compound of general formula (I) is hydrogen, CN, $S(O)_nR''$, $NR'R''$, $(C=O)-R''$, $CR'=NR''$, C_{1-12} -alkyl, C_{2-6} -alkenyl, C_{2-6} -alkynyl, C_{1-12} -haloalkyl, C_{3-8} -cycloalkyl, C_{3-6} -heterocyclyl, C_{3-6} -heterocyclalkyl;

15

In one another embodiment preferred substitution, R^9 on compound of general formula (I) are X, CN, SCN, SF_5 , R'' , OR'' , NO_2 , NR''_2 , SiR'_3 , $(C=O)-R''$, $S(O)_nR''$, $OS(O)_nR''$, $OSiR'_3$, $NR'S(O)_nR''$, C_{1-8} -alkyl- $S(O)_nR''$, C_{1-8} -alkyl- $(C=O)-R''$, $CR'=NR''$, SC_{1-12} -alkyl, C_{2-12} -alkenyl, C_{2-12} -alkynyl, C_{1-12} -haloalkyl, C_{2-12} -haloalkenyl, C_{1-12} -alkoxy, C_{1-12} -alkylthio, C_{1-12} -haloalkoxy, C_{1-12} -haloalkylthio, C_{3-12} -cycloalkyl, C_{4-8} -cycloalkenyl, C_{3-8} -cycloalkyloxy, C_{3-8} -cycloalkylthio

20

In one another embodiment two R^9 substitutions together with the atom to which they are attached or together with further atoms selected from the group consisting of C, N, O, S and optionally including 1 to 3 ring members selected from the group consisting of $C(=O)$, $C(=S)$, $S(O)_m$ and SiR'_2 may form a four to ten membered ring, which for its part may be substituted by one or more X, R' , OR' , SR' , NR'_2 , SiR'_3 , $COOR'$, CN, and $CONR'_2$;

25

In one another embodiment preferred A is phenyl, naphthalenyl, furyl, thienyl, pyrrolyl, thiazolyl, isoxazolyl, isothiazolyl, thiadiazolyl, pyrazolyl, oxazolyl, imidazolyl, oxadiazolyl, triazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolyl, benzimidazolyl, indazolyl, benzofuranyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, quinazolinyl, cinnonyl; substituted with one or more R^9

30

In one another embodiment A is phenyl, naphthalenyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinolinyl; substituted with one or more R^9

35

In one another embodiment R^1 to R^8 may further optionally substituted by one or more groups selected from the group consisting of X, R'' , OR' , SR' , NR'_2 , SiR'_3 , $COOR'$, CN, and $CONR'_2$;

In one another embodiment preferred compound of general formula (I) are:

- N'-(2,5-dimethyl-4-(phenylamino)phenyl)-N-ethyl-N-methylformimidamide;
N'-(2,5-dimethyl-4-(methyl(phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
N'-(2-chloro-5-methyl-4-(phenylamino)phenyl)-N-ethyl-N-methylformimidamide;
N'-(2-chloro-5-methyl-4-(methyl(phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
5 N'-(2,5-dimethyl-4-(N-phenylmethylsulfonamido)phenyl)-N-ethyl-N-methylformimidamide;
N'-(2,5-dimethyl-4-(methyl(2-methyl-4-(perfluoropropan-2-yl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
N'-(4-((4-chlorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
N'-(4-((3-chlorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
10 N'-(4-((3,4-dichlorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
N'-(2-chloro-5-methyl-4-(methyl(3,4,5-trifluorophenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
N'-(2-chloro-5-methyl-4-(methyl(m-tolyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
N'-(2-chloro-4-((3,4-dichlorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
15 N'-(2-chloro-4-((3-methoxyphenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
N'-(2-chloro-5-methyl-4-(methyl(4-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
20 N'-(2-chloro-5-methyl-4-(methyl(p-tolyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
N'-(2-chloro-4-((2-methoxyphenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
N'-(2-chloro-5-methyl-4-(N-phenylmethylsulfonamido)phenyl)-N-ethyl-N-methylformimidamide;
N'-(2-chloro-4-((2-chlorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
25 N'-(2-chloro-4-((4-chlorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
N'-(2-chloro-4-((4-methoxyphenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
N'-(2-chloro-4-((4-methoxy-3-methylphenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
30 N'-(2-chloro-4-((3,4-dimethoxyphenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
N'-(2-chloro-4-((3,5-dimethoxyphenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
N'-(2,5-dimethyl-4-(methyl(m-tolyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
35 N-ethyl-N'-(4-((3-methoxyphenyl)(methyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
N'-(2,5-dimethyl-4-(methyl(p-tolyl)amino)phenyl)-N-ethyl-N-methylformimidamide;

- N-ethyl-N'-(4-((4-methoxyphenyl)(methyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
N-ethyl-N'-(4-((3-methoxyphenyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
N'-(2,5-dimethyl-4-(m-tolylamino)phenyl)-N-ethyl-N-methylformimidamide;
N'-(2,5-dimethyl-4-(p-tolylamino)phenyl)-N-ethyl-N-methylformimidamide;
5 N'-(4-((4-(tert-butyl)phenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
N'-(4-((4-(tert-butyl)phenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
N'-(4-((2-chlorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
N'-(2-chloro-4-((2-chlorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
N-ethyl-N'-(4-((2-fluorophenyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
10 N-ethyl-N'-(4-((2-fluorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
N'-(2-chloro-4-((2-fluorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
N-ethyl-N'-(4-((3-fluorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
N-ethyl-N'-(4-((4-fluorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
N'-(4-((2-chlorophenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
15 N-(4-(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylphenyl)-N-phenylacetamide;
N'-(2-chloro-5-methyl-4-(methyl(pyridin-2-yl)amino)phenyl)-N-ethyl-N-methylformimidamide;
N'-(4-((4-chlorophenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
N-ethyl-N'-(4-((4-fluorophenyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
N-ethyl-N'-(4-((2-methoxyphenyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
20 N-ethyl-N'-(4-((3-fluorophenyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
N'-(2-chloro-4-((2-fluorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
N'-(2-chloro-4-((3-chlorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
N-(3-chlorophenyl)-N,2,5-trimethyl-4-((morpholinomethylene)amino)aniline;
N'-(2-chloro-4-((3-chlorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
25 N-(3-Chlorophenyl)-N, 2, 5-trimethyl-4-((piperidin-1-ylmethylene) amino) aniline;
N-allyl-N'-(4-((3-chlorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
N'-(4-((3-chlorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-isopropyl-N-methylformimidamide;
N'-(4-((2-bromophenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
N'-(4-((3-chlorophenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
30 N-ethyl-N'-(4-((4-methoxyphenyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
N'-(2,5-dimethyl-4-((2-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
N'-(2,5-dimethyl-4-(methyl(2-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
N'-(2,5-dimethyl-4-((4-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
35 N'-(2,5-dimethyl-4-((3-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;

- N'-(2,5-dimethyl-4-(methyl(4-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-(methyl(3-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- 5 N'-(2,5-dimethyl-4-((3-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((2-bromophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- N-ethyl-N'-(4-((2-methoxyphenyl)(methyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
- N'-(2,5-dimethyl-4-(methyl(3-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-((3-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- 10 N'-(2-chloro-5-methyl-4-(m-tolylamino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-4-((3-methoxyphenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-(o-tolylamino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-4-((4-chlorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-(o-tolylamino)phenyl)-N-ethyl-N-methylformimidamide;
- 15 N'-(2-chloro-4-((4-methoxyphenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-(methyl(o-tolyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((2-bromophenyl)amino)-2-chloro-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((2-bromophenyl)(methyl)amino)-2-chloro-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-(methyl(o-tolyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- 20 N'-(2-chloro-4-((2-methoxyphenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-((2-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-(methyl(2-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- 25 N'-(2-chloro-5-methyl-4-((4-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-4-((3-fluorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-4-((4-fluorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-4-((3-fluorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- 30 N'-(2-chloro-4-((4-fluorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-((3-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-((3-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-(methyl(3-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- 35 methylformimidamide;

- N'-(2,5-dimethyl-4-(methyl(3-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((2,6-difluorophenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-4-((2,6-difluorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- 5 N'-(4-((2,6-difluorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-4-((2,6-difluorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((2-chloro-6-fluorophenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-4-((2-chloro-6-fluorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- 10 N'-(4-((2-chloro-6-fluorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-((4-(pentafluoro-16-sulfaneyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((2,6-dichloro-4-(trifluoromethyl)phenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-
- 15 methylformimidamide;
- N'-(2,5-dimethyl-4-((2-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-((2-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-((3-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-
- 20 methylformimidamide;
- N'-(2,5-dimethyl-4-((4-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-((4-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-(methyl(2-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-
- 25 methylformimidamide;
- N'-(2-chloro-5-methyl-4-(methyl(2-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-(methyl(4-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- 30 N'-(2-chloro-5-methyl-4-(methyl(4-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-(methyl(3-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-(N-phenylethylsulfonamido)phenyl)-N-ethyl-N-methylformimidamide;
- 35 N'-(2-chloro-4-((2,4-dichloro-6-(trifluoromethyl)phenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;

- N'-(2-chloro-5-methyl-4-((4-(pentafluoro-16-sulfaneyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-4-((2-chloro-6-fluorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- 5 N'-(2,5-dimethyl-4-(methyl(4-(pentafluoro-16-sulfaneyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-(methyl(4-(pentafluoro-16-sulfaneyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-(methyl(3-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-
- 10 methylformimidamide;
- N'-(2,5-dimethyl-4-((2-((trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-((2-((trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- 15 N'-(4-((3-((difluoromethyl)thio)phenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-((4-((trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-((4-((trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-
- 20 methylformimidamide;
- N'-(2,5-dimethyl-4-(methyl(2-((trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-(methyl(2-((trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- 25 N'-(2,5-dimethyl-4-(methyl(4-((trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-(methyl(4-((trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((3-((difluoromethyl)thio)phenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-
- 30 methylformimidamide;
- N'-(2,5-dimethyl-4-((3-((trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-((4-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-((4-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- 35 N'-(2,5-dimethyl-4-(methyl(3-((trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;

- N'-(2-chloro-5-methyl-4-(methyl(3-((trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-(methyl(4-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-(methyl(4-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-
- 5 methylformimidamide;
- N'-(2,5-dimethyl-4-((3-(pentafluoro-l6-sulfaneyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-((3-(pentafluoro-l6-sulfaneyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- 10 N'-(2,5-dimethyl-4-(methyl(3-(pentafluoro-l6-sulfaneyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-(methyl(3-(pentafluoro-l6-sulfaneyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((3,5-bis(trifluoromethyl)phenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- 15 N'-(4-((3,5-bis(trifluoromethyl)phenyl)amino)-2-chloro-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-((3-((trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-4-((4-(dimethylamino)phenyl)amino)-5-methylphenyl)-N-ethyl-N-
- 20 methylformimidamide;
- N'-(4-((4-(dimethylamino)phenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-4-((3-((difluoromethyl)thio)phenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-4-((3-((difluoromethyl)thio)phenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-
- 25 methylformimidamide;
- N'-(4-((3-(difluoromethoxy)phenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((3-(difluoromethoxy)phenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-4-((3-(difluoromethoxy)phenyl)amino)-5-methylphenyl)-N-ethyl-N-
- 30 methylformimidamide;
- N'-(2,5-dimethyl-4-((2-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-((2-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-((2-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-4-((4-(difluoromethoxy)phenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-
- 35 methylformimidamide;
- N'-(4-((2,5-difluorophenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;

- N'-(2-chloro-4-((2,5-difluorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
N'-(4-((3,5-bis(trifluoromethyl)phenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
N'-(4-((3,5-bis(trifluoromethyl)phenyl)(methyl)amino)-2-chloro-5-methylphenyl)-N-ethyl-N-methylformimidamide;
5 N'-(2,5-dimethyl-4-((5-methyl-2-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
N'-(4-((2,5-difluorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
N'-(2-chloro-4-((2,5-difluorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
10 N'-(2,5-dimethyl-4-(methyl(5-methyl-2-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
N'-(4-((4-chloro-2-(trifluoromethyl)phenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
15 N'-(2-chloro-4-((4-chloro-2-(trifluoromethyl)phenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
N'-(4-((4-chloro-2-(trifluoromethyl)phenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
N'-(2-chloro-4-((4-chloro-2-(trifluoromethyl)phenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
20 N'-(2-chloro-5-methyl-4-(methyl(2-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
N'-(2-chloro-4-((3-(difluoromethoxy)phenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
25 N'-(2-chloro-5-methyl-4-((2-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
N'-(4-((2-chloro-4-(trifluoromethyl)phenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
N'-(2-chloro-4-((2-chloro-4-(trifluoromethyl)phenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
30 N'-(4-((2-chloro-4-(trifluoromethyl)phenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
N'-(2-chloro-4-((2-chloro-4-(trifluoromethyl)phenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
N'-(2,5-dimethyl-4-((2-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
35 N-ethyl-N'-(4-((4-fluoro-3-(1,1,2,2-tetrafluoroethoxy)phenyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;

- N'-(2-chloro-4-((4-fluoro-3-(1,1,2,2-tetrafluoroethoxy)phenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- 5-chloro-N-(2-fluorophenyl)-N,2-dimethyl-4-((morpholinomethylene)amino)aniline;
- N'-(2-chloro-4-(N-(2-fluorophenyl)methylsulfonamido)-5-methylphenyl)-N-ethyl-N-
- 5 methylformimidamide;
- N-(5-chloro-4-(((ethyl(methyl)amino)methylene)amino)-2-methylphenyl)-N-(2-fluorophenyl)acetamide;
- N'-(2-chloro-4-((2-fluorophenyl)(methyl)amino)-5-methylphenyl)-N,N-dimethylformimidamide;
- N'-(2-chloro-4-(ethyl(2-fluorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- 10 5-chloro-N-(2-fluorophenyl)-N,2-dimethyl-4-((morpholinomethylene)amino)aniline;
- 5-chloro-N-(2-fluorophenyl)-N,2-dimethyl-4-((thiomorpholinomethylene)amino)aniline;
- N-ethyl-N'-(5-fluoro-4-((4-fluoro-3-(1,1,2,2-tetrafluoroethoxy)phenyl)amino)-2-methylphenyl)-N-methylformimidamide;
- N-ethyl-N'-(5-fluoro-4-((4-fluoro-3-(1,1,2,2-tetrafluoroethoxy)phenyl)(methyl)amino)-2-
- 15 methylphenyl)-N-methylformimidamide;
- N-(5-chloro-4-(((ethyl(methyl)amino)methylene)amino)-2-methylphenyl)-N-(2-chlorophenyl)acetamide;
- N'-(2-chloro-4-(N-(2-chlorophenyl)methylsulfonamido)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- 20 N'-(4-((4-((difluoromethyl)thio)phenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-4-((4-((difluoromethyl)thio)phenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((4-((difluoromethyl)thio)phenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-
- 25 methylformimidamide;
- N'-(2-chloro-4-((4-((difluoromethyl)thio)phenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-4-(ethyl(phenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N-(5-chloro-4-(((ethyl(methyl)amino)methylene)amino)-2-methylphenyl)-N-phenylacetamide;
- 30 N'-(2-chloro-4-((2-((difluoromethyl)thio)phenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-4-((2-((difluoromethyl)thio)phenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-4-(ethyl(3-methoxyphenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- 35 N'-(2-chloro-4-((3-(difluoromethoxy)-4-fluorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;

- N'-(2-chloro-4-(N-(3-methoxyphenyl)methylsulfonamido)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((3-(difluoromethoxy)-4-fluorophenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- 5 N'-(2-chloro-4-((3-(difluoromethoxy)-4-fluorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((3-(difluoromethoxy)-4-fluorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((2,5-dimethylphenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- 10 N'-(2-chloro-4-((2,5-dimethylphenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N-(5-chloro-4-(((ethyl(methyl)amino)methylene)amino)-2-methylphenyl)-N-(2-chlorophenyl)propionamide;
- N-ethyl-N'-(5-fluoro-4-((4-methoxyphenyl)amino)-2-methylphenyl)-N-methylformimidamide;
- N-ethyl-N'-(5-fluoro-4-((4-methoxyphenyl)(methyl)amino)-2-methylphenyl)-N-
- 15 methylformimidamide;
- N-(5-chloro-4-(((ethyl(methyl)amino)methylene)amino)-2-methylphenyl)-N-(2-fluorophenyl)propionamide
- N'-(2-chloro-4-(N-(4-fluoro-3-(1,1,2,2-tetrafluoroethoxy)phenyl)methylsulfonamido)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- 20 N'-(2,5-dimethyl-4-((3-(1,1,2,2-tetrafluoroethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-(methyl(3-(1,1,2,2-tetrafluoroethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N-ethyl-N'-(4-((2-fluoro-5-methylphenyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
- 25 N-ethyl-N'-(5-fluoro-4-((2-fluorophenyl)amino)-2-methylphenyl)-N-methylformimidamide;
- N-ethyl-N'-(4-((2-fluoro-5-methylphenyl)(methyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
- N'-(2-chloro-4-((2-fluoro-5-methylphenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- 30 N-ethyl-N'-(5-fluoro-2-methyl-4-(phenylamino)phenyl)-N-methylformimidamide;
- N'-(4-((2-chlorophenyl)amino)-5-fluoro-2-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((4-(tert-butyl)phenyl)amino)-5-fluoro-2-methylphenyl)-N-ethyl-N-methylformimidamide;
- N-ethyl-N'-(5-fluoro-2-methyl-4-(m-tolylamino)phenyl)-N-methylformimidamide;
- N-(5-chloro-4-(((ethyl(methyl)amino)methylene)amino)-2-methylphenyl)-N-phenylpropionamide;
- 35 N-(5-chloro-4-(((ethyl(methyl)amino)methylene)amino)-2-methylphenyl)-N-(3-methoxyphenyl)acetamide

- N'-(2-chloro-4-((4-fluoro-3-methoxyphenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
 N-ethyl-N'-(4-((4-fluoro-3-methoxyphenyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
 N-ethyl-N'-(4-((4-fluoro-3-methoxyphenyl)(methyl)amino)-2,5-dimethylphenyl)-N-
 5 methylformimidamide;
 N'-(4-((2-((difluoromethyl)thio)phenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
 N'-(4-((2-((difluoromethyl)thio)phenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
 10 N'-(2-chloro-4-((4-fluoro-3-methoxyphenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
 N'-(2-bromo-6-fluoro-3-methyl-4-(phenylamino)phenyl)-N-ethyl-N-methylformimidamide;
 N'-(2-chloro-5-methyl-4-((5-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)amino)phenyl)-N-ethyl-N-methylformimidamide;
 15 N'-(2-bromo-6-fluoro-3-methyl-4-(methyl(phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
 N'-(2-chloro-5-methyl-4-((1-methylindolin-5-yl)amino)phenyl)-N-ethyl-N-methylformimidamide;
 N'-(2,5-dimethyl-4-((5-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)amino)phenyl)-N-ethyl-N-methylformimidamide;
 N-ethyl-N'-(5-fluoro-2-methyl-4-(methyl(phenyl)amino)phenyl)-N-methylformimidamide;
 20 N'-(4-((4-(tert-butyl)phenyl)(methyl)amino)-5-fluoro-2-methylphenyl)-N-ethyl-N-methylformimidamide;
 N-ethyl-N'-(5-fluoro-2-methyl-4-(methyl(m-tolyl)amino)phenyl)-N-methylformimidamide;
 N-ethyl-N'-(7-((2-methoxyphenyl)amino)-2,3-dihydro-1H-inden-4-yl)-N-methylformimidamide;
 N-ethyl-N-methyl-N'-(7-(p-tolylamino)-2,3-dihydro-1H-inden-4-yl)formimidamide;
 25 N'-(7-((4-chlorophenyl)amino)-2,3-dihydro-1H-inden-4-yl)-N-ethyl-N-methylformimidamide;
 N-ethyl-N-methyl-N'-(4-(phenylamino)naphthalen-1-yl)formimidamide;
 N'-(2,5-dimethyl-4-(pyridin-2-ylamino)phenyl)-N-ethyl-N-methylformimidamide;
 N'-(2,5-dimethyl-4-(methyl(pyridin-2-yl)amino)phenyl)-N-ethyl-N-methylformimidamide and
 N'-(2-chloro-5-methyl-4-(pyridin-2-ylamino)phenyl)-N-ethyl-N-methylformimidamide;

30

* Compound names generated using Chemdraw Professional 16.0

Any of the compounds according to the invention can exist in one or more optical, geometric or chiral isomer forms depending on the number of asymmetric centres in the compound. The invention thus
 35 relates equally to all the optical isomers and to their racemic or scalemic mixtures (the term "scalemic" denotes a mixture of enantiomers in different proportions), and to the mixtures of all the possible

stereoisomers, in all proportions. The diastereoisomers and/or the optical isomers can be separated according to the methods which are known *per se* by a person ordinary skilled in the art.

Any of the compounds according to the invention can also exist in one or more geometric isomer forms depending on the number of double bonds in the compound. The invention thus relates equally
5 to all geometric isomers and to all possible mixtures, in all proportions. The geometric isomers can be separated according to general methods, which are known *per se* by a person ordinary skilled in the art.

Any of the compounds according to the invention, can also exist in one or more amorphous or isomorphous or polymorphic forms, depending on their preparation, purification storage and various
10 other influencing factors. The invention thus relates all the possible amorphous, isomorphous and polymorphic forms, in all proportions. The amorphous, isomorphous and polymorphic forms can be prepared and/or separated and/or purified according to general methods, which are known *per se* by a person ordinary skilled in the art.

In the above description, the term "alkyl", used either alone or in compound words such as "alkylthio"
15 or "haloalkyl" includes straight-chain or branched alkyl, such as, methyl, ethyl, n-propyl, iso-propyl, or the different butyl, pentyl or hexyl isomers.

"Alkenyl" includes straight-chain or branched alkenes such as ethenyl, 1-propenyl, 2-propenyl, and the different butenyl, pentenyl and hexenyl isomers. "Alkenyl" also includes polyenes such as 1, 2-propadienyl and 2,4-hexadienyl.

20 "Alkynyl" includes straight-chain or branched alkynes such as ethynyl, 1-propynyl, 2-propynyl and the different butynyl, pentynyl and hexynyl isomers. "Alkynyl" can also include moieties comprised of multiple triple bonds such as 2,5-hexadiynyl.

"cycloalkyl" or "cycloalkyl" includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. cycloalkenyl includes, for example, cyclopropenyl, cyclobutenyl, cyclopentenyl, and
25 cyclohexenyl. cycloalkynyl, similarly refers to cyclic pentynyl, hexynyl, heptynyl and octynyl.

"cycloalkyloxy" includes, for example, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy.

"cycloalkylthio" includes, for example, cyclopropylthio, cyclobutylthio, cyclopentylthio.

The term "aryl" as used herein is a group that contains any carbon-based aromatic group including, but not limited to phenyl, naphthalene, biphenyl, anthracene, and the like. The aryl group can be
30 substituted or unsubstituted. In addition, the aryl group can be a single ring structure or comprise

multiple ring structures that are either fused ring structures or attached via one or more bridging groups such as a carbon-carbon bond.

The term "aralkyl" refers to aryl hydrocarbon radicals including an alkyl portion as defined above. Examples include benzyl, phenylethyl, and 6-naphthylhexyl. As used herein, the term "aralkenyl" refers to aryl hydrocarbon radicals including an alkenyl portion, as defined above, and an aryl portion, as defined above. Examples include styryl, 3-(benzyl) prop-2-enyl, and 6-naphthylhex-2-enyl.

The term "alkaryl" refers to an aryl group which bears an alkyl group; as used herein, the term "alkaryl" includes both substituted and unsubstituted groups. One example of an alkaryl group is the 4-methylphenyl radical.

10 "Alkoxy" includes, for example, methoxy, ethoxy, n-propyloxy, isopropyloxy and the different butoxy, pentoxy and hexyloxy isomers.

"Alkylthio" includes branched or straight-chain alkylthio moieties such as methylthio, ethylthio, and the different propylthio, butylthio, pentylthio and hexylthio isomers.

15 The term "hetero" in connection with rings refers to a ring in which at least one ring atom is not carbon and which can contain 1 to 4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur, provided that each ring contains no more than 4 nitrogens, no more than 2 oxygens and no more than 2 sulfurs.

20 The term "heterocycle" means a cyclic ring system in which at least one ring atom is not carbon and which can contain heteroatoms independently selected from the group comprising of nitrogen, oxygen, sulfur, phosphorous, boron etc.

The term "heterocycle" may be further classified as "non-aromatic heterocycle" and "aromatic heterocycle or heteroaryl".

25 The term "non-aromatic heterocycle" includes fused or unfused three- to fifteen-membered, preferably three- to twelve-membered, saturated or fully or partially unsaturated heterocycle, monocyclic or polycyclic (spiro, fused, bridged, nonfused) heterocycle wherein heteroatom is selected from the group of oxygen, nitrogen and sulphur; and if the ring contains more than one oxygen atom, they are not directly adjacent; Non-limiting examples of non-aromatic heterocycle include oxetanyl, oxiranyl; aziridinyl; thiiranyl, azetidiny, thiethanyl, dithiethanyl, diazetidinyl, 2-tetrahydrofuranyl; 3-tetrahydrofuranyl; 2-tetrahydrothienyl; 3-tetrahydrothienyl; 2-pyrrolidinyl; 3-pyrrolidinyl; 3-isoxazolidinyl; 4-isoxazolidinyl; 5-isoxazolidinyl; 3-isothiazolidinyl; 4-isothiazolidinyl; 2-tetrahydropyranyl; 4-tetrahydropyranyl; . This definition also applies to heterocyclyl as a part of a composite substituent, for example heterocyclylalkyl (heterocycle radicals including an alkyl portion

30

as defined above) etc., unless specifically defined elsewhere.

The term "heteroaryl" as used herein is a group that contains fused or unfused three to fifteen membered, preferably three to twelve membered, more preferably 5 or 6 membered; monocyclic or polycyclic unsaturated ring system, containing heteroatoms selected from the group of oxygen, nitrogen, sulphur, phosphorous, boron etc.

Non-limiting examples of 5 membered heteroaryl groups include 2-furyl; 3-furyl; 2-thienyl; 3-thienyl; 2-pyrrolyl; 3-pyrrolyl; 3-isoxazolyl; 4-isoxazolyl; 5-isoxazolyl; 3-isothiazolyl; 4-isothiazolyl; 5-isothiazolyl; 3-pyrazolyl; 4-pyrazolyl; 5-pyrazolyl; 2-oxazolyl; 4-oxazolyl; 5-oxazolyl; 2-thiazolyl; 4-thiazolyl; 5-thiazolyl; 2-imidazolyl; 4-imidazolyl; 1,2,4-oxadiazol-3-yl; 1,2,4-oxadiazol-5-yl; 1,2,4-thiadiazol-3-yl; 1,2,4-thiadiazol-5-yl; 1,2,4-triazol-3-yl; 1,3,4-oxadiazol-2-yl; 1,3,4-thiadiazol-2-yl and 1,3,4-triazol-2-yl; 1-pyrrolyl; 1-pyrazolyl; 1,2,4-triazol-1-yl; 1-imidazolyl; 1,2,3-triazol-1-yl; 1,3,4-triazol-1-yl and the like.

Non-limiting examples of 6 membered heteroaryl groups include 2-pyridinyl; 3-pyridinyl; 4-pyridinyl; 3-pyridazinyl; 4-pyridazinyl; 2-pyrimidinyl; 4-pyrimidinyl; 5-pyrimidinyl; 2-pyrazinyl; 1,3,5-triazin-2-yl; 1,2,4-triazin-3-yl; 1,2,4,5-tetrazin-3-yl and the like.

Non-limiting examples of benzofused 5-membered heteroaryl include indol-1-yl; indol-2-yl; indol-3-yl; indol-4-yl; indol-5-yl; indol-6-yl; indol-7-yl; benzimidazol-1-yl; benzimidazol-2-yl; benzimidazol-4-yl; benzimidazol-5-yl; indazol-1-yl; indazol-3-yl; indazol-4-yl; indazol-5-yl; indazol-6-yl; indazol-7-yl; indazol-2-yl; 1-benzofuran-2-yl; 1-benzofuran-3-yl; 1-benzofuran-4-yl; 1-benzofuran-5-yl; 1-benzofuran-6-yl; 1-benzofuran-7-yl; 1-benzothiophen-2-yl; 1-benzothiophen-3-yl; 1-benzothiophen-4-yl; 1-benzothiophen-5-yl; 1-benzothiophen-6-yl; 1-benzothiophen-7-yl; 1,3-benzothiazol-2-yl; 1,3-benzothiazol-4-yl; 1,3-benzothiazol-5-yl; 1,3-benzothiazol-6-yl; 1,3-benzothiazol-7-yl; 1,3-benzoxazol-2-yl; 1,3-benzoxazol-4-yl; 1,3-benzoxazol-5-yl; 1,3-benzoxazol-6-yl; 1,3-benzoxazol-7-yl and the like.

Non-limiting examples of benzofused 6-membered heteroaryl include quinolin-2-yl; quinolin-3-yl; quinolin-4-yl; quinolin-5-yl; quinolin-6-yl; quinolin-7-yl; quinolin-8-yl; isoquinolin-1-yl; isoquinolin-3-yl; isoquinolin-4-yl; isoquinolin-5-yl; isoquinolin-6-yl; isoquinolin-7-yl; isoquinolin-8-yl and the like.

The term "halogen", either alone or in compound words such as "haloalkyl", includes fluorine, chlorine, bromine or iodine. Further, when used in compound words such as "haloalkyl", said alkyl may be partially or fully substituted with halogen atoms which may be the same or different. Non-limiting examples of "haloalkyl" include chloromethyl, bromomethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorofluoromethyl, dichlorofluoromethyl, chlorodifluoromethyl, 1-chloroethyl, 1-bromoethyl, 1-fluoroethyl, 2-

fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-chloro-2-fluoroethyl, 2-chloro-2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2,2,2-trichloroethyl, pentafluoroethyl, 1,1-dichloro-2,2,2-trifluoroethyl, and 1,1,1-trifluoroprop-2-yl.

The terms "haloalkenyl", "haloalkynyl", "haloalkoxy", "haloalkylthio" are defined analogously except that, instead of alkyl groups, alkenyl, alkynyl, alkoxy and alkylthio groups are present as a part of the substituent.

The total number of carbon atoms in a substituent group is indicated by the "Ci-j" prefix where i and j are numbers from 1 to 21. For example, C₁₋₃ alkoxy designates methoxy through propoxy. In the above recitations, when a compound of Formula I is comprised of one or more heterocyclic rings, all substituents are attached to these rings through any available carbon or nitrogen by replacement of a hydrogen on said carbon or nitrogen.

When a compound is substituted with a substituent bearing a subscript that indicates the number of said substituents can exceed 1, said substituents (when they exceed 1) are independently selected from the group of defined substituents. Further, when the subscript indicates a range, e. g. (R)_{i-j} then the number of substituents may be selected from the integers between i and j inclusive.

When a group contains a substituent which can be hydrogen, for example R¹ or R², then, when this substituent is taken as hydrogen, it is recognized that this is equivalent to said group being unsubstituted.

The present invention further relates to a composition for controlling unwanted microorganisms comprising at least one of the compounds of the formula (I) and one or more inert carrier. The inert carrier further comprises agriculturally suitable auxiliaries, solvents, diluents, surfactants and/or extenders and the like.

The present invention further relates to a composition for controlling unwanted microorganisms, comprising at least one of the compounds of the formula (I) and/or one or more active compatible compound selected from fungicides, bactericides, acaricides, insecticides, nematocides, herbicides, biopesticides, plant growth regulators, antibiotics, fertilizers and/or mixtures thereof.

The present invention further relates to a composition wherein the concentration of compounds having general formula (I) ranges from 1 to 90% by weight with respect to the total weight of the composition, preferably from 5 to 50% by weight with respect to the total weight of the composition.

The present invention also relates to a method for controlling unwanted microorganisms, wherein compounds of the formula (I) are applied to the microorganisms and/or in their habitat.

The present invention further provides a method for protecting seed against unwanted microorganisms by using seed treated with at least one compound of the formula (I).

5 The compounds of the formula (I) can possess potent microbicidal activity and can be used for the control of unwanted microorganisms, such as fungi, insect, mites, nematodes and bacteria, in agricultural or horticultural crop protection and in the protection of such materials.

The compounds of the formula (I) can possess very good fungicidal properties and can be used in crop protection, for example for control of *Plasmodiophoromycetes*, *Oomycetes*, *Chytridiomycetes*, *Zygomycetes*, *Ascomycetes*, *Basidiomycetes* and *Deuteromycetes*.

10 The compounds of the formula (I) can be used as nematocides in crop protection, for example, for control of *Rhabditida*, *Dorylaimida*, and *Tryplonchida*.

The compounds of the formula (I) can be used as insecticides in crop protection, for example, for control of Lepidoptera, Coleoptera, Hemiptera, Homoptera, Thysanoptera, Diptera, Orthoptera & Isoptera.

15 The compounds of the formula (I) can be used as acaricides in crop protection, for example, for control of Eriophyoidea, Tetranychoidae, Eupodoidea and Tarsonemidae.

The compounds of the formula (I) can be used as bactericides in crop protection, for example, for control of *Pseudomonadaceae*, *Rhizobiaceae*, *Enterobacteriaceae*, *Corynebacteriaceae* and *Streptomycetaceae*.

20 The compounds of the formula (I) can be used as herbicides and can be effective against a broad spectrum of economically important mono- and dicotyledonous harmful plants. Monocotyledonous broad-leaved weed species may include Avena, Lolium, Alopecurus, Phalaris, Echinochloa, Digitaria, Setaria and Cyperus species from the annual group and perennial species Agropyron, Cynodon, Imperata and Sorghum and also perennial Cyperus species. Dicotyledonous broad-leaved weed species may include Galium, Viola, Veronica, Lamium, Stellaria, Amaranthus, Sinapis, Ipomoea, Sida,
25 Matricaria and Abutilon on the annual side, and also Convolvulus, Cirsium, Rumex and Artemisia in the case of the perennial broad-leaved weeds. Harmful plants that occur in rice, such as, for example, Echinochloa, Sagittaria, Alisma, Eleocharis, Scirpus and Cyperus, can be controlled by the compounds of formula (I).

30 The compounds of the formula (I) can be used for curative or protective control of phytopathogenic fungi. The invention therefore also relates to curative and protective methods for controlling

phytopathogenic fungi by the use of the inventive active ingredients or compositions, which are applied to the seed, the plant or plant parts, the fruit or the soil in which the plants grow.

The compounds of the formula (I) can be used for controlling or preventing against phytopathogenic fungi, bacteria, insects, nematodes, mites of agricultural crops and or horticultural crops.

- 5 The compounds of the formula (I) can be used in crop protection, wherein the agricultural crops are cereals, corn, rice, soybean and other leguminous plants, fruits and fruit trees, nuts and nut trees, citrus and citrus trees, any horticultural plants, cucurbitaceae, oleaginous plants, tobacco, coffee, tea, cacao, sugar beet, sugar cane, cotton, potato, tomato, onions, peppers and other vegetables, and ornamentals.

- 10 According to the invention, as defined above a carrier is a natural or synthetic, organic or inorganic substance with which the active ingredients are mixed or combined for better applicability, in particular for application to plants or plant parts or seed. The carrier, which may be solid or liquid, are generally inert and should be suitable for use in agriculture.

- Useful solid carriers include for example ammonium salts and natural rock flours, such as kaolins, clays, talc, chalk, quartz, attapulgite, montmorillonite or diatomaceous earth, and synthetic rock flours, such as finely divided silica, alumina and silicates; useful solid carriers for granules include: for example, 15 crushed and fractionated natural rocks such as calcite, marble, pumice, sepiolite and dolomite, and also synthetic granules of inorganic and organic flours, and granules of organic material such as paper, sawdust, coconut shells, maize cobs and tobacco stalks; useful emulsifiers and/or foam-formers include: for example nonionic and anionic emulsifiers, such as polyoxyethylene fatty acid esters, polyoxyethylene fatty alcohol ethers, for example alkylaryl polyglycol ethers, alkylsulphonates, alkyl sulphates, arylsulphonates and also 20 protein hydrolysates; suitable dispersants are nonionic and/or ionic substances, for example from the classes of the alcohol-POE and/or -POP ethers, acid and/or POP POE esters, alkylaryl and/or POP POE ethers, fat and/or POP POE adducts, POE- and/or POP-polyol derivatives, POE- and/or POP-sorbitan or -sugar adducts, alkyl or aryl sulphates, alkyl- or arylsulphonates and alkyl or aryl phosphates or the 25 corresponding PO-ether adducts. Additionally, suitable are oligo- or polymers, for example those derived from vinylic monomers, from acrylic acid, from EO and/or PO alone or in combination with, for example, (poly) alcohols or (poly) amines. It is also possible to use lignin and its sulphonic acid derivatives, unmodified and modified celluloses, aromatic and/or aliphatic sulphonic acids and also their adducts with formaldehyde.

- 30 The active ingredients can be applied as such or converted to the customary formulations or in the form of their formulations or the use forms prepared therefrom, such as ready-to-use solutions, emulsions, water- or oil-based suspensions, powders, wettable powders, pastes, soluble powders, soluble tablets, dusts, soluble granules, granules for broadcasting, suspoemulsion concentrates, natural products impregnated with

active ingredient, synthetic substances impregnated with active ingredient, fertilizers and also microencapsulations in polymeric substances. Application is accomplished in a customary manner, for example by watering, spraying, atomizing, nursery boxes, broadcasting, dusting, foaming, spreading-on and the like. It is also possible to deploy the active ingredients by the ultra-low volume method or to inject
5 the active ingredient preparation/the active ingredient itself into the soil. It is also possible to treat the seed of the plants.

The active ingredients can be further converted to the nanoformulation with intent to further improve water solubility, thermal stability, bioavailability, sensory attributes, and physiological performance.

Furthermore, the choice of the type of formulation will depend on the specific use.

10 The formulations mentioned can be prepared in a manner known *per se*, for example by mixing the active ingredients with at least one customary extender, solvent or diluent, emulsifier, dispersant and/or binder or fixing agent, wetting agent, a water repellent, if appropriate siccatives and UV stabilizers and if appropriate dyes and pigments, antifoams, preservatives, secondary thickeners, stickers, gibberellins and also other processing auxiliaries.

15 The present invention includes not only formulations which are already ready for use and can be deployed with a suitable apparatus to the plant or the seed, but also commercial concentrates which have to be diluted with water prior to use.

The auxiliaries used may be those substances which are suitable for imparting particular properties to the composition itself and/or to preparations derived therefrom (for example spray liquors, seed dressings),
20 such as certain technical properties and/or also particular biological properties. Typical auxiliaries include extenders, solvents and carriers.

Suitable extenders are, for example, water, polar and nonpolar organic chemical liquids, for example from the classes of the aromatic and nonaromatic hydrocarbons (such as paraffins, alkylbenzenes, alkylnaphthalenes, chlorobenzenes), the alcohols and polyols (which may optionally also be substituted,
25 etherified and/or esterified), the ketones (such as acetone, cyclohexanone), esters (including fats and oils) and (poly) ethers, the unsubstituted and substituted amines, amides, lactams (such as N-alkylpyrrolidones) and lactones, the sulphones and sulfoxides (such as dimethyl sulphoxide).

Liquefied gaseous extenders or carriers are understood to mean liquids which are gaseous at standard temperature and under standard pressure, for example aerosol propellants such as halohydrocarbons, or else
30 butane, propane, nitrogen and carbon dioxide.

In the formulations it is possible to use tackifiers such as carboxymethylcellulose, natural and synthetic

polymers in the form of powders, granules or latices, such as gum arabic, polyvinyl alcohol and polyvinyl acetate, or else natural phospholipids such as cephalins and lecithins and synthetic phospholipids. Further additives may be mineral, vegetable oils and methylated seed oils.

If the extender used is water, it is also possible to use, for example, organic solvents as auxiliary solvents.

- 5 Useful liquid solvents are essentially: aromatics such as xylene, toluene or alkylnaphthalenes, chlorinated aromatics or chlorinated aliphatic hydrocarbons such as chlorobenzenes, chloroethylenes or methylene chloride, aliphatic hydrocarbons such as cyclohexane or paraffins, for example petroleum fractions, alcohols such as butanol or glycol and their ethers and esters, ketones such as acetone, methyl ethyl ketone, methyl isobutyl ketone or cyclohexanone, strongly polar solvents such as dimethylformamide and dimethyl
10 sulphoxide, or else water.

- Compositions comprising compounds of the formula (I) may additionally comprise further components, for example surfactants. Suitable surfactants are emulsifiers and/or foam formers, dispersants or wetting agents having ionic or nonionic properties, or mixtures of these surfactants. Examples thereof are salts of polyacrylic acid, salts of lignosulphonic acid, salts of phenolsulphonic
15 acid or naphthalenesulphonic acid, polycondensates of ethylene oxide with fatty alcohols or with fatty acids or with fatty amines, substituted phenols (preferably alkylphenols or arylphenols), salts of sulphosuccinic esters, taurine derivatives (preferably alkyl taurates), phosphoric esters of polyethoxylated alcohols or phenols, fatty esters of polyols, and derivatives of the compounds containing sulphates, sulphonates and phosphates, for example alkylaryl polyglycol ethers,
20 alkylsulphonates, alkyl sulphates, arylsulphonates, protein hydrolysates, lignosulphite waste liquors and methylcellulose. The presence of a surfactant is necessary if one of the active ingredients and/or one of the inert carriers is insoluble in water and when application is effected in water. The proportion of surfactants is between 5 and 40 per cent by weight of the inventive composition.

- It is possible to use dyes such as inorganic pigments, for example iron oxide, titanium oxide and Prussian
25 Blue, and organic dyes such as alizarin dyes, azo dyes and metal phthalocyanine dyes, and trace nutrients such as salts of iron, manganese, boron, copper, cobalt, molybdenum and zinc.

Further additives may be perfumes, mineral or vegetable, optionally modified oils, waxes and nutrients (including trace nutrients), such as salts of iron, manganese, boron, copper, cobalt, molybdenum and zinc.

- Additional components may be stabilizers, such as cold stabilizers, preservatives, antioxidants, light
30 stabilizers, or other agents which improve chemical and/or physical stability.

If appropriate, other additional components may also be present, for example protective colloids, binders, adhesives, thickeners, thixotropic substances, penetrants, stabilizers, sequestering agents,

complex formers. In general, the active ingredients can be combined with any solid or liquid additive commonly used for formulation purposes.

The formulations contain generally between 0.05 and 99% by weight, 0.01 and 98% by weight, preferably between 0.1 and 95% by weight, more preferably between 0.5 and 90% of active ingredient, most preferably between 10 and 70% by weight.

The formulations described above can be used for controlling unwanted microorganisms, in which the compositions comprising compounds of the formula (I) are applied to the microorganisms and/or in their habitat.

Compounds of the formula (I) according to this invention, as well as salts, N-oxides, metal complexes, stereoisomers or polymorphs can be used as such or in formulations thereof and can be mixed with known mixing partners in order to broaden, for example, the activity spectrum or to prevent development of resistance. Useful mixing partners include, for example, known fungicides, insecticides, acaricides, nematocides, biopesticides and bactericides. A mixture with other known active ingredients, such as herbicides, or with fertilizers and growth regulators, safeners and/or semiochemicals, is also possible.

Examples for such chemical ingredients are given herein in a not limiting way. Some of them are specified herein by their common names that are known and described, for example in *The Pesticide Manual 17th Ed.*, or can be searched in the internet (e.g. under www.alanwood.net/pesticides). Others are described by their systematic name following the IUPAC rules for nomenclature.

All named mixing partners of the classes (A) to (O) as described below can, if their functional groups enable this, optionally form salts with suitable bases or acids, appear as stereoisomers, even if not specifically mentioned in each case, or as polymorphs. They are also understood as being included herein. These examples are

A) Inhibitors of the ergosterol biosynthesis, for example (A01) aldimorph, (A02) azaconazole, (A03) bitertanol, (A04) bromuconazole, (A05) cyproconazole, (A06) diclobutrazole, (A07) difenoconazole, (A08) diniconazole, (A09) diniconazole-M, (A10) dodemorph, (A11) dodemorph acetate, (A12) epoxiconazole, (A13) etaconazole, (A14) fenarimol, (A15) fenbuconazole, (A16) fenhexamid, (A17) fenpropidin, (A18) fenpropimorph, (A19) fluquinconazole, (A20) flurprimidol, (A21) flusilazole, (A22) flutriafol, (A23) furconazole, (A24) furconazole-cis, (A25) hexaconazole, (A26) imazalil, (A27) imazalil sulfate, (A28) imibenconazole, (A29) ipconazole, (A30) metconazole, (A31) myclobutanil, (A32) naftifine, (A33) nuarimol, (A34) oxpoconazole, (A35) paclobutrazol, (A36) pefiirazoate, (A37) penconazole, (A38) piperalin, (A39) prochloraz, (A40) propiconazole, (A41) prothioconazole, (A42)

pyributicarb, (A43) pyrifenoxy, (A44) quinconazole, (A45) simeconazole, (A46) spiroxamine, (A47) tebuconazole, (A48) terbinafine, (A49) tetraconazole, (A50) triadimefon, (A51) triadimenol, (A52) tridemorph, (A53) triflumizole, (A54) triforine, (A55) triticonazole, (A56) uniconazole, (A57) uniconazole-p, (A58) viniconazole, (A59) voriconazole, (A60) 1-(4-chlorophenyl)-2-(1H-1,2,4-triazol-1-yl)cycloheptanol, (A61) methyl 1-(2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)-1H-imidazole-5-carboxylate, (A62) N'-{5-(difluoromethyl)-2-methyl-4-[3-(trimethylsilyl) propoxy]phenyl}-N-ethyl-N-methylimidoforamide, (A63) N-ethyl-N-methyl-N'-{2-methyl-5-(trifluoromethyl)-4-[3-(trimethylsilyl)propoxy]phenyl} imidoforamide, (A64) O-[1-(4-methoxyphenoxy)-3,3-dimethylbutan-2-yl]-1H-imidazole-1-carbothioate, (A65) Pyrisoxazole, (A66) 2-{[3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-2,4-dihydro-3H-1,2,4-triazole-3-thione, (A67) 1-{[3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-1H-1,2,4-triazol-5-yl thiocyanate, (A68) 5-(allylsulfanyl)-1-{[3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-1H-1,2,4-triazole, (A69) 2-[1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-1,2,4-triazole-3-thione, (A70) 2-{[rel(2R,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl) oxiran-2-yl]methyl}-2,4-dihydro-3H-1,2,4-triazole-3-thione, (A71) 2-{[rel(2R,3R)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-2,4-dihydro-3H-1,2,4-triazole-3-thione, (A72) 1-{[rel(2R,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-1H-1,2,4-triazol-5-yl thiocyanate, (A73) 1-{[rel(2R,3R)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-1H-1,2,4-triazol-5-yl thiocyanate, (A74) 5-(allylsulfanyl)-1-{[rel(2R,3S)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-1H-1,2,4-triazole, (A75) 5-(allylsulfanyl)-1-{[rel(2R,3R)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl) oxiran-2-yl]methyl}-1H-1,2,4-triazole, (A76) 2-[(2S,4S,5S)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-1,2,4-triazole-3-thione, (A77) 2-[(2R,4S,5S)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-1,2,4-triazole-3-thione, (A78) 2-[(2R,4R,5R)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-1,2,4-triazole-3-thione, (A79) 2-[(2S,4R,5R)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-1,2,4-triazole-3-thione, (A80) 2-[(2S,4S,5R)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-1,2,4-triazole-3-thione, (A81) 2-[(2R,4S,5R)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-1,2,4-triazole-3-thione, (A82) 2-[(2R,4R,5S)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-1,2,4-triazole-3-thione, (A83) 2-[(2S,4R,5S)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-1,2,4-triazole-3-thione, (A84) 2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol, (A85) 2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)butan-2-ol, (A86) 2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)pentan-2-ol, (A87) 2-[2-chloro-4-(4-chlorophenoxy)phenyl]-1-(1H-1,2,4-triazol-1-yl)butan-2-ol, (A88) 2-[2-chloro-4-(2,4-dichlorophenoxy)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol, (A89) (2R)-2-(1-chlorocyclopropyl)-4-

- [(1R)-2,2-dichlorocyclopropyl]-1-(1H-1,2,4-triazol-1-yl)butan-2-ol, (A90) (2R)-2-(1-chlorocyclopropyl)-4-[(1S)-2,2-dichlorocyclopropyl]-1-(1H-1,2,4-triazol-1-yl)butan-2-ol, (A91) (2S)-2-(1-chlorocyclopropyl)-4-[(1S)-2,2-dichlorocyclopropyl]-1-(1H-1,2,4-triazol-1-yl)butan-2-ol, (A92) (2S)-2-(1-chlorocyclopropyl)-4-[(1R)-2,2-dichlorocyclopropyl]-1-(1H-1,2,4-triazol-1-yl)butan-2-ol, (A93) (1S,2R,5R)-5-(4-chlorobenzyl)-2-(chloromethyl)-2-methyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentanol, (A94) (1R,2S,5S)-5-(4-chlorobenzyl)-2-(chloromethyl)-2-methyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentanol, (A95) 5-(4-chlorobenzyl)-2-(chloromethyl)-2-methyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentanol.
- 10B) Inhibitors of the respiratory chain at complex I or II, for example (B01) bixafen, (B02) boscalid, (B03) carboxin, (B04) cypropanamide, (B05) diflufenican, (B06) fenfuram, (B07) fluopyram, (B08) flutolanil, (B09) fluxapyroxad, (B10) furametpyr, (B11) furmecyclox, (B12) isopyrazam (mixture of syn-epimeric racemate 1RS,4SR,9RS and anti-epimeric racemate 1RS,4SR,9SR), (B13) isopyrazam (anti-epimeric racemate 1RS,4SR,9SR), (B14) isopyrazam (anti-epimeric enantiomer 1R,4S,9S), (B15) isopyrazam (anti-epimeric enantiomer 1S,4R,9R), (B16) isopyrazam (syn-epimeric racemate 1RS,4SR,9RS), (B17) isopyrazam (syn-epimeric enantiomer 1R,4S,9R), (B18) isopyrazam (syn-epimeric enantiomer 1S,4R,9S), (B19) mepronil, (B20) oxycarboxin, (B21) penflufen, (B22) penthiopyrad, (B23) pydiflumetofen, (B24) sedaxane, (B25) thifluzamide, (B26) 1-methyl-N-[2-(1,1,2,2-tetrafluoroethoxy)phenyl]-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide, (B27) 3-(difluoromethyl)-1-methyl-N-[2-(1,1,2,2-tetrafluoroethoxy)phenyl]-1H-pyrazole-4-carboxamide, (B28) 3-(difluoromethyl)-N-[4-fluoro-2-(1,1,2,3,3,3-hexafluoropropoxy)phenyl]-1-methyl-1H-pyrazole-4-carboxamide, (B29) N-[1-(2,4-dichlorophenyl)-1-methoxypropan-2-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, (B30) 5,8-difluoro-N-[2-(2-fluoro-4-{4-(trifluoromethyl)pyridin-2-yl}oxy}phenyl)ethyl]quinazolin-4-amine, (B31) benzovindiflupyr, (B32) N-[(1S,4R)-9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, (B33) N-[(1R,4S)-9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, (B34) 3-(difluoromethyl)-1-methyl-N-(1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)-1H-pyrazole-4-carboxamide, (B35) 1,3,5-trimethyl-N-(1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)-1H-pyrazole-4-carboxamide, (B36) 1-methyl-3-(trifluoromethyl)-N-(1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)-1H-pyrazole-4-carboxamide, (B37) 1-methyl-3-(trifluoromethyl)-N-[(3R)-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1H-pyrazole-4-carboxamide, (B38) 1-methyl-3-(trifluoromethyl)-N-[(3S)-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1H-pyrazole-4-carboxamide, (B39) 3-(difluoromethyl)-1-methyl-N-[(3S)-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1H-pyrazole-4-carboxamide, (B40) 3-(difluoromethyl)-1-methyl-N-[(3R)-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-

- yl]-1H-pyrazole-4-carboxamide, (B41) 1,3,5-trimethyl-N-[(3R)-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1H-pyrazole-4-carboxamide, (B42) 1,3,5-trimethyl-N-[(3S)-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1H-pyrazole-4-carboxamide, (B43) benodanil, (B44) 2-chloro-N-(1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)pyridine-3-carboxamide, (B45) Isofetamid, (B46) 1-methyl-3-(trifluoromethyl)-N-[2'-(trifluoromethyl)biphenyl-2-yl]-1H-pyrazole-4-carboxamide, (B47) N-(4'-chlorobiphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, (B48) N-(2',4'-dichlorobiphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, (B49) 3-(difluoromethyl)-1-methyl-N-[4'-(trifluoromethyl)biphenyl-2-yl]-1H-pyrazole-4-carboxamide, (B50) N-(2',5'-difluorobiphenyl-2-yl)-1-methyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide, (B51) 3-(difluoromethyl)-1-methyl-N-[4'-(prop-1-yn-1-yl)biphenyl-2-yl]-1H-pyrazole-4-carboxamide, (B52) 5-fluoro-1,3-dimethyl-N-[4'-(prop-1-yn-1-yl)biphenyl-2-yl]-1H-pyrazole-4-carboxamide, (B53) 2-chloro-N-[4'-(prop-1-yn-1-yl)biphenyl-2-yl]nicotinamide, (B54) 3-(difluoromethyl)-N-[4'-(3,3-dimethylbut-1-yn-1-yl)biphenyl-2-yl]-1-methyl-1H-pyrazole-4-carboxamide, (B55) N-[4'-(3,3-dimethylbut-1-yn-1-yl)biphenyl-2-yl]-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide, (B56) 3-(difluoromethyl)-N-(4'-ethynylbiphenyl-2-yl)-1-methyl-1H-pyrazole-4-carboxamide, (B57) N-(4'-ethynylbiphenyl-2-yl)-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide, (B58) 2-chloro-N-(4'-ethynylbiphenyl-2-yl)nicotinamide, (B59) 2-chloro-N-[4'-(3,3-dimethylbut-1-yn-1-yl)biphenyl-2-yl]nicotinamide, (B60) 4-(difluoromethyl)-2-methyl-N-[4'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-5-carboxamide, (B61) 5-fluoro-N-[4'-(3-hydroxy-3-methylbut-1-yn-1-yl)biphenyl-2-yl]-1,3-dimethyl-1H-pyrazole-4-carboxamide, (B62) 2-chloro-N-[4'-(3-hydroxy-3-methylbut-1-yn-1-yl)biphenyl-2-yl]nicotinamide, (B63) 3-(difluoromethyl)-N-[4'-(3-methoxy-3-methylbut-1-yn-1-yl)biphenyl-2-yl]-1-methyl-1H-pyrazole-4-carboxamide, (B64) 5-fluoro-N-[4'-(3-methoxy-3-methylbut-1-yn-1-yl)biphenyl-2-yl]-1,3-dimethyl-1H-pyrazole-4-carboxamide, (B65) 2-chloro-N-[4'-(3-methoxy-3-methylbut-1-yn-1-yl)biphenyl-2-yl]nicotinamide, (B66) 1,3-dimethyl-N-(1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)-1H-pyrazole-4-carboxamide, (B67) 1,3-dimethyl-N-[(3R)-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1H-pyrazole-4-carboxamide, (B68) 1,3-dimethyl-N-[(3S)-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1H-pyrazole-4-carboxamide, (B69) 3-(difluoromethyl)-N-methoxy-1-methyl-N-[1-(2,4,6-trichlorophenyl)propan-2-yl]-1H-pyrazole-4-carboxamide, (B70) 3-(difluoromethyl)-N-(7-fluoro-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)-1-methyl-1H-pyrazole-4-carboxamide, (B71) 3-(difluoromethyl)-N-[(3R)-7-fluoro-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1-methyl-1H-pyrazole-4-carboxamide, (B72) 3-(difluoromethyl)-N-[(3S)-7-fluoro-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1-methyl-1H-pyrazole-4-carboxamide.

C) Inhibitors of the respiratory chain at complex III, for example (C01)

- 35 ametocetradin, (C02) amisulbrom, (C03) azoxystrobin, (C04) cyazofamid, (C05) coumethoxystrobin, (C06) coumoxystrobin, (C07) dimoxystrobin, (C08) enoxastrobin, (C09) famoxadone, (C10)

fenamidone, (C11) fenaminstrobin, (C12) flufenoxystrobin, (C13) fluoxastrobin, (C14) kresoxim-methyl, (C15) metominostrobin, (C16) mandestrobin, (C17) orysastrobin, (C18) picoxystrobin, (C19) pyraclostrobin, (C20) pyrametostrobin, (C21) pyraoxystrobin, (C22) pyribencarb, (C23) triclopyricarb, (C24) trifloxystrobin, (C25) (2E)-2-(2-{{6-(3-chloro-2-methylphenoxy)-5-fluoropyrimidin-4-yl}oxy}phenyl)-2-(methoxyimino)-N-methylacetamide, (C26) (2E)-2-(methoxyimino)-N-methyl-2-(2-{{((1E)-1-[3-(trifluoromethyl)phenyl]ethylidene} amino)oxy)methyl} phenyl) acetamide, (C27) (2E)-2-(methoxyimino)-N-methyl-2-{2-[(E)-({1-[3-(trifluoromethyl)phenyl]ethoxy}imino)methyl]phenyl}acetamide, (C28) (2E)-2-{2-[[{(1E)-1-(3-{{(E)-1-fluoro-2-phenylvinyl}oxy} phenyl)ethylidene] amino}oxy)methyl]phenyl}-2-(methoxyimino)-N-methylacetamide, (C29) Fenaminostrobin, (C30) 5-methoxy-2-methyl-4-(2-{{((1E)-1-[3-(trifluoromethyl)phenyl]ethylidene} amino)oxy)methyl} phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one, (C31) methyl (2E)-2-{2-[(cyclopropyl[(4-methoxyphenyl)imino]methyl)sulfanyl)methyl]phenyl}-3-methoxyacrylate, (C32) N-(3-ethyl-3,5,5-trimethylcyclohexyl)-3-formamido-2-hydroxybenzamide, (C33) 2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-methoxy-N-methylacetamide, (C34) 2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-methoxy-N-methylacetamide, (C35) (2E,3Z)-5-{{1-(4-chlorophenyl)-1H-pyrazol-3-yl}oxy}-2-(methoxyimino)-N,3-dimethylpent-3-enamide.

D) Inhibitors of the mitosis and cell division, for example (D01) benomyl, (D02) carbendazim, (D03) chlorfenazole, (D04) diethofencarb, (D05) ethaboxam, (D06) fluopicolide, (D07) fiiberidazole, (D08) pencycuron, (D09) thiabendazole, (D10) thiophanate-methyl, (D11) thiophanate, (D12) zoxamide, (D13) 5-chloro-7-(4-methylpiperidin-1-yl)-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine, (D14) 3-chloro-5-(6-chloropyridin-3-yl)-6-methyl-4-(2,4,6-trifluorophenyl) pyridazine.

E) Compounds capable to have a multisite action, for example (E01) bordeaux mixture, (E02) captafol, (E03) captan, (E04) chlorothalonil, (E05) copper hydroxide, (E06) copper naphthenate, (E07) copper oxide, (E08) copper oxychloride, (E09) copper(2+) sulfate, (E10) dichlofluanid, (E11) dithianon, (E12) dodine, (E13) dodine free base, (E14) ferbam, (E15) fluorofolpet, (E16) folpet, (E17) guazatine, (E18) guazatine acetate, (E19) iminoctadine, (E20) iminoctadine albesilate, (E21) iminoctadine triacetate, (E22) mancopper, (E23) mancozeb, (E24) maneb, (E25) metiram, (E26) metiram zinc, (E27) oxine- copper, (E28) propamidine, (E29) propineb, (E30) sulfur and sulfur preparations including calcium polysulfide, (E31) thiram, (E32) tolylfluanid, (E33) zineb, (E34) ziram, (E35) anilazine.

F) Compounds capable to induce a host defence, for example (F01) acibenzolar-S-methyl, (F02) isotianil, (F03) probenazole, (F04) tiadinil, (F05) laminarin.

- G) Inhibitors of the amino acid and/or protein biosynthesis, for example (G01) andoprim, (G02) blasticidin-S, (G03) cyprodinil, (G04) kasugamycin, (G05) kasugamycin hydrochloride hydrate, (G06) mepanipyrin, (G07) pyrimethanil, (G08) 3-(5-fluoro-3,3,4,4-tetramethyl-3,4-dihydroisoquinolin-1-yl)quinoline, (G09) oxytetracycline, (G10) streptomycin.
- 5
- H) Inhibitors of the ATP production, for example (H01) fentin acetate, (H02) fentin chloride, (H03) fentin hydroxide, (H04) silthiofam.
- I) Inhibitors of the cell wall synthesis, for example (I01) benthiavalicarb, (I02) dimethomorph, (I03) flumorph, (I04) iprovalicarb, (I05) mandipropamid, (I06) polyoxins, (I07) polyoxorim, (I08) validamycin A, (I09) valifenalate, (I10) polyoxin B, (I11) (2E)-3-(4-tert-butylphenyl)-3-(2-chloropyridin-4-yl)-1-(morpholin-4-yl)prop-2-en-1-one, (I12) (2Z)-3-(4-tert-butylphenyl)-3-(2-chloropyridin-4-yl)-1-(morpholin-4-yl)prop-2-en-1-one.
- 10
- 15J) Inhibitors of the lipid and membrane synthesis, for example (J01) biphenyl, (J02) chloroneb, (J03) dicloran, (J04) edifenphos, (J05) etridiazole, (J06) iodocarb, (J07) iprobenfos, (J08) isoprothiolane, (J09) propamocarb, (J10) propamocarb hydrochloride, (J11) prothiocarb, (J12) pyrazophos, (J13) quintozone, (J14) tecnazene, (J15) toclofos-methyl.
- 20K) Inhibitors of the melanin biosynthesis, for example (K01) carpropamid, (K02) diclocymet, (K03) fenoxanil, (K04) phthalide, (K05) pyroquilon, (K06) tolprocarb, (K07) tricyclazole.
- L) Inhibitors of the nucleic acid synthesis, for example (L01) benalaxyl, (L02) benalaxyl-M (kiralaxyl), (L03) bupirimate, (L04) clozylacon, (L05) dimethirimol, (L06) ethirimol, (L07) furalaxyl, (L08) hymexazol, (L09) metalaxyl, (L10) metalaxyl-M (mefenoxam), (L11) ofurace, (L12) oxadixyl, (L13) oxolinic acid, (L14) octhilonone.
- 25
- M) Inhibitors of the signal transduction, for example (M01) chlozolate, (M02) fenpiclonil, (M03) fludioxonil, (M04) iprodione, (M05) procymidone, (M06) quinoxifen, (M07) vinclozolin, (M08) proquinazid.
- 30
- N) Compounds capable to act as an uncoupler, for example (N01) binapacryl, (N02) dinocap, (N03) ferimzone, (N04) fluazinam, (N05) meptyldinocap.
- 35O) Further compounds, for example (O01) benthiazole, (O02) bethoxazin, (O03) capsimycin, (O04) carvone, (O05) chinomethionat, (O06) pyriofenone (chlazafenone), (O07) cufraneb, (O08)

- cyflufenamid, (O09) cymoxanil, (O10) cyprosulfamide, (O11) dazomet, (O12) debacarb, (O13) dichlorophen, (O14) dichlobentiazox, (O15) diclomezine, (O16) difenzoquat, (O17) difenzoquat metilsulfate, (O18) diphenylamine, (O19) ecomate, (O20) fenpyrazamine, (O21) fenhexamine, (O22) flumetover, (O23) fluoroimide, (O24) flusulfamide, (O25) flutianil, (O26) fosetyl-aluminium, (O27) 5 fosetyl-calcium, (O28) fosetyl-sodium, (O29) hexachlorobenzene, (O30) irumamycin, (O31) isothianil, (O32) methasulfocarb, (O33) methyl isothiocyanate, (O34) metrafenone, (O35) mildiomyacin, (O36) natamycin, (O37) nickel dimethyldithiocarbamate, (O38) nitrothal-isopropyl, (O39) oxamocarb, (O40) oxyfenthiiin, (O41) pentachlorophenol and salts, (O42) phenothrin, (O43) picarbutrazox (O44) phosphorous acid and its salts, (O45) propamocarb-fosetilate, (O46) 10 propanosine-sodium, (O47) pyrimorph, (O48) pyraziflumid (O49) pyrrolnitrine, (O50) tebufloquin, (O51) tecloftalam, (O52) tolnifanide, (O53) triazoxide, (O54) trichlamide, (O55) zarilamid, (O56) (3S,6S,7R,8R)-8-benzyl-3-[(3-[(isobutyryloxy)methoxy]-4-methoxypyridin-2-yl)carbonyl]amino]-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl 2-methylpropanoate, (O57) 1-(4-{4-[(5R)-5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone, (O58) 1-(4-{4-[(5S)-5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone, (O59) 15 oxathiapirolin, (O60) 1-(4-methoxyphenoxy)-3,3-dimethylbutan-2-yl-1H-imidazole-1-carboxylate, (O61) 2,3,5,6-tetrachloro-4-(methylsulfonyl)pyridine, (O62) 2,3-dibutyl-6-chlorothieno[2,3-d]pyrimidin-4(3H)-one, (O63) 2,6-dimethyl-1H,5H-[1,4]dithiino[2,3-c:5,6-c']dipyrrole-1,3,5,7(2H,6H)-tetrone, (O64) 2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-(4-{4-[(5R)-5-phenyl-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)ethanone, (O65) 2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-(4-{4-[(5S)-5-phenyl-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)ethanone, (O66) 2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-(4-{4-(5-phenyl-4,5-dihydro-1,2-oxazol-3-yl)-1,3-thiazol-2-yl}piperidin-1-yl)ethanone, (O67) 2-butoxy-6-iodo-3-propyl-4H-chromen-4-one, (O68) 2-chloro-5-[2-chloro-1-(2,6-difluoro-4-methoxyphenyl)-4-methyl-1H-imidazol-5-yl]pyridine, (O69) 2-phenylphenol and salts, (O70) 3-(4,4,5-trifluoro-3,3-dimethyl-3,4-dihydroisoquinolin-1-yl)quinoline, (O71) 3,4,5-trichloropyridine-2,6-dicarbonitrile, (O72) 3-chloro-5-(4-chlorophenyl)-4-(2,6-difluorophenyl)-6-methylpyridazine, (O73) 4-(4-chlorophenyl)-5-(2,6-difluorophenyl)-3,6-dimethylpyridazine, (O74) 3-chloro-4-(2,6-difluorophenyl)-6-methyl-5-phenylpyridazine, (O75) 5-amino-1,3,4-thiadiazole-2-thiol, (O76) 5-chloro-N'-phenyl-N'-(prop-2-yn-1-yl)thiophene-2-sulfonohydrazide, (O77) 5-fluoro-2-[(4-fluorobenzyl)oxy]pyrimidin-4-amine, (O78) 5-fluoro-2-[(4-methylbenzyl)oxy]pyrimidin-4-amine, (O79) 5-methyl-6-octyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine, (O80) ethyl (2Z)-3-amino-2-cyano-3-phenylacrylate, (O81) N'-(4-{3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl}oxy)-2,5-dimethylphenyl)-N-ethyl-N-methylimidoformamide, (O82) N-(4-chlorobenzyl)-3-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]propanamide, (O83) N-[(4-chlorophenyl)(cyano)methyl]-3-[3-methoxy-4-(prop-2-yn-1-

- yloxy)phenyl]propanamide, (O84) N-[(5-bromo-3-chloropyridin-2-yl)methyl]-2,4-dichloronicotinamide, (O85) N-[1-(5-bromo-3-chloropyridin-2-yl)ethyl]-2,4-dichloronicotinamide, (O86) N-[1-(5-bromo-3-chloropyridin-2-yl)ethyl]-2-fluoro-4-iodonicotinamide, (O87) N-[(E)-[(cyclopropylmethoxy)imino][6-(difluoromethoxy)-2,3-difluorophenyl]methyl]-2-phenylacetamide, (O88) N-[(Z)-[(cyclopropylmethoxy)imino][6-(difluoromethoxy)-2,3-difluorophenyl] methyl]-2-phenylacetamide, (O89) N'-{4-[(3-tert-butyl-4-cyano-1,2-thiazol-5-yl)oxy]-2-chloro-5-methylphenyl}-N-ethyl-N-methylimidofornamide, (O90) N-methyl-2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,3-thiazole-4-carboxamide, (O91) N-methyl-2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-N-[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl]-1,3-thiazole-4-carboxamide, (O92) N-methyl-2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-N-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1,3-thiazole-4-carboxamide, (O93) pentyl {6-[(1-methyl-1H-tetrazol-5-yl)(phenyl)methylene]amino}oxy)methyl]pyridin-2-yl} carbamate, (O94) phenazine-1-carboxylic acid, (O95) quinolin-8-ol, (O96) quinolin-8-ol sulfate (2:1), (O97) tert-butyl {6-[(1-methyl-1H-tetrazol-5-yl)(phenyl)methylene]amino}oxy)methyl]pyridin-2-yl} carbamate, (O98) (5-bromo-2-methoxy-4-methylpyridin-3-yl)(2,3,4-trimethoxy-6-methylphenyl) methanone, (O99) N-[2-(4-{[3-(4-chlorophenyl)prop-2-yn-1-yl]oxy}-3-methoxyphenyl)thyl]-N2-(methylsulfonyl)valinamide, (O100) 4-oxo-4-[(2-phenylethyl)amino]butanoic acid, (O101) but-3-yn-1-yl {6-[(1-methyl-1H-tetrazol-5-yl)(phenyl)methylene]amino}oxy)methyl]pyridin-2-yl} carbamate, (O102) 4-amino-5-fluoropyrimidin-2-ol (tautomeric form: 4-amino-5-fluoropyrimidin-2(1H)-one), (O103) propyl 3,4,5-trihydroxybenzoate, (O104) [3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-1,2-oxazol-4-yl](pyridin-3-yl)methanol, (O105) (S)-[3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-1,2-oxazol-4-yl](pyridin-3-yl)methanol, (O106) (R)-[3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-1,2-oxazol-4-yl](pyridin-3-yl)methanol, (O107) 2-fluoro-6-(trifluoromethyl)-N-(1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)benzamide, (O108) 2-(6-benzylpyridin-2-yl)quinazoline, (O109) 2-[6-(3-fluoro-4-methoxyphenyl)-5-methylpyridin-2-yl]quinazoline, (O110) 3-(4,4-difluoro-3,3-dimethyl-3,4-dihydroisoquinolin-1-yl)quinoline, (O111) Absciscic acid, (O112) N'-[5-bromo-6-(2,3-dihydro-1H-inden-2-yloxy)-2-methylpyridin-3-yl]-N-ethyl-N-methylimidofornamide, (O113) N'-{5-bromo-6-[1-(3,5-difluorophenyl)ethoxy]-2-methylpyridin-3-yl}-N-ethyl-N-methylimidofornamide, (O114) N'-{5-bromo-6-[(1R)-1-(3,5-difluorophenyl)ethoxy]-2-methylpyridin-3-yl}-N-ethyl-N-methylimidofornamide, (O115) N'-{5-bromo-6-[(1S)-1-(3,5-difluorophenyl)ethoxy]-2-methylpyridin-3-yl}-N-ethyl-N-methylimidofornamide, (O116) N'-{5-bromo-6-[(cis-4-isopropylcyclohexyl)oxy]-2-methylpyridin-3-yl}-N-ethyl-N-methylimidofornamide, (O117) N'-{5-bromo-6-[(trans-4-isopropylcyclohexyl)oxy]-2-methylpyridin-3-yl}-N-ethyl-N-methylimidofornamide, (O118) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N-(2-isopropylbenzyl)-1-methyl-1H-pyrazole-4-carboxamide, (O119) N-cyclopropyl-N-(2-cyclopropylbenzyl)-3-(difluoromethyl)-5-fluoro-1-methyl-

- 1H-pyrazole-4-carboxamide, (O120) N-(2-tert-butylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (O121) N-(5-chloro-2-ethylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (O122) N-(5-chloro-2-isopropylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (O123) N-cyclopropyl-3-(difluoromethyl)-N-(2-ethyl-5-fluorobenzyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (O124) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N-(5-fluoro-2-isopropylbenzyl)-1-methyl-1H-pyrazole-4-carboxamide, (O125) N-cyclopropyl-N-(2-cyclopropyl-5-fluorobenzyl)-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (O126) N-(2-cyclopentyl-5-fluorobenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (O127) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N-(2-fluoro-6-isopropylbenzyl)-1-methyl-1H-pyrazole-4-carboxamide, (O128) N-cyclopropyl-3-(difluoromethyl)-N-(2-ethyl-5-methylbenzyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (O129) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N-(2-isopropyl-5-methylbenzyl)-1-methyl-1H-pyrazole-4-carboxamide, (O130) N-cyclopropyl-N-(2-cyclopropyl-5-methylbenzyl)-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (O131) N-(2-tert-butyl-5-methylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (O132) N-[5-chloro-2-(trifluoromethyl)benzyl]-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (O133) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-N-[5-methyl-2-(trifluoromethyl)benzyl]-1H-pyrazole-4-carboxamide, (O134) N-[2-chloro-6-(trifluoromethyl)benzyl]-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (O135) N-[3-chloro-2-fluoro-6-(trifluoromethyl)benzyl]-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (O136) N-cyclopropyl-3-(difluoromethyl)-N-(2-ethyl-4,5-dimethylbenzyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide, (O137) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N-(2-isopropylbenzyl)-1-methyl-1H-pyrazole-4-carbothioamide, (O138) N'-(2,5-dimethyl-4-phenoxyphenyl)-N-ethyl-N-methylimidoforamide, (O139) N'-{4-[(4,5-dichloro-1,3-thiazol-2-yl)oxy]-2,5-dimethylphenyl}-N-ethyl-N-methylimidoforamide, (O140) N-(4-chloro-2,6-difluorophenyl)-4-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (O141) 9-fluoro-2,2-dimethyl-5-(quinolin-3-yl)-2,3-dihydro-1,4-benzoxazepine, (O142) 2-{2-fluoro-6-[(8-fluoro-2-methylquinolin-3-yl)oxy]phenyl}propan-2-ol, (O143) 2-{2-[(7,8-difluoro-2-methylquinolin-3-yl)oxy]-6-fluorophenyl}propan-2-ol, (O144) 4-(2-chloro-4-fluorophenyl)-N-(2-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (O145) 4-(2-chloro-4-fluorophenyl)-N-(2,6-difluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (O146) 4-(2-chloro-4-fluorophenyl)-N-(2-chloro-6-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (O147) 4-(2-bromo-4-fluorophenyl)-N-(2-chloro-6-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (O148) N-(2-bromo-6-fluorophenyl)-4-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (O149) 4-(2-bromo-4-fluorophenyl)-N-(2-bromophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (O150) 4-(2-bromo-4-fluorophenyl)-N-(2-bromo-6-fluorophenyl)-1,3-dimethyl-1H-pyrazol-

5-amine, (O151) 4-(2-bromo-4-fluorophenyl)-N-(2-chlorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (O152) N-(2-bromophenyl)-4-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (O153) 4-(2-chloro-4-fluorophenyl)-N-(2-chlorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (O154) 4-(2-bromo-4-fluorophenyl)-N-(2,6-difluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (O155) 4-(2-bromo-4-fluorophenyl)-N-(2-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine, (O156) N'-(4-{3-[(difluoromethyl)sulfanyl]phenoxy}-2,5-dimethylphenyl)-N-ethyl-N-methylimidofomamide, (O157) N'-(2,5-dimethyl-4-{3-[(1,1,2,2-tetrafluoroethyl)sulfanyl]phenoxy}phenyl)-N-ethyl-N-methylimidofomamide, (O158) N'-(2,5-dimethyl-4-{3-[(2,2,2-trifluoroethyl)sulfanyl]phenoxy}phenyl)-N-ethyl-N-methylimidofomamide, (O159) N'-(2,5-dimethyl-4-{3-[(2,2,3,3-tetrafluoropropyl)sulfanyl]phenoxy}phenyl)-N-ethyl-N-methylimidofomamide, (O160) N'-(2,5-dimethyl-4-{3-[(pentafluoroethyl)sulfanyl]phenoxy}phenyl)-N-ethyl-N-methylimidofomamide, (O161) N'-(4-{[3-(difluoromethoxy)phenyl]sulfanyl}-2,5-dimethylphenyl)-N-ethyl-N-methylimidofomamide, (O162) N'-(2,5-dimethyl-4-{[3-(1,1,2,2-tetrafluoroethoxy)phenyl]sulfanyl}phenyl)-N-ethyl-N-methylimidofomamide, (O163) N'-(2,5-dimethyl-4-{[3-(2,2,2-trifluoroethoxy)phenyl]sulfanyl}phenyl)-N-ethyl-N-methylimidofomamide, (O164) N'-(2,5-dimethyl-4-{[3-(2,2,3,3-tetrafluoropropoxy)phenyl]sulfanyl}phenyl)-N-ethyl-N-methylimidofomamide, (O165) N'-(2,5-dimethyl-4-{[3-(pentafluoroethoxy)phenyl]sulfanyl}phenyl)-N-ethyl-N-methylimidofomamide, (O166) 2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]-1-[4-(4-{5-[2-(prop-2-yn-1-yloxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-1-yl]ethanone, (O167) 2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]-1-[4-(4-{5-[2-fluoro-6-(prop-2-yn-1-yloxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-1-yl]ethanone, (O168) 2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]-1-[4-(4-{5-[2-chloro-6-(prop-2-yn-1-yloxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-1-yl]ethanone, (O169) 2-{3-[2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazol-4-yl]-4,5-dihydro-1,2-oxazol-5-yl}phenyl methanesulfonate, (O170) 2-{3-[2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazol-4-yl]-4,5-dihydro-1,2-oxazol-5-yl}-3-chlorophenyl methanesulfonate, (O171) 2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]-1-[4-(4-{(5S)-5-[2-(prop-2-yn-1-yloxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-1-yl]ethanone, (O172) 2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]-1-[4-(4-{(5R)-5-[2-(prop-2-yn-1-yloxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-1-yl]ethanone, (O173) 2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]-1-[4-(4-{(5S)-5-[2-fluoro-6-(prop-2-yn-1-yloxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-1-yl]ethanone, (O174) 2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]-1-[4-(4-{(5R)-5-[2-fluoro-6-(prop-2-yn-1-yloxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-1-yl]ethanone, (O175) 2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]-1-[4-(4-{(5S)-5-[2-chloro-6-(prop-2-yn-1-yloxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-1-yl]ethanone, h(O176) 2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]-1-[4-(4-{(5R)-5-[2-

chloro-6-(prop-2-yn-1-yloxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-1-yl]ethanone, (O177) 2-((5S)-3-[2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazol-4-yl]-4,5-dihydro-1,2-oxazol-5-yl}phenyl methanesulfonate, (O178) 2-((5R)-3-[2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazol-4-yl]-4,5-dihydro-1,2-oxazol-5-yl}phenyl methanesulfonate, (O179) 2-((5S)-3-[2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazol-4-yl]-4,5-dihydro-1,2-oxazol-5-yl}-3-chlorophenyl methanesulfonate, (O180) 2-((5R)-3-[2-(1-{[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-1,3-thiazol-4-yl]-4,5-dihydro-1,2-oxazol-5-yl}-3-chlorophenyl methanesulfonate, (O181) (3S,6S,7R,8R)-8-benzyl-3-{3-[(isobutyryloxy)methoxy]-4-methoxypicolinamido}-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl isobutyrate.

As described above the compound of formula (I) can be mixed with one or more active compatible compound selected from insecticides/acaricides/nematicides class. The active ingredients from the classes of insecticides/acaricides/ nematicides are specified herein by their common names that are known and described, for example in *The Pesticide Manual 17th Ed.*, or can be searched in the internet (e.g. under www.alanwood.net/pesticides).

(1) Acetylcholinesterase (AChE) inhibitors such as carbamates, for example alanycarb, aldicarb, bendiocarb, benfuracarb, butocarboxim, butoxycarboxim, carbaryl, carbofuran, carbosulfan, ethiofencarb, fenobucarb, formetanate, furathiocarb, isoprocarb, methiocarb, methomyl, metolcarb, oxamyl, pirimicarb, propoxur, thiodicarb, thiofanox, triazamate, trimethacarb, XMC and xylylcarb or organophosphates, such as acephate, azamethiphos, azinphos-ethyl, azinphos-methyl, cadusafos, chlorethoxyfos, chlorfenvinphos, chlormephos, chlorpyrifos, chlorpyrifos-methyl, coumaphos, cyanophos, demeton-S-methyl, diazinon, dichlorvos / DDVP, dicrotophos, dimethoate, dimethylvinphos, disulfoton, EPN, ethion, ethoprophos, famphur, fenamiphos, fenitrothion, fenthion, fosthiazate, heptenophos, imicyafos, isofenphos, isopropyl O-(methoxyaminothio-phosphoryl) salicylate, isoxathion, malathion, mecarbam, methamidophos, methidathion, mevinphos, monocrotophos, naled, omethoate, oxydemeton-methyl, parathion, parathion-methyl, phenthoate, phorate, phosalone, phosmet, phosphamidon, phoxim, pirimiphos-methyl, profenofos, propetamphos, prothiofos, pyraclofos, pyridaphenthion, quinalphos, sulfotep, tebupirimfos, temephos, terbufos, tetrachlorvinphos, thiometon, triazophos, trichlorfon and vamidothion.

(2) GABA-gated chloride channel antagonists, such as cyclodiene organochlorines, for example chlordane and endosulfan or phenylpyrazoles (fiproles), for example ethiprole and fipronil.

- (3) Sodium channel modulators / voltage-dependent sodium channel blockers, such as pyrethroids, for example acrinathrin, allethrin, d-*cis-trans* allethrin, d-*trans* allethrin, bifenthrin, bioallethrin, bioallethrin S-cyclopentenyl isomer, bioresmethrin, cycloprothrin, cyfluthrin, beta-cyfluthrin, cyhalothrin, lambda-cyhalothrin, gamma-cyhalothrin, cypermethrin, alpha-cypermethrin, beta-cypermethrin, theta-cypermethrin, zeta-cypermethrin, cyphenothrin [(1R)-*trans*-isomers], deltamethrin, empenethrin [(EZ)-(1R)-isomers], esfenvalerate, etofenprox, fenpropathrin, fenvalerate, flucythrinate, flumethrin, tau-fluvalinate, halfenprox, imiprothrin, kadethrin, momfluorothrin, permethrin, phenothrin [(1R)-*trans*-isomer), prallethrin, pyrethrins (pyrethrum), resmethrin, silafluofen, tefluthrin, tetramethrin, tetramethrin [(1R)-isomers]], tralomethrin and transfluthrin or DDT or methoxychlor.
- (4) Nicotinic acetylcholine receptor (nAChR) competitive modulators, such as neonicotinoids, for example acetamiprid, clothianidin, dinotefuran, imidacloprid, nitenpyram, thiacloprid and thiamethoxam or nicotine or sulfoxaflo or flupyradifurone.
- (5) Nicotinic acetylcholine receptor (nAChR) allosteric modulators, such as spinosyns, for example spinetoram and spinosad.
- (6) Glutamate-gated chloride channel (GluCl) allosteric modulators, such as avermectins / milbemycins, for example abamectin, emamectin benzoate, lepimectin and milbemectin.
- (7) Juvenile hormone mimics such as juvenile hormone analogues, for example hydroprene, kinoprene and methoprene or fenoxycarb or pyriproxyfen.
- (8) Active compounds with unknown or non-specific mechanisms of action, such as alkyl halides for example as methyl bromide and other alkyl halides or chloropicrin or fluorides or borates or tartar emetic or methyl isocyanate generators.
- (9) Chordotonal organ TRPV channel modulators such as pyridine azomethine derivatives, for example pymetrozine and pyrifluquinazon or flonicamid.
- (10) Mite growth inhibitors, for example clofentezine, hexythiazox and diflovidazin or etoxazole.
- (11) Microbial disruptors of insect gut midgut, for example *Bacillus thuringiensis* subspecies *israelensis*, *Bacillus thuringiensis* subspecies *aizawai*, *Bacillus thuringiensis* subspecies *kurstaki*,

Bacillus thuringiensis subspecies *tenebrionis* and *Bacillus sphaericus* and BT crop proteins: Cry1Ab, Cry1Ac, Cry1Fa, Cry1A 105, Cry2Ab, Vip3a, mCry3A, Cry3Ab, Cry3Bb, Cry34Ab1 / Cry35Ab1.

5 (12) Inhibitors of mitochondrial ATP synthase such as organotin miticides, for example azocyclotin, cyhexatin and fenbutatin oxide or diafenthiuron or propargite or tetradifon.

(13) Uncouplers of oxidative phosphorylation acting via disruption of the proton gradient, for example chlorfenapyr, DNOC and sulfluramid.

10 (14) Nicotinic acetylcholine receptor (nAChR) channel blockers, such as bensultap, cartap-hydrochloride, thiocyclam and thiosultap-sodium.

15 (15) Inhibitors of chitin biosynthesis, type 0, such as bistrifluoron, chlorfluazuron, diflubenzuron, flucycloxuron, flufenoxuron, hexaflumuron, lufenuron, novaluron, noviflumuron, teflubenzuron and triflumuron.

(16) Inhibitors of chitin biosynthesis, type 1, such as buprofezin.

20 (17) Molting disruptors (particularly in Dipteran), such as cyromazine.

(18) Ecdysone receptor agonists, such as chromafenozide, halofenozide, methoxyfenozide and tebufenozide.

25 (19) Octopamine receptor agonists, such as amitraz.

(20) Mitochondrial complex III electron transport inhibitors such as hydramethylnon or acequinocyl or fluacrypyrim or bifenazate.

30 (21) Mitochondrial complex I electron transport inhibitors, for example, METI acaricides and insecticides, for example fenazaquin, fenpyroximate, pyrimidifen, pyridaben, tebufenpyrad and tolfenpyrad or rotenone (Derris).

(22) Voltage-dependent sodium channel blockers such as indoxacarb or metaflumizone.

35 (23) Inhibitors of acetyl CoA carboxylase, such as tetronic and tetramic acid derivatives, for example spirodiclofen, spiromesifen and spirotetramat.

(24) Mitochondrial complex IV electron transport inhibitors, such as phosphides, for example aluminum phosphide, calcium phosphide, zinc phosphide and phosphine or cyanides.

- 5 (25) Mitochondrial complex II electron transport inhibitors such as beta-ketonitrile derivatives, for example cyenopyrafen and cyflumetofen or carboxanilides.

(28) Ryanodine receptor modulators such as diamides, for example chlorantraniliprole, cyantraniliprole and flubendiamide.

10

(29) Chordotonal organ modulators on undefined target site such as flonicamid.

Further active ingredients with unknown or indeterminate mode of action, such as afidopyropen, afoxolaner, azadirachtin, benclothiaz, benzoximate, bifenazate, broflanilide, bromopropylate, chinomethionat, cryolite, cyclaniliprole, cycloxaprid, cyhalodiamide, dicloromezotiaz, dicofol, diflovidazin, flometoquin, fluazaindolizine, fluensulfone, flufenerim, flufenoxystrobin, flufiprole, fluhexafon, fluopyram, fluralaner, fluxametamide, fufenozide, guadipyr, heptafluthrin, imidaclothiz, iprodione, lotilaner, meperfluthrin, paichongding, pyflubumide, pyridalyl, pyrifluquinazon, pyriminostrobin, sarolaner, tetramethylfluthrin, tetraniliprole, tetrachlorantraniliprole, tioxazafen, triflumezopyrim and iodomethane; furthermore, preparations based on *Bacillus firmus* (I-1582,

- 20 BioNeem, Votivo), and the following known active compounds: 1-{2-fluoro-4-methyl-5-[(2,2,2-trifluoroethyl)sulfinyl]phenyl}-3-(trifluoromethyl)-1H-1,2,4-triazol-5-amine (known from WO2006043635), {1'-[(2E)-3-(4-chlorophenyl)prop-2-ene-1-yl]-5-fluorospiro[indole-3,4'-piperidine]-1(2H)-yl}(2-chloropyridin-4-yl)methanone (known from WO2003106457), 2-chloro-N-[2-{1-[(2E)-3-(4-chlorophenyl)prop-2-en-1-yl]piperidin-4-yl}-4-(trifluoromethyl)phenyl]isonicotinamide (known from WO2006003494), 3-(2,5-dimethylphenyl)-4-hydroxy-8-methoxy-1,8-diazaspiro[4.5]dec-3-en-2-one (known from WO2009049851), 3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1,8-diazaspiro[4.5]dec-3-en-4-yl ethylcarbonate (known from WO2009049851), 4-(but-2-in-1-yloxy)-6-(3,5-dimethylpiperidin-1-yl)-5-fluoropyrimidine (known from WO2004099160), 4-(but-2-in-1-yloxy)-6-(3-chlorophenyl)pyrimidine (known from WO2003076415), PF1364 (CAS-Reg.No. 1204776-60-2), methyl-2-[2-({[3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-yl]carbonyl}amino)-5-chloro-3-methylbenzoyl]-2-methylhydrazincarboxylate (known from WO2005085216), methyl-2-[2-({[3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-yl]carbonyl}amino)-5-cyano-3-methylbenzoyl]-2-ethylhydrazincarboxylate (known from WO2005085216), methyl-2-[2-({[3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-yl]carbonyl}amino)-5-cyano-3-methylbenzoyl]-2-methylhydrazincarboxylate (known from WO2005085216), methyl-2-[3,5-dibromo-2-({[3-bromo-1-(3-chloro-pyridin-2-yl)-1H-pyrazol-5-yl]carbonyl}amino)benzoyl]-2-ethylhydrazincarboxylate
- 35

(known from WO2005085216), N-[2-(5-amino-1,3,4-thiadiazol-2-yl)-4-chloro-6-methylphenyl]-3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazole-5-carboxamide (known from CN102057925), 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-methyl-N-(1-oxidothietan-3-yl)benzamide (known from WO2009080250), N-[(2E)-1-[(6-chloropyridine-3-yl)methyl]pyridin-2(1H)-ylidene]-2,2,2-trifluoroacetamide (known from WO2012029672), 1-[(2-chloro-1,3-thiazol-5-yl)methyl]-4-oxo-3-phenyl-4H-pyrido[1,2-a]pyrimidin-1-ium-2-olate (known from WO2009099929), 1-[(6-chloropyridin-3-yl)methyl]-4-oxo-3-phenyl-4H-pyrido[1,2-a]pyrimidin-1-ium-2-olate (known from WO2009099929), 4-(3-{2,6-dichloro-4-[(3,3-dichloroprop-2-en-1-yl)oxy]phenoxy}propoxy)-2-methoxy-6-(trifluoromethyl)pyrimidine (known from CN101337940), N-[2-(*tert*-butylcarbamoyl)-4-chloro-6-methylphenyl]-1-(3-chloropyridin-2-yl)-3-(fluoromethoxy)-1H-pyrazole-5-carboxamide (known from WO2008134969), butyl-[2-(2,4-dichlorophenyl)-3-oxo-4-oxaspiro[4.5]dec-1-en-1-yl]carbonate (disclosed in CN102060818), 3(E)-3-[1-[(6-chloro-3-pyridyl)methyl]-2-pyridyliden]-1,1,1-trifluoropropan-2-one (known from WO2013144213), N-(methylsulfonyl)-6-[2-(pyridin-3-yl)-1,3-thiazol-5-yl]pyridine-2-carboxamide (known from WO2012000896), N-[3-(benzylcarbamoyl)-4-chlorophenyl]-1-methyl-3-(pentafluoroethyl)-4-(trifluoromethyl)-1H-pyrazole-5-carboxamide (known from WO2010051926).

The compounds of formula (I) may be used to treat several fungal pathogens. Non-limiting examples of pathogens of fungal diseases which can be treated in accordance with the invention include:

diseases caused by powdery mildew pathogens, for example *Blumeria* species, for example *Blumeria graminis*; *Podosphaera* species, for example *Podosphaera leucotricha*; *Sphaerotheca* species, for example *Sphaerotheca fuliginea*; *Uncinula* species, for example *Uncinula necator*; *Erysiphe* species, for example *Erysiphe cichoracearu*;

diseases caused by rust disease pathogens, for example *Gymnosporangium* species, for example *Gymnosporangium sabinae*; *Hemileia* species, for example *Hemileia vastatrix*; *Phakopsora* species, for example *Phakopsora pachyrhizi* or *Phakopsora meibomia*; *Puccinia* species, for example *Puccinia recondita*, *Puccinia graminis* oder *Puccinia striiformis*; *Uromyces* species, for example *Uromyces appendiculatus*;

diseases caused by pathogens from the group of the Oomycetes, for example *Albugo* species, for example *Albugo candida*; *Bremia* species, for example *Bremia lactucae*; *Peronospora* species, for example *Peronospora pisi* or *P. brassicae*; *Phytophthora* species, for example *Phytophthora infestans*; *Plasmopara* species, for example *Plasmopara viticola*; *Pseudoperonospora* species, for example *Pseudoperonospora humuli* or *Pseudoperonospora cubensis*; *Pythium* species, for example *Pythium ultimum*;

leaf blotch diseases and leaf wilt diseases caused, for example, by *Alternaria* species, for example *Alternaria solani*; *Cercospora* species, for example *Cercospora beticola*; *Cladosporium* species, for example *Cladosporium cucumerinum*; *Cochliobolus* species, for example *Cochliobolus sativus* (conidial form: *Drechslera*, syn: *Helminthosporium*) or *Cochliobolus miyabeanus*; *Colletotrichum* species, for example *Colletotrichum lindemuthianum*; *Cycloconium* species, for example *Cycloconium oleaginum*; *Diaporthe* species, for example *Diaporthe citri*; *Elsinoe* species, for example *Elsinoe fawcettii*; *Gloeosporium* species, for example *Gloeosporium laeticolor*; *Glomerella* species, for example *Glomerella cingulata*; *Guignardia* species, for example *Guignardia bidwelli*; *Leptosphaeria* species, for example *Leptosphaeria maculans*; *Magnaporthe* species, for example *Magnaporthe grisea*; *Microdochium* species, for example *Microdochium nivale*; *Mycosphaerella* species, for example *Mycosphaerella graminicola*, *Mycosphaerella arachidicola* or *Mycosphaerella fijiensis*; *Phaeosphaeria* species, for example *Phaeosphaeria nodorum*; *Pyrenophora* species, for example *Pyrenophora teres* or *Pyrenophora tritici repentis*; *Ramularia* species, for example *Ramularia collo-cygni* or *Ramularia areola*; *Rhynchosporium* species, for example *Rhynchosporium secalis*; *Septoria* species, for example *Septoria apii* or *Septoria lycopersici*; *Stagonospora* species, for example *Stagonospora nodorum*; *Typhula* species, for example *Typhula incarnata*; *Venturia* species, for example *Venturia inaequalis*;

root and stem diseases caused, for example, by *Corticium* species, for example *Corticium graminearum*; *Fusarium* species, for example *Fusarium oxysporum*; *Gaeumannomyces* species, for example *Gaeumannomyces graminis*; *Plasmidiophora* species, for example *Plasmidiophora brassicae*; *Rhizoctonia* species, for example *Rhizoctonia solani*; *Sarocladium* species, for example *Sarocladium oryzae*; *Sclerotium* species, for example *Sclerotium oryzae*; *Tapesia* species, for example *Tapesia acuformis*; *Thielaviopsis* species, for example *Thielaviopsis basicola*; *Ganoderma* species, for example *Ganoderma lucidum*;

ear and panicle diseases (including corn cobs) caused, for example, by *Alternaria* species, for example *Alternaria spp.*; *Aspergillus* species, for example *Aspergillus flavus*; *Cladosporium* species, for example *Cladosporium cladosporioides*; *Claviceps* species, for example *Claviceps purpurea*; *Fusarium* species, for example *Fusarium culmorum*; *Gibberella* species, for example *Gibberella zeae*; *Monographella* species, for example *Monographella nivalis*; *Stagnospora* species, for example *Stagnospora nodorum*;

diseases caused by smut fungi, for example *Sphacelotheca* species, for example *Sphacelotheca reiliana*; *Tilletia* species, for example *Tilletia caries* or *Tilletia controversa*; *Urocystis* species, for example *Urocystis occulta*; *Ustilago* species, for example *Ustilago nuda*;

fruit rot caused, for example, by *Aspergillus* species, for example *Aspergillus flavus*; *Botrytis* species, for example *Botrytis cinerea*; *Penicillium* species, for example *Penicillium expansum* or *Penicillium purpurogenum*; *Rhizopus* species, for example *Rhizopus stolonifer*; *Sclerotinia* species, for example *Sclerotinia sclerotiorum*; *Verticillium* species, for example *Verticillium alboatrum*;

- 5 seed- and soil-borne rot and wilt diseases, and also diseases of seedlings, caused, for example, by *Alternaria* species, for example *Alternaria brassicicola*; *Aphanomyces* species, for example *Aphanomyces euteiches*; *Ascochyta* species, for example *Ascochyta lentis*; *Aspergillus* species, for example *Aspergillus flavus*; *Cladosporium* species, for example *Cladosporium herbarum*; *Cochliobolus* species, for example *Cochliobolus sativus* (conidial form: *Drechslera*, *Bipolaris* Syn: Helminthosporium); *Colletotrichum* species, for example *Colletotrichum coccodes*; *Fusarium* species, for example *Fusarium culmorum*; *Gibberella* species, for example *Gibberella zeae*; *Macrophomina* species, for example *Macrophomina phaseolina*; *Microdochium* species, for example *Microdochium nivale*; *Monographella* species, for example *Monographella nivalis*; *Penicillium* species, for example *Penicillium expansum*; *Phoma* species, for example *Phoma lingam*; *Phomopsis* species, for example *Phomopsis sojae*; *Phytophthora* species, for example *Phytophthora cactorum*; *Pyrenophora* species, for example *Pyrenophora graminea*; *Pyricularia* species, for example *Pyricularia oryzae*; *Pythium* species, for example *Pythium ultimum*; *Rhizoctonia* species, for example *Rhizoctonia solani*; *Rhizopus* species, for example *Rhizopus oryzae*; *Sclerotium* species, for example *Sclerotium rolfsii*; *Septoria* species, for example *Septoria nodorum*; *Typhula* species, for example *Typhula incarnata*; *Verticillium* species, for example *Verticillium dahliae*;

cancers, galls and witches' broom caused, for example, by *Nectria* species, for example *Nectria galligena*;

wilt diseases caused, for example, by *Monilinia* species, for example *Monilinia laxa*;

- 25 deformations of leaves, flowers and fruits caused, for example, by *Exobasidium* species, for example *Exobasidium vexans*; *Taphrina* species, for example *Taphrina deformans*;

degenerative diseases in woody plants, caused, for example, by *Esca* species, for example *Phaeomoniella chlamydospora*, *Phaeoacremonium aleophilum* or *Fomitiporia mediterranea*; *Ganoderma* species, for example *Ganoderma boninense*;

diseases of flowers and seeds caused, for example, by *Botrytis* species, for example *Botrytis cinerea*;

- 30 diseases of plant tubers caused, for example, by *Rhizoctonia* species, for example *Rhizoctonia solani*; *Helminthosporium* species, for example *Helminthosporium solani*;

diseases caused by bacterial pathogens, for example *Xanthomonas* species, for example *Xanthomonas campestris* pv. *oryzae*; *Pseudomonas* species, for example *Pseudomonas syringae* pv. *lachrymans*; *Erwinia* species, for example *Erwinia amylovora*; *Ralstonia* species, for example *Ralstonia solanacearum*;

- 5 Fungal diseases on roots and the stem base caused, for example, by black root rot (*Calonectria crotalariae*), charcoal rot (*Macrophomina phaseolina*), fusarium blight or wilt, root rot, and pod and collar rot (*Fusarium oxysporum*, *Fusarium orthoceras*, *Fusarium semitectum*, *Fusarium equiseti*), mycoleptodiscus root rot (*Mycoleptodiscus terrestris*), neocosmospora (*Neocosmospora vasinfecta*), pod and stem blight (*Diaporthe phaseolorum*), stem canker (*Diaporthe phaseolorum* var. *caulivora*),
10 phytophthora rot (*Phytophthora megasperma*), brown stem rot (*Phialophora gregata*), pythium rot (*Pythium aphanidermatum*, *Pythium irregulare*, *Pythium debaryanum*, *Pythium myriotylum*, *Pythium ultimum*), rhizoctonia root rot, stem decay, and damping-off (*Rhizoctonia solani*), sclerotinia stem decay (*Sclerotinia sclerotiorum*), sclerotinia southern blight (*Sclerotinia rolfsii*), thielaviopsis root rot (*Thielaviopsis basicola*).
- 15 Plants which can be treated in accordance with the invention include the following: *Rosaceae* sp (for example pome fruits such as apples, pears, apricots, cherries, almonds and peaches), *Ribesioideae* sp., *Juglandaceae* sp., *Betulaceae* sp., *Anacardiaceae* sp., *Fagaceae* sp., *Moraceae* sp., *Oleaceae* sp., *Actinidaceae* sp., *Lauraceae* sp., *Musaceae* sp. (for example banana trees and plantations), *Rubiaceae* sp. (for example coffee), *Theaceae* sp., *Sterculiaceae* sp., *Rutaceae* sp. (for example lemons, oranges and
20 grapefruit); *Vitaceae* sp. (for example grapes); *Solanaceae* sp. (for example tomatoes, peppers), *Liliaceae* sp., *Asteraceae* sp. (for example lettuce), *Umbelliferae* sp., *Cruciferae* sp., *Chenopodiaceae* sp., *Cucurbitaceae* sp. (for example cucumber), *Alliaceae* sp. (for example leek, onion), *Papilionaceae* sp. (for example peas); major crop plants, such as *Poaceae*/*Gramineae* sp. (for example maize, turf, cereals such as wheat, rye, rice, barley, oats, millet and triticale), *Asteraceae* sp. (for example sunflower), *Brassicaceae* sp.
25 (for example white cabbage, red cabbage, broccoli, cauliflower, Brussels sprouts, pak choi, kohlrabi, radishes, and oilseed rape, mustard, horseradish and cress), *Fabaceae* sp. (for example bean, peanuts), *Papilionaceae* sp. (for example soya bean), *Solanaceae* sp. (for example potatoes), *Chenopodiaceae* sp. (for example sugar beet, fodder beet, swiss chard, beetroot); *Malvaceae* (for example cotton); useful plants and ornamental plants for gardens and wooded areas; and genetically modified varieties of each of these
30 plants.

All plants and plant parts can be treated in accordance with the invention. Plants are understood here to mean all plants and plant populations, such as desired and undesired wild plants or crop plants (including naturally occurring crop plants). Crop plants may be plants which can be obtained by conventional breeding and optimization methods or by biotechnological and genetic engineering

methods or combinations of these methods, including the transgenic plants and including the plant cultivars which are protectable and non-protectable by plant breeders' rights. Plant parts are understood to mean all parts and organs of plants above and below the ground, such as shoot, leaf, flower and root, examples of which include leaves, needles, stalks, stems, flowers, fruit bodies, fruits and seeds, and also roots, tubers and rhizomes. The plant parts also include harvested material and vegetative and generative propagation material, for example cuttings, tubers, rhizomes, slips and seeds.

The invention furthermore includes a method for treating seed, particularly seeds (dormant, primed, pregerminated or even with emerged roots and leaves) treated with at least one of the compounds of the formula (I) and compositions thereof. The inventive seeds are used in methods for protection of seeds and emerged plants from the seeds from phytopathogenic harmful fungi. In these methods, seed treated with at least one inventive active ingredient is used.

It is also desirable to optimize the amount of the active ingredient used so as to provide the best possible protection for the seeds, the germinating plants and emerged seedlings from attack by phytopathogenic fungi, but without damaging the plants themselves by the active ingredient used. In particular, methods for the treatment of seed should also take into consideration the intrinsic phenotypes of transgenic plants in order to achieve optimum protection of the seed and the germinating plant with a minimum of crop protection compositions being employed.

The present invention therefore also relates to a method for protecting seeds, germinating plants and emerged seedlings against attack by animal pests and/or phytopathogenic harmful microorganisms by treating the seeds with an inventive composition. The invention also relates to the use of the compositions according to the invention for treating seeds for protecting the seeds, the germinating plants and emerged seedlings against animal pests and/or phytopathogenic microorganisms. The invention further relates to seeds which have been treated with an inventive composition for protection from animal pests and/or phytopathogenic microorganisms.

One of the advantages of the present invention is that the treatment of the seeds with these compositions not only protects the seed itself, but also the resulting plants after emergence, from animal pests and/or phytopathogenic harmful microorganisms. In this way, the immediate treatment of the crop at the time of sowing or shortly thereafter protect plants as well as seed treatment in prior to sowing. It is likewise considered to be advantageous that the inventive active ingredients or compositions can be used especially also for transgenic seed, in which case the plant which grows from this seed is capable of expressing a protein which acts against pests, herbicidal damage or abiotic stress. The treatment of such seeds with the inventive active ingredients or compositions, for example

an insecticidal protein, can result in control of certain pests. Surprisingly, a further synergistic effect can be observed in this case, which additionally increases the effectiveness for protection against attack by pests, microorganisms, weeds or abiotic stress.

The compounds of the formula (I) are suitable for protection of seed of any plant variety which is used in agriculture; in the greenhouse, in forests or in horticulture. More particularly, the seed is that of cereals (such as wheat, barley, rye, millet and oats), oilseed rape, maize, cotton, soybean, rice, potatoes, sunflower, beans, coffee, beet (e.g. sugar beet and fodder beet), peanut, vegetables (such as tomato, cucumber, onions and lettuce), lawns and ornamental plants. Of particular significance is the treatment of the seed of wheat, soybean, oilseed rape, maize and rice.

- As also described below, the treatment of transgenic seed with the inventive active ingredients or compositions is of particular significance. This refers to the seed of plants containing at least one heterologous gene which allows the expression of a polypeptide or protein, e.g. having insecticidal properties. These heterologous genes in transgenic seeds may originate, for example, from microorganisms of the species *Bacillus*, *Rhizobium*, *Pseudomonas*, *Serratia*, *Trichoderma*, *Clavibacter*, *Glomus* or *Gliocladium*. These heterologous genes preferably originate from *Bacillus sp.*, in which case the gene product is effective against the European corn borer and/or the Western corn rootworm. Particularly preferably, the heterologous genes originate from *Bacillus thuringiensis*.

- In the context of the present invention, the inventive composition is applied to seeds either alone or in a suitable formulation. Preferably, the seed is treated in a state in which it is sufficiently stable for no damage to occur in the course of treatment. In general, seeds can be treated at any time between harvest and some time after sowing. It is customary to use seed which has been separated from the plant and freed from cobs, shells, stalks, coats, hairs or the flesh of the fruits. For example, it is possible to use seed which has been harvested, cleaned and dried down to a moisture content of less than 15% by weight. Alternatively, it is also possible to use seed which, after drying, for example, has been treated with water and then dried again, or seeds just after priming, or seeds stored in primed conditions or pre-germinated seeds, or seeds sown on nursery trays, tapes or paper.

- When treating the seeds, it generally has to be ensured that the amount of the inventive composition applied to the seed and/or the amount of further additives is selected such that the germination of the seed is not impaired, or that the resulting plant is not damaged. This must be ensured particularly in the case of active ingredients which can exhibit phytotoxic effects at certain application rates.

The compounds of the formula (I) can be applied directly, i.e. without containing any other components and without having been diluted. In general, it is preferable to apply the compositions to

the seed in the form of a suitable formulation. Suitable formulations and methods for seed treatment are known to those skilled in the art. The compounds of the formula (I) can be converted to the customary formulations relevant to on-seed applications, such as solutions, emulsions, suspensions, powders, foams, slurries or combined with other coating compositions for seed, such as film forming materials, pelleting materials, fine iron or other metal powders, granules, coating material for inactivated seeds, and also ULV formulations.

In the treatment of seeds to facilitate plantability seeds can be coated with polymer. The polymer coating is comprised of a binder, a wax and a pigment, and one or more stabilizers in an amount effective to stabilize the suspension. The binder can be a polymer selected from the group consisting of vinyl acetate-ethylene copolymer, vinyl acetate homopolymer, vinyl acetate-acrylic copolymer, vinylacrylic, acrylic, ethylene-vinyl chloride, vinyl ether maleic anhydride, or butadiene styrene. Other similar polymers can be used.

These formulations are prepared in a known manner, by mixing the active ingredients or active ingredient combinations with customary additives, for example customary extenders and solvents or diluents, dyes, wetting agents, dispersants, emulsifiers, antifoams, preservatives, secondary thickeners, adhesives, gibberellins, and also water.

Useful dyes which may be present in the seed dressing formulations usable in accordance with the invention are all dyes which are customary for such purposes. It is possible to use either pigments, which are sparingly soluble in water, or dyes, which are soluble in water. Examples include the dyes known by the names Rhodamine B, C.I. Pigment Red 112 and C.I. Solvent Red 1.

Useful wetting agents which may be present in the seed dressing formulations usable in accordance with the invention are all substances which promote wetting and which are conventionally used for the formulation of active agrochemical ingredients. Usable with preference are alkylnaphthalenesulphonates, such as diisopropyl- or diisobutylnaphthalenesulphonates.

Useful dispersants and/or emulsifiers which may be present in the seed dressing formulations usable in accordance with the invention are all nonionic, anionic and cationic dispersants conventionally used for the formulation of active agrochemical ingredients. Usable with preference are nonionic or anionic dispersants or mixtures of nonionic or anionic dispersants. Useful nonionic dispersants include especially ethylene oxide/propylene oxide block polymers, alkylphenol polyglycol ethers and tristrylphenol polyglycol ether, and the phosphated or sulphated derivatives thereof. Suitable anionic dispersants are especially lignosulphonates, polyacrylic acid salts and arylsulphonate/formaldehyde condensates.

Antifoams which may be present in the seed dressing formulations usable in accordance with the invention are all foam-inhibiting substances conventionally used for the formulation of active agrochemical ingredients. Silicone antifoams and magnesium stearate can be used with preference.

5 Preservatives which may be present in the seed dressing formulations usable in accordance with the invention are all substances usable for such purposes in agrochemical compositions. Examples include dichlorophene and benzyl alcohol hemiformal.

10 Secondary thickeners which may be present in the seed dressing formulations usable in accordance with the invention are all substances usable for such purposes in agrochemical compositions. Preferred examples include cellulose derivatives, acrylic acid derivatives, xanthan, modified clays and finely divided silica.

Adhesives which may be present in the seed dressing formulations usable in accordance with the invention are all customary binders usable in seed dressing products. Preferred examples include polyvinylpyrrolidone, polyvinyl acetate, polyvinyl alcohol and tylose.

15 The formulations for on-seed applications usable in accordance with the invention can be used to treat a wide variety of different kinds of seed either directly or after prior dilution with water. For instance, the concentrates or the preparations obtainable therefrom by dilution with water can be used to dress the seed of cereals, such as wheat, barley, rye, oats, and triticale, and also seeds of maize, soybean, rice, oilseed rape, peas, beans, cotton, sunflowers, and beets, or else a wide variety of different vegetable seeds. The formulations usable in accordance with the invention, or the dilute preparations
20 thereof, can also be used for seeds of transgenic plants. In this case, additional synergistic effects may also occur in interaction with the substances formed by expression.

For treatment of seeds with the formulations usable in accordance with the invention, or the preparations prepared therefrom by adding water, all mixing units usable customarily for on-seed applications are useful. Specifically, the procedure in on-seed applications is to place the seeds into a
25 mixer, to add the particular desired amount of the formulations, either as such or after prior dilution with water, and to mix everything until all applied formulations are distributed homogeneously on the seeds. If appropriate, this is followed by a drying operation.

The application rate of the formulations usable in accordance with the invention can be varied within a relatively wide range. It is guided by the particular content of the active ingredients in the formulations
30 and by the seeds. The application rates of each single active ingredient are generally between 0.001 and 15 g per kilogram of seed, preferably between 0.01 and 5 g per kilogram of seed.

When using the compounds of the formula (I) as fungicides, the application rates can be varied within a relatively wide range, depending on the kind of application. The application rate of the inventive active ingredients is:

- 5 in the case of treatment of plant parts, for example leaves: from 0.1 to 10000 g/ha, preferably from 10 to 1000 g/ha, more preferably from 30 to 300 g/ha (in the case of application by watering or dripping, it is even possible to reduce the application rate, especially when inert substrates such as rockwool or perlite are used);
- 10 in the case of seed treatment: from 0.1 to 200 g per 100 kg of seed, preferably from 1 to 150 g per 100 kg of seed, more preferably from 2.5 to 25 g per 100 kg of seed, even more preferably from 2.5 to 12.5 g per 100 kg of seed;

in the case of soil treatment: from 0.1 to 10000 g/ha, preferably from 1 to 5000 g/ha.

15

These application rates are merely by way of example and are not limiting for the purposes of the invention.

- 20 In some cases, the compounds of the formula (I) can, at particular concentrations or application rates, also be used as herbicides, safeners, growth regulators or agents to improve plant properties, or as microbicides, for example as fungicides, antimycotics, bactericides, viricides (including compositions against viroids) or as compositions against MLO (Mycoplasma-like organisms) and RLO (Rickettsia-like organisms).

- 25 The compounds of the formula (I) intervene in physiological processes of plants and can therefore also be used as plant growth regulators. Plant growth regulators may exert various effects on plants. The effect of the substances depends essentially on the time of application in relation to the developmental stage of the plant, the plant variety and also on the amounts of active ingredient applied to the plants or their environment and on the type of application. In each case, growth regulators should have a
- 30 particular desired effect on the crop plants.

- Growth regulating effects, comprise earlier germination, better emergence, more developed root system and/or improved root growth, increased ability of tillering, more productive tillers, earlier flowering, increased plant height and/or biomass, shorting of stems, improvements in shoot growth,
- 35 number of kernels/ear, number of ears/m², number of stolons and/or number of flowers, enhanced harvest index, bigger leaves, less dead basal leaves, improved phyllotaxy, earlier maturation / earlier

fruit finish, homogenous riping, increased duration of grain filling, better fruit finish, bigger fruit/vegetable size, sprouting resistance and reduced lodging.

Increased or improved yield is referring to total biomass per hectare, yield per hectare, kernel/fruit weight, seed size and/or hectolitre weight as well as to improved product quality, comprising:

- 5 improved processability relating to size distribution (kernel, fruit, etc.), homogenous riping, grain moisture, better milling, better vinification, better brewing, increased juice yield, harvestability, digestibility, sedimentation value, falling number, pod stability, storage stability, improved fiber length/strength/uniformity, increase of milk and/or meat quality of silage fed animals, adaption to cooking and frying;
- 10 further comprising improved marketability relating to improved fruit/grain quality, size distribution (kernel, fruit, etc.), increased storage / shelf-life, firmness /softness, taste (aroma, texture, etc.), grade (size, shape, number of berries, etc.), number of berries/fruits per bunch, crispness, freshness, coverage with wax, frequency of physiological disorders, colour, etc.;

- 15 further comprising increased desired ingredients such as e.g. protein content, fatty acids, oil content, oil quality, aminoacid composition, sugar content, acid content (pH), sugar/acid ratio (Brix), polyphenols, starch content, nutritional quality, gluten content/index, energy content, taste, etc.;

and further comprising decreased undesired ingredients such as e.g. less mycotoxines, less aflatoxines, geosmin level, phenolic aromas, lacchase, polyphenol oxidases and peroxidases, nitrate content etc.

- 20 Plant growth-regulating compounds can be used, for example, to slow down the vegetative growth of the plants. Such growth depression is of economic interest, for example, in the case of grasses, since it is thus possible to reduce the frequency of grass cutting in ornamental gardens, parks and sport facilities, on roadsides, at airports or in fruit crops. Also of significance is the inhibition of the growth of herbaceous and woody plants on roadsides and in the vicinity of pipelines or overhead cables, or quite generally in areas where vigorous plant growth is unwanted.

- 25 Also important is the use of growth regulators for inhibition of the longitudinal growth of cereal. This reduces or completely eliminates the risk of lodging of the plants prior to harvest. In addition, growth regulators in the case of cereals can strengthen the culm, which also counteracts lodging. The employment of growth regulators for shortening and strengthening culms allows the deployment of
- 30 higher fertilizer volumes to increase the yield, without any risk of lodging of the cereal crop.

In many crop plants, vegetative growth depression allows denser planting, and it is thus possible to achieve higher yields based on the soil surface. Another advantage of the smaller plants obtained in this way is that the crop is easier to cultivate and harvest.

- 5 Reduction of the vegetative plant growth may also lead to increased or improved yields because the nutrients and assimilates are of more benefit to flower and fruit formation than to the vegetative parts of the plants.

- 10 Alternatively, growth regulators can also be used to promote vegetative growth. This is of great benefit when harvesting the vegetative plant parts. However, promoting vegetative growth may also promote generative growth in that more assimilates are formed, resulting in more or larger fruits.

- 15 Furthermore, beneficial effects on growth or yield can be achieved through improved nutrient use efficiency, especially nitrogen (N)-use efficiency, phosphorus (P)-use efficiency, water use efficiency, improved transpiration, respiration and/or CO₂ assimilation rate, better nodulation, improved Ca-metabolism etc.

- 20 Likewise, growth regulators can be used to alter the composition of the plants, which in turn may result in an improvement in quality of the harvested products. Under the influence of growth regulators, parthenocarpic fruits may be formed. In addition, it is possible to influence the sex of the flowers. It is also possible to produce sterile pollen, which is of great importance in the breeding and production of hybrid seed.

- 25 Use of growth regulators can control the branching of the plants. On the one hand, by breaking apical dominance, it is possible to promote the development of side shoots, which may be highly desirable particularly in the cultivation of ornamental plants, also in combination with an inhibition of growth. On the other hand, however, it is also possible to inhibit the growth of the side shoots. This effect is of particular interest, for example, in the cultivation of tobacco or in the cultivation of tomatoes.

- 30 Under the influence of growth regulators, the amount of leaves on the plants can be controlled such that defoliation of the plants is achieved at a desired time. Such defoliation plays a major role in the mechanical harvesting of cotton, but is also of interest for facilitating harvesting in other crops, for example in viticulture. Defoliation of the plants can also be undertaken to lower the transpiration of the plants before they are transplanted.

35

Furthermore, growth regulators can modulate plant senescence, which may result in prolonged green leaf area duration, a longer grain filling phase, improved yield quality, etc.

Growth regulators can likewise be used to regulate fruit dehiscence. On the one hand, it is possible to prevent premature fruit dehiscence. On the other hand, it is also possible to promote fruit dehiscence or even flower abortion to achieve a desired mass ("thinning"). In addition, it is possible to use growth regulators at the time of harvest to reduce the forces required to detach the fruits, in order to allow mechanical harvesting or to facilitate manual harvesting.

Growth regulators can also be used to achieve faster or else delayed ripening of the harvested material before or after harvest. This is particularly advantageous as it allows optimal adjustment to the requirements of the market. Moreover, growth regulators in some cases can improve the fruit colour. In addition, growth regulators can also be used to synchronize maturation within a certain period of time. This establishes the prerequisites for complete mechanical or manual harvesting in a single operation, for example in the case of tobacco, tomatoes or coffee.

By using growth regulators, it is additionally possible to influence the resting of seed or buds of the plants, such that plants such as pineapple or ornamental plants in nurseries, for example, germinate, sprout or flower at a time when they are normally not inclined to do so. In areas where there is a risk of frost, it may be desirable to delay budding or germination of seeds with the aid of growth regulators, in order to avoid damage resulting from late frosts.

Finally, growth regulators can induce resistance of the plants to frost, drought or high salinity of the soil. This allows the cultivation of plants in regions which are normally unsuitable for this purpose.

The compounds of the formula (I) also exhibit a potent strengthening effect in plants. Accordingly, they can be used for mobilizing the defences of the plant against attack by undesirable microorganisms.

Plant-strengthening (resistance-inducing) substances in the present context are substances capable of stimulating the defence system of plants in such a way that the treated plants, when subsequently inoculated with undesirable microorganisms, develop a high degree of resistance to these microorganisms.

Further, in context with the present invention plant physiology effects comprise the following:

Abiotic stress tolerance, comprising tolerance to high or low temperatures, drought tolerance and recovery after drought stress, water use efficiency (correlating to reduced water consumption), flood tolerance, ozone stress and UV tolerance, tolerance towards chemicals like heavy metals, salts, pesticides etc.

- 5 Biotic stress tolerance comprising increased fungal resistance and increased resistance against nematodes, viruses and bacteria. In context with the present invention, biotic stress tolerance preferably comprises increased fungal resistance and increased resistance against nematodes.

Increased plant vigor, comprising plant health / plant quality and seed vigor, reduced stand failure, improved appearance, increased recovery after periods of stress, improved pigmentation (e.g.
10 chlorophyll content, stay-green effects, etc.) and improved photosynthetic efficiency.

In addition, the compounds of the formula (I) can reduce the mycotoxin content in the harvested material and the foods and feeds prepared therefrom. Mycotoxins include particularly, but not exclusively, the following: deoxynivalenol (DON), nivalenol, 15-Ac-DON, 3-Ac-DON, T2- and HT2-toxin, fumonisins, zearalenon, moniliformin, fusarin, diacetoxyscirpenol (DAS), beauvericin,
15 enniatin, fusaroproliferin, fusarenol, ochratoxins, patulin, ergot alkaloids and aflatoxins which can be produced, for example, by the following fungi: *Fusarium* spec., such as *F. acuminatum*, *F. asiaticum*, *F. avenaceum*, *F. crookwellense*, *F. culmorum*, *F. graminearum* (*Gibberella zeae*), *F. equiseti*, *F. fujikoro*i, *F. musarum*, *F. oxysporum*, *F. proliferatum*, *F. poae*, *F. pseudograminearum*, *F. sambucinum*, *F. scirpi*, *F. semitectum*, *F. solani*, *F. sporotrichoides*, *F. langsethiae*, *F. subglutinans*, *F.*
20 *tricinctum*, *F. verticillioides* etc., and also by *Aspergillus* spec., such as *A. flavus*, *A. parasiticus*, *A. nomius*, *A. ochraceus*, *A. clavatus*, *A. terreus*, *A. versicolor*, *Penicillium* spec., such as *P. verrucosum*, *P. viridicatum*, *P. citrinum*, *P. expansum*, *P. claviforme*, *P. roqueforti*, *Claviceps* spec., such as *C. purpurea*, *C. fusiformis*, *C. paspali*, *C. africana*, *Stachybotrys* spec. and others.

- 25 The compounds of the formula (I) can also be used in the protection of materials, for protection of industrial materials against attack and destruction by phytopathogenic fungi.

In addition, the compounds of the formula (I) can be used as antifouling compositions, alone or in combinations with other active ingredients.

30

Industrial materials in the present context are understood to mean inanimate materials which have been prepared for use in industry. For example, industrial materials which are to be protected by inventive compositions from microbial alteration or destruction may be adhesives, glues, paper, wallpaper and board/cardboard, textiles, carpets, leather, wood, fibers and tissues, paints and plastic articles, cooling

lubricants and other materials which can be infected with or destroyed by microorganisms. Parts of production plants and buildings, for example cooling-water circuits, cooling and heating systems and ventilation and air-conditioning units, which may be impaired by the proliferation of microorganisms may also be mentioned within the scope of the materials to be protected. Industrial materials within the scope of the present invention preferably include adhesives, sizes, paper and card, leather, wood, paints, cooling lubricants and heat transfer fluids, more preferably wood.

The compounds of the formula (I) may prevent adverse effects, such as rotting, decay, discoloration, decoloration or formation of mould.

In the case of treatment of wood the compounds of the formula (I) may also be used against fungal diseases liable to grow on or inside timber. The term "timber" means all types of species of wood, and all types of working of this wood intended for construction, for example solid wood, high-density wood, laminated wood, and plywood. The method for treating timber according to the invention mainly consists in contacting a composition according to the invention; this includes for example direct application, spraying, dipping, injection or any other suitable means.

In addition, the compounds of the formula (I) can be used to protect objects which come into contact with saltwater or brackish water, especially hulls, screens, nets, buildings, moorings and signalling systems, from fouling.

The compounds of the formula (I) can also be employed for protecting storage goods. Storage goods are understood to mean natural substances of vegetable or animal origin or processed products thereof which are of natural origin, and for which long-term protection is desired.

Storage goods of vegetable origin, for example plants or plant parts, such as stems, leaves, tubers, seeds, fruits, grains, can be protected freshly harvested or after processing by (pre)drying, moistening, comminuting, grinding, pressing or roasting. Storage goods also include timber, both unprocessed, such as construction timber, electricity poles and barriers, or in the form of finished products, such as furniture. Storage goods of animal origin are, for example, hides, leather, furs and hairs. The inventive compositions may prevent adverse effects, such as rotting, decay, discoloration, decoloration or formation of mould.

Microorganisms capable of degrading or altering the industrial materials include, for example, bacteria, fungi, yeasts, algae and slime organisms. The compounds of the formula (I) preferably act against fungi, especially moulds, wood-discoloring and wood-destroying fungi (*Ascomycetes*, *Basidiomycetes*, *Deuteromycetes* and *Zygomycetes*), and against slime organisms and algae. Examples include microorganisms of the following genera: *Alternaria*, such as *Alternaria tenuis*; *Aspergillus*, such as

Aspergillus niger; *Chaetomium*, such as *Chaetomium globosum*; *Coniophora*, such as *Coniophora puetana*; *Lentinus*, such as *Lentinus tigrinus*; *Penicillium*, such as *Penicillium glaucum*; *Polyporus*, such as *Polyporus versicolor*; *Aureobasidium*, such as *Aureobasidium pullulans*; *Sclerophoma*, such as *Sclerophoma pityophila*; *Trichoderma*, such as *Trichoderma viride*; *Ophiostoma* spp., *Ceratocystis* spp.,
 5 *Humicola* spp., *Petriella* spp., *Trichurus* spp., *Coriolus* spp., *Gloeophyllum* spp., *Pleurotus* spp., *Poria* spp., *Serpula* spp. and *Tyromyces* spp., *Cladosporium* spp., *Paecilomyces* spp. *Mucor* spp., *Escherichia*, such as *Escherichia coli*; *Pseudomonas*, such as *Pseudomonas aeruginosa*; *Staphylococcus*, such as *Staphylococcus aureus*, *Candida* spp. and *Saccharomyces* spp., such as *Saccharomyces cerevisiae*.

In addition, the compounds of the formula (I) also have very good antimycotic effects. They have a
 10 very broad antimycotic activity spectrum, especially against dermatophytes and yeasts, moulds and diphasic fungi (for example against *Candida* species, such as *Candida albicans*, *Candida glabrata*), and *Epidermophyton floccosum*, *Aspergillus* species, such as *Aspergillus niger* and *Aspergillus fumigatus*, *Trichophyton* species, such as *Trichophyton mentagrophytes*, *Microsporon* species such as *Microsporon canis* and *audouinii*. The enumeration of these fungi by no means constitutes a
 15 restriction of the mycotic spectrum covered, and is merely of illustrative character.

The compounds can be used also to control important fungal pathogens in fish and crustacea farming, e.g. *saprolegnia diclina* in trouts, *saprolegnia parasitica* in crayfish.

The compounds of the formula (I) can therefore be used both in medical and in non-medical applications.

20

The compounds of the formula (I) can be used as such, in the form of their formulations or the use forms prepared therefrom, such as ready-to-use solutions, suspensions, wettable powders, pastes, soluble powders, dusts and granules. Application is accomplished in a customary manner, for example by watering, spraying, atomizing, broadcasting, dusting, foaming, spreading-on and the like. It is also
 25 possible to deploy the active ingredients by the ultra-low volume method or to inject the active ingredient preparation/the active ingredient itself into the soil. It is also possible to treat the seed of the plants.

It is possible to treat all plants and their parts in accordance with the invention, preferably with wild plant
 30 species and plant cultivars, or those obtained by conventional biological breeding methods, such as crossing or protoplast fusion, and also parts thereof. In a further preferred embodiment, transgenic plants and plant cultivars obtained by genetic engineering methods, if appropriate in combination with conventional methods (Genetically Modified Organisms), and parts thereof are treated. The terms "parts" or "parts of plants" or "plant parts" have been explained above. More preferably, plants of the plant

cultivars which are commercially available or are in use are treated in accordance with the invention. Plant cultivars are understood to mean plants which have new properties ("traits") and have been obtained by conventional breeding, by mutagenesis or by recombinant DNA techniques. They can be cultivars, varieties, bio- or genotypes.

- 5 The method of treatment according to the invention can be used in the treatment of genetically modified organisms (GMOs), e.g. plants or seeds. Genetically modified plants (or transgenic plants) are plants of which a heterologous gene has been stably integrated into genome. The expression "heterologous gene" essentially means a gene which is provided or assembled outside the plant and when introduced in the nuclear, chloroplastic or mitochondrial genome gives the transformed plant new or improved agronomic or
- 10 other properties by expressing a protein or polypeptide of interest or by downregulating or silencing other gene(s) which are present in the plant (using for example, antisense technology, cosuppression technology, RNA interference – RNAi – technology or microRNA – miRNA - technology). A heterologous gene that is located in the genome is also called a transgene. A transgene that is defined by its particular location in the plant genome is called a transformation or transgenic event.
- 15 Plants and plant cultivars which are preferably to be treated according to the invention include all plants which have genetic material which impart particularly advantageous, useful traits to these plants (whether obtained by breeding and/or biotechnological means).

- Plants and plant cultivars which are also preferably to be treated according to the invention are resistant against one or more biotic stresses, i.e. said plants show a better defense against animal and
- 20 microbial pests, such as against nematodes, insects, mites, phytopathogenic fungi, bacteria, viruses and/or viroids.

- Plants and plant cultivars which may also be treated according to the invention are those plants which are resistant to one or more abiotic stresses. Abiotic stress conditions may include, for example, drought, cold temperature exposure, heat exposure, osmotic stress, flooding, increased soil salinity, increased mineral
- 25 exposure, ozone exposure, high light exposure, limited availability of nitrogen nutrients, limited availability of phosphorus nutrients, shade avoidance.

- Plants and plant cultivars which may also be treated according to the invention, are those plants characterized by enhanced yield characteristics. Increased yield in said plants can be the result of, for example, improved plant physiology, growth and development, such as water use efficiency, water
- 30 retention efficiency, improved nitrogen use, enhanced carbon assimilation, improved photosynthesis, increased germination efficiency and accelerated maturation. Yield can furthermore be affected by improved plant architecture (under stress and non-stress conditions), including but not limited to, early flowering, flowering control for hybrid seed production, seedling vigor, plant size, internode number and

distance, root growth, seed size, fruit size, pod size, pod or ear number, seed number per pod or ear, seed mass, enhanced seed filling, reduced seed dispersal, reduced pod dehiscence and lodging resistance. Further yield traits include seed composition, such as carbohydrate content and composition for example cotton or starch, protein content, oil content and composition, nutritional value, reduction in anti-nutritional compounds, improved processability and better storage stability.

Plants that may be treated according to the invention are hybrid plants that already express the characteristic of heterosis or hybrid vigor which results in generally higher yield, vigor, health and resistance towards biotic and abiotic stresses).

Plants or plant cultivars (obtained by plant biotechnology methods such as genetic engineering) which may be treated according to the invention are herbicide-tolerant plants, i.e. plants made tolerant to one or more given herbicides. Such plants can be obtained either by genetic transformation, or by selection of plants containing a mutation imparting such herbicide tolerance.

Plants or plant cultivars (obtained by plant biotechnology methods such as genetic engineering) which may also be treated according to the invention are insect-resistant transgenic plants, i.e. plants made resistant to attack by certain target insects. Such plants can be obtained by genetic transformation, or by selection of plants containing a mutation imparting such insect resistance.

Plants or plant cultivars (obtained by plant biotechnology methods such as genetic engineering) which may also be treated according to the invention are tolerant to abiotic stresses. Such plants can be obtained by genetic transformation, or by selection of plants containing a mutation imparting such stress resistance.

Plants or plant cultivars (obtained by plant biotechnology methods such as genetic engineering) which may also be treated according to the invention show altered quantity, quality and/or storage-stability of the harvested product and/or altered properties of specific ingredients of the harvested product.

Plants or plant cultivars (that can be obtained by plant biotechnology methods such as genetic engineering) which may also be treated according to the invention are plants, such as cotton plants, with altered fiber characteristics. Such plants can be obtained by genetic transformation, or by selection of plants contain a mutation imparting such altered fiber characteristics.

Plants or plant cultivars (that can be obtained by plant biotechnology methods such as genetic engineering) which may also be treated according to the invention are plants, such as oilseed rape or related Brassica plants, with altered oil profile characteristics. Such plants can be obtained by genetic

transformation, or by selection of plants contain a mutation imparting such altered oil profile characteristics.

Plants or plant cultivars (that can be obtained by plant biotechnology methods such as genetic engineering) which may also be treated according to the invention are plants, such as oilseed rape or related Brassica plants, with altered seed shattering characteristics. Such plants can be obtained by genetic transformation, or by selection of plants contain a mutation imparting such altered seed shattering characteristics and include plants such as oilseed rape plants with delayed or reduced seed shattering.

Plants or plant cultivars (that can be obtained by plant biotechnology methods such as genetic engineering) which may also be treated according to the invention are plants, such as Tobacco plants, with altered post-translational protein modification patterns.

Accordingly compounds of present invention have been illustrated in table 1 and 2.


The following tables illustrate in a non-limiting manner examples of compounds according to the invention. In the following examples, M+1 (or M-1) means the molecular ion peak, plus or minus 1 a.m.u. (atomic mass unit) respectively, as observed in mass spectroscopy ^1H -NMR data of selected examples are written in form of ^1H -NMR-peak lists. To each signal peak are listed the δ -value in ppm and the no of proton in round brackets.

For calibrating chemical shift for ^1H spectra, we use tetramethylsilane and/or the chemical shift of the solvent used, especially in the case of spectra measured in DMSO. Therefore in NMR peak lists, tetramethylsilane peak can occur but not necessarily.

The ^1H -NMR peak lists are similar to classical ^1H -NMR prints and contains therefore usually all peaks, which are listed at classical NMR-interpretation.

Additionally they can show like classical ^1H -NMR prints signals of solvents, stereoisomers of the target compounds, which are also object of the invention, and/ or peaks of impurities.

Table 1 provides compounds of general formula (I)



(I)

Sr.No	Compound Name	Analytical Data
1.	N'-(2,5-dimethyl-4-(phenylamino)phenyl)-N-ethyl-N-methylformimidamide	Example:1
2.	N'-(2,5-dimethyl-4-(methyl(phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	Exempl:2
3.	N'-(2-chloro-5-methyl-4-(phenylamino)phenyl)-N-ethyl-N-methylformimidamide	Exempl:3
4.	N'-(2-chloro-5-methyl-4-(methyl(phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	Example:4
5.	N'-(2,5-dimethyl-4-(N-phenylmethylsulfonamido)phenyl)-N-ethyl-N-methylformimidamide	Example:5
6.	N'-(2,5-dimethyl-4-(methyl(2-methyl-4-(perfluoropropan-2-yl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.5 (s, 1H), 7.36 (s, 1H), 7.14 (s, 1H), 7.12 (s, 1H), 6.63 (s, 1H), 6.47 (s, 1H), 3.36 (q, 2H), 3.02 (s, 3H), 2.87 (s, 3H), 2.07 (s, 3H), 1.98 (s, 3H), 1.73 (s, 3H), 1.13 (t, 3H); (M+1): 478.1
7.	N'-(4-((4-chlorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	Example:6
8.	N'-(4-((3-chlorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	Example:7
9.	N'-(4-((3,4-dichlorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	Example:8
10.	N'-(2-chloro-5-methyl-4-(methyl(3,4,5-trifluorophenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	Example:9
11.	N'-(2-chloro-5-methyl-4-(methyl(m-tolyl)amino)phenyl)-N-ethyl-N-methylformimidamide	Example:10
12.	N'-(2-chloro-4-((3,4-dichlorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	Example:11
13.	N'-(2-chloro-4-((3-methoxyphenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	Example:12
14.	N'-(2-chloro-5-methyl-4-(methyl(4-	Example:13 ¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.73 (s,

	(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H), 7.44 (d, 2H), 7.15 (s, 1H), 6.96 (d, 1H), 6.53 (d, 2H), 3.45-3.35 (m, 2H), 3.18 (s, 3H), 2.97 (s, 3H), 1.97 (s, 3H), 1.14 (t, 3H); (M+1): 384.15
15.	N'-(2-chloro-5-methyl-4-(methyl(p-tolyl)amino)phenyl)-N-ethyl-N-methylformimidamide	Example:14
16.	N'-(2-chloro-4-((2-methoxyphenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	Example:15
17.	N'-(2-chloro-5-methyl-4-(N-phenylmethylsulfonamido)phenyl)-N-ethyl-N-methylformimidamide	Example:16
18.	N'-(2-chloro-4-((2-chlorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	Example:17
19.	N'-(2-chloro-4-((4-chlorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	Example:18
20.	N'-(2-chloro-4-((4-methoxyphenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	Example:19
21.	N'-(2-chloro-4-((4-methoxy-3-methylphenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	Example:20
22.	N'-(2-chloro-4-((3,4-dimethoxyphenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	Example:21
23.	N'-(2-chloro-4-((3,5-dimethoxyphenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	Example:22
24.	N'-(2,5-dimethyl-4-(methyl(m-tolyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.74 (s, 1H), 7.09 (s, 1H), 6.95 (t, 1H), 6.85 (s, 1H), 6.64 (s, 1H), 6.44-6.41 (m, 3H), 3.37 (q, 2H), 2.92 (s, 3H), 2.15 (s, 3H), 2.09 (s, 3H), 2.06 (s, 3H), 1.12 (t, 3H); (M+1):310.2
25.	N-ethyl-N'-(4-((3-methoxyphenyl)(methyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.78 (s, 1H), 6.98 (t, 1H), 6.85 (s, 1H), 6.77 (s, 1H), 6.20 (dd, 1H), 6.00 (dd, 1H), 5.95 (t, 1H), 3.62 (d, 3H), 3.45-3.40 (m, 2H), 3.10 (s, 3H), 3.02 (s, 3H), 2.13 (s, 3H), 1.97 (s, 3H), 1.14 (t, 3H); (M+1):326.1
26.	N'-(2,5-dimethyl-4-(methyl(p-tolyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.72 (s, 1H), 6.90 (d, 2H), 6.81 (s, 1H), 6.72 (s, 1H), 6.34 (d, 2H), 3.37 (q, 2H), 3.08 (s, 3H), 2.99 (s, 3H), 2.07 (s, 6H), 1.96 (s, 3H), 1.13 (t, 3H); (M+1):310.1
27.	N-ethyl-N'-(4-((4-methoxyphenyl)(methyl)amino)-2,5-dimethylphenyl)-N-	Example:24

	methylformimidamide	
28.	N-ethyl-N'-4-((3-methoxyphenyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide	Example:23
29.	N'-(2,5-dimethyl-4-(m-tolylamino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.74 (s, 1H), 7.09 (s, 1H), 6.95 (t, 1H), 6.85 (s, 1H), 6.64 (s, 1H), 6.44-6.41 (m, 3H), 3.37 (q, 2H), 2.92 (s, 3H), 2.15 (s, 3H), 2.09 (s, 3H), 2.06 (s, 3H), 1.12 (t, 3H); (M+1):295.8
30.	N'-(2,5-dimethyl-4-(p-tolylamino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.58 (s, 1H), 6.95-6.83 (m, 4H), 6.60-6.56 (m, 3H), 3.40-3.37 (m, 2H), 2.91 (s, 3H), 2.15 (s, 3H), 2.06 (s, 6H), 1.11 (t, 3H); (M+1):296.4
31.	N'-(4-((4-(tert-butyl)phenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.62 (s, 1H), 7.07 (q, 2H), 6.75 (d, 1H), 6.65 (s, 1H), 6.32 (q, 2H), 3.28 (q, 2H), 3.04 (s, 3H), 2.89 (s, 3H), 2.06 (s, 3H), 1.94 (s, 3H), 1.17 (s, 9H), 1.09 (t, 3H); (M+1):352.1
32.	N'-(4-((4-(tert-butyl)phenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.67 (s, 1H), 7.14-7.10 (m, 2H), 6.97 (s, 1H), 6.86 (s, 1H), 6.63-6.60 (m, 3H), 3.36 (q, 2H), 2.91 (s, 3H), 2.07 (s, 6H), 1.19 (s, 9H), 1.11 (t, 3H); (M+1): 338.4
33.	N'-(4-((2-chlorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.59 (s, 1H), 7.33 (dd, 1H), 7.26-7.22 (m, 1H), 7.03-6.95 (m, 2H), 6.60 (d, 2H), 3.35 (q, 2H), 3.02 (s, 3H), 2.89 (s, 3H), 2.04 (s, 3H), 1.98 (s, 3H), 1.08 (t, 3H); (M+1):330.2
34.	N'-(2-chloro-4-((2-chlorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.69 (s, 1H), 7.32 (dd, 1H), 7.09-7.03 (m, 3H), 6.89 (s, 1H), 6.70 (td, 1H), 6.39 (dd, 1H), 3.49-3.28 (m, 2H), 2.96 (s, 3H), 2.05 (s, 3H), 1.13 (t, 3H); (M+1): 336.55
35.	N-ethyl-N'-4-((2-fluorophenyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.66 (s, 1H), 7.37-7.11 (m, 4H), 7.02 (d, 1H), 6.80-6.78 (m, 1H), 6.69 (d, 1H), 3.41-3.33 (m, 2H), 2.91 (s, 3H), 2.16 (s, 3H), 2.05 (s, 3H), 1.96 (s, 3H), 1.11 (t, 3H); (M+1): 300.15
36.	N-ethyl-N'-4-((2-fluorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.60 (s, 1H), 7.04-6.97 (m, 2H), 6.84-6.79 (m, 2H), 6.72 (s, 1H), 6.60 (s, 1H), 3.35-3.25 (m, 2H), 3.06 (s, 3H), 2.91 (s, 3H), 2.06 (s, 3H), 2.02 (s, 3H), 1.11 (t, 3H); (M+1): 314.30
37.	N'-(2-chloro-4-((2-fluorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.66 (s, 1H), 7.08-7.03 (m, 2H), 6.94 (s, 1H), 6.92-6.87 (m, 2H), 6.83 (s, 1H), 3.38-3.24 (m, 2H), 3.07 (s, 3H), 2.94 (s, 3H), 2.02 (s, 3H), 1.12 (t, 3H); (M+1): 334.05
38.	N-ethyl-N'-4-((3-fluorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide	¹ H-NMR (400 MHz, CHLOROFORM-D) δ 7.47 (s, 1H), 7.06 (td, 1H), 6.88 (s, 1H), 6.67 (s, 1H), 6.36-6.31 (m, 1H), 6.25 (dd, 1H), 6.18 (dt, 1H), 3.61-3.25 (m, 2H), 3.18 (s, 3H), 3.03 (s, 3H), 2.22 (s, 3H), 2.05 (s, 3H), 1.21 (t, 3H); (M+1): 314.35
39.	N-ethyl-N'-4-((4-fluorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide	¹ H-NMR (400 MHz, CHLOROFORM-D) δ 7.46 (s, 1H), 6.82-6.78 (m, 3H), 6.65 (s, 1H), 6.41-6.34 (m, 2H), 3.48-3.32 (m, 2H), 3.16 (s, 3H), 3.01 (s, 3H), 2.20 (s, 3H), 2.03 (s, 3H), 1.22 (t, 3H); (M+1): 314.15
40.	N'-(4-((2-chlorophenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	Example:25
41.	N-(4-	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.64 (s, 1H), 7.26-7.06

	((ethyl(methylamino)methylene)amino)-2,5-dimethylphenyl)-N-phenylacetamide	(m, 6H), 6.66 (s, 1H), 3.37-3.28(m, 2H), 2.87 (s, 3H), 2.10 (s, 6H), 1.95 (s, 3H), 1.12 (t, 3H); (M+1):324.1
42.	N'-(2-chloro-5-methyl-4-(methyl(pyridin-2-yl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 8.10 (s, 1H), 7.72 (d, 1H), 7.39-7.34 (m, 1H), 7.15 (s, 1H), 6.94 (d, 1H), 6.58 (dd, 1H), 6.05 (d, 1H), 3.46-3.34 (m, 2H), 3.25 (s, 3H), 3.00 (s, 3H), 1.97 (s, 3H), 1.14 (t, 3H); (M+1): 318.10
43.	N'-(4-((4-chlorophenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.63 (s, 1H), 7.39 (s, 1H), 7.11-7.08 (m, 2H), 6.85 (s, 1H), 6.65 (s, 1H), 6.62-6.58 (m, 2H), 3.37 (q, 2H), 2.92 (s, 3H), 2.10 (s, 3H), 2.05 (s, 3H), 1.12 (t, 3H); (M+1): 316.10
44.	N-ethyl-N'-(4-((4-fluorophenyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide	¹ H-NMR (400 MHz, CHLOROFORM-D) δ 7.43 (s, 1H), 6.92-6.86 (m, 3H), 6.75-6.71 (m, 2H), 6.64 (s, 1H), 5.55-4.48 (m, 1H), 3.39-3.43 (m, 2H), 3.02 (s, 3H), 2.22 (s, 3H), 2.15 (s, 3H), 1.24 (t, 3H); (M+1): 300.25
45.	N-ethyl-N'-(4-((2-methoxyphenyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide	¹ H-NMR (400 MHz, CHLOROFORM-D) δ 7.45 (s, 1H), 7.05 (s, 1H), 6.86-6.70 (m, 4H), 6.64 (s, 1H), 5.71 (s, 1H), 3.91 (s, 3H), 3.39-3.38 (m, 2H), 3.02 (s, 3H), 2.22 (s, 3H), 2.17 (s, 3H), 1.20 (t, 3H); (M+1): 312.20
46.	N-ethyl-N'-(4-((3-fluorophenyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide	¹ H-NMR (400 MHz, CHLOROFORM-D) δ 7.44 (s, 1H), 7.10 (dd, 1H), 7.00 (s, 1H), 6.68 (s, 1H), 6.50-6.37 (m, 3H), 5.33 (s, 1H), 3.43-3.37 (m, 2H), 3.21 (s, 3H), 2.20 (s, 3H), 2.16 (s, 3H), 1.19 (t, 3H); (M+1): 300.10
47.	N'-(2-chloro-4-((2-fluorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, CHLOROFORM-D) δ 7.53 (s, 1H), 7.23 (s, 1H), 7.05 (ddd, 1H), 6.96 (t, 1H), 6.85-6.73 (m, 3H), 5.38 (s, 1H), 3.36 (q, 2H), 3.08 (s, 3H), 2.21 (s, 3H), 1.29-1.23 (m, 3H);(M+1):320.1
48.	N'-(2-chloro-4-((3-chlorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	Example:26
49.	N-(3-chlorophenyl)-N,2,5-trimethyl-4-((morpholinomethylene)amino)aniline	Example:28
50.	N'-(2-chloro-4-((3-chlorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	Example:27
51.	N-(3-Chlorophenyl)-N, 2, 5-trimethyl-4-((piperidin-1-ylmethylene) amino) aniline	Example:29
52.	N-allyl-N'-(4-((3-chlorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide	Example:31
53.	N'-(4-((3-chlorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-isopropyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.67 (s, 1H), 7.11-7.07 (m, 1H), 6.83 (s, 1H), 6.71 (s, 1H), 6.60-6.58 (m, 1H), 6.36-6.35 (m, 2H), 3.79-3.65 (m, 1H), 3.11 (s, 3H), 2.83 (s, 3H), 2.12 (s, 3H), 1.95 (s, 3H), 1.22 (d, 6H);(M+1):344.4
54.	N'-(4-((2-bromophenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.63 (s, 1H), 7.46-7.43 (m, 2H), 7.26-7.13 (m, 1H), 7.08-7.04 (m, 1H), 6.86 (s, 1H), 6.66 (d, 2H), 6.59-6.55 (m, 1H), 6.32 (dd, 1H), 2.93

		(s, 3H), 2.14 (s, 3H), 2.02 (s, 3H), 1.15 (t, 3H); (M+1): 362.0
55.	N'-(4-((3-chlorophenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, CHLOROFORM-D) δ 7.45 (s, 1H), 7.06 (t, 1H), 6.97 (s, 1H), 6.70-6.68 (m, 2H), 6.64 (d, 1H), 6.56 (dd, 1H), 6.27 (s, 1H), 3.37-3.33 (m, 2H), 3.01 (s, 3H), 2.22 (s, 3H), 2.14 (s, 3H), 1.22 (t, 3H); (M+1): 316.10
56.	N-ethyl-N'-(4-((4-methoxyphenyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d6) δ 7.57 (s, 1H), 6.78-6.66 (m, 6H), 6.59 (s, 1H), 3.65 (s, 3H), 3.44-3.33 (m, 2H), 2.90 (s, 3H), 2.07 (s, 3H), 2.01 (s, 3H), 1.11 (t, 3H); (M+1): 312.0
57.	N'-(2,5-dimethyl-4-((2-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.46-7.44 (m, 1H), 7.26 (t, 1H), 6.91 (s, 1H), 6.87 (s, 1H), 6.73-6.69 (m, 2H), 6.36 (d, 1H), 3.35-3.29 (m, 2H), 2.93 (s, 3H), 2.11 (s, 3H), 1.99 (s, 3H), 1.10 (t, 3H); (M+1): 350.30
58.	N'-(2,5-dimethyl-4-(methyl(2-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d6) δ 7.51-7.42 (m, 3H), 7.15 (dd, 2H), 6.65 (s, 1H), 6.56 (s, 1H), 3.35-3.29 (m, 2H), 3.08 (s, 3H), 2.90 (s, 3H), 2.06 (s, 3H), 1.95 (s, 3H), 1.10 (t, 3H); (M+1): 364.15
59.	N'-(2,5-dimethyl-4-((4-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d6) δ 7.89 (s, 1H), 7.62 (s, 1H), 7.37 (d, 2H), 6.88 (s, 1H), 6.67-6.64 (m, 3H), 3.35 (q, 2H), 2.92 (s, 3H), 2.11 (s, 3H), 2.06 (s, 3H), 1.12 (t, 3H); (M+1): 350.15
60.	N'-(2,5-dimethyl-4-((3-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d6) δ 7.64 (s, 1H), 7.16 (t, 1H), 6.87 (s, 1H), 6.66 (s, 1H), 6.58 (dd, 2H), 6.49 (dd, 1H), 6.43 (d, 1H), 3.39-3.35 (m, 2H), 2.92 (s, 3H), 2.10 (s, 3H), 2.05 (s, 3H), 1.12 (t, 3H); (M+1): 366.15
61.	N'-(2,5-dimethyl-4-(methyl(4-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d6) δ 7.67 (s, 1H), 7.40 (d, 2H), 6.85 (s, 1H), 6.73 (s, 1H), 6.51 (d, 2H), 3.39-3.34 (m, 2H), 3.17 (s, 3H), 2.93 (s, 3H), 2.12 (s, 3H), 1.95 (s, 3H), 1.12 (t, 3H); (M+1): 364.35
62.	N'-(2,5-dimethyl-4-(methyl(3-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d6) δ 7.66 (s, 1H), 7.18 (t, 1H), 6.85 (s, 1H), 6.71 (s, 1H), 6.52-6.50 (m, 1H), 6.40 (dd, 1H), 6.24 (s, 1H), 3.37-3.31 (m, 2H), 3.13 (s, 3H), 2.92 (s, 3H), 2.11 (s, 3H), 1.95 (s, 3H), 1.12 (t, 3H); (M+1): 380.35
63.	N'-(2,5-dimethyl-4-((3-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d6) δ 7.61 (s, 1H), 7.27 (s, 1H), 7.01 (t, 1H), 6.86 (s, 1H), 6.63 (s, 1H), 6.50-6.47 (m, 2H), 6.40-6.37 (m, 1H), 3.54-3.26 (m, 2H), 2.91 (s, 3H), 2.35 (s, 3H), 2.10 (s, 3H), 2.06 (s, 3H), 1.11 (t, 3H); (M+1): 328.15
64.	N'-(4-((2-bromophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-D6) δ 7.58-7.53 (m, 2H), 7.30-7.26 (m, 1H), 6.99 (dd, 1H), 6.92 (td, 1H), 6.64 (s, 1H), 6.57 (s, 1H), 3.35-3.21 (m, 2H), 3.02 (s, 3H), 2.90 (s, 3H), 2.07 (s, 3H), 1.95 (s, 3H), 1.10 (t, 3H); (M+1): 376.05
65.	N-ethyl-N'-(4-((2-methoxyphenyl)(methyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d6) δ 7.57 (s, 1H), 6.88-6.84 (m, 2H), 6.74-6.71 (m, 2H), 6.60 (dd, 1H), 6.52 (s, 1H), 3.67 (s, 3H), 3.47-3.33 (m, 2H), 3.02 (s, 3H), 2.90 (s, 3H), 2.10 (s, 3H), 1.83 (s, 3H), 1.10 (t, 3H); (M+1): 326.35
66.	N'-(2,5-dimethyl-4-(methyl(3-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d6) δ 7.66 (s, 1H), 7.03 (t, 1H), 6.81 (s, 1H), 6.69 (s, 1H), 6.49 (dd, 1H), 6.28 (t, 1H), 6.18 (dd, 1H), 3.54-3.26 (m, 2H), 3.11 (s, 3H), 2.92 (s,

		3H), 2.40 (s, 3H), 2.11 (s, 3H), 1.95 (s, 3H), 1.12 (t, 3H); (M+1): 342.25
67.	N'-(2-chloro-5-methyl-4-((3-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.72 (s, 1H), 7.42 (s, 1H), 7.09-7.04 (m, 2H), 6.85 (s, 1H), 6.57-6.56(m, 2H), 6.47-6.45 (m, 1H), 3.47-3.45 (m, 2H), 2.94 (s, 3H), 2.38 (s, 3H), 2.08 (s, 3H), 1.13 (t, 3H); (M+1): 348.10
68.	N'-(2-chloro-5-methyl-4-(m-tolylamino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.76 (s, 1H), 7.30-7.14 (m, 1H), 7.08-6.89 (m, 2H), 6.89-6.71 (m, 1H), 6.56-6.38 (m, 3H), 3.51-3.19 (m, 2H), 3.04 (s, 3H), 2.19 (s, 6H), 1.20 (t, 3H); (M+1): 316.1
69.	N'-(2-chloro-4-((3-methoxyphenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.66 (s, 1H), 7.34 (s, 1H), 7.06-7.01 (m, 2H), 6.84 (s, 1H), 6.30-6.24 (m, 3H), 3.65 (s, 3H), 3.47-3.36 (m, 2H), 2.94 (s, 3H), 2.09 (s, 3H), 1.12 (t, 3H); (M+1):332.1
70.	N'-(2-chloro-5-methyl-4-(o-tolylamino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.70 (s, 1H), 7.09 (d, 1H), 6.97-7.91 (m, 1H), 6.83 (s, 1H), 6.78 (s, 1H), 6.73 (td, 1H), 6.61 (s, 1H), 6.46 (d, 1H), 3.34-3.22 (m, 2H), 2.94 (s, 3H), 2.16 (s, 3H), 2.05 (s, 3H), 1.16 (t, 3H); (M+1): 316.10
71.	N'-(2-chloro-4-((4-chlorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.66 (d, 1H), 7.53 (s, 1H), 7.15 (d, 2H), 7.05 (s, 1H), 6.86 (s, 1H), 6.67 (d, 2H), 3.44-3.36 (m, 2H), 2.94 (s, 3H), 2.08 (s, 3H), 1.12 (t, 3H); (M+1): 337.10
72.	N'-(2,5-dimethyl-4-(o-tolylamino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.60 (s, 1H), 7.03 (d, 1H), 6.92-6.88 (m, 1H), 6.72 (s, 1H), 6.63-6.57 (m, 2H), 6.39 (s, 1H), 6.30 (d, 1H), 3.39-3.33 (m, 2H), 2.92 (s, 3H), 2.18 (s, 3H), 2.09 (s, 3H), 2.02 (s, 3H), 1.12 (t, 3H); (M+1): 296.20
73.	N'-(2-chloro-4-((4-methoxyphenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.67 (s, 1H), 6.92 (s, 1H), 6.89 (s, 1H), 6.84-6.78 (m, 5H), 3.40-3.37 (m, 2H), 3.33 (s, 3H), 2.90 (s, 3H), 2.09 (s, 3H), 1.15-1.10 (t, 3H); (M+1): 332.15
74.	N'-(2-chloro-5-methyl-4-(methyl(o-tolyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.69 (s, 1H), 7.13 (t, 2H), 6.96-6.91 (m, 2H), 6.80 (s, 1H), 6.74 (s, 1H), 3.37 (q, 2H), 2.93 (s, 6H), 1.96 (s, 6H), 1.11 (t, 3H); (M+1):330.20
75.	N'-(4-((2-bromophenyl)amino)-2-chloro-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.68 (s, 1H), 7.49 (dd, 1H), 7.13-7.09 (m, 1H), 7.03 (s, 1H), 6.88 (d, 2H), 6.65 (td, 1H), 6.39 (dd, 1H), 3.46-3.36 (m, 2H), 2.96 (s, 3H), 2.03 (s, 3H), 1.16 (t, 3H); (M+1): 381.95
76.	N'-(4-((2-bromophenyl)(methyl)amino)-2-chloro-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.70 (s, 1H), 7.59-7.57 (m, 1H), 7.33 (t, 1H), 7.03-6.96 (m, 2H), 6.83 (s, 1H), 6.79 (s, 1H), 3.40-3.28 (m, 2H), 3.02 (s, 3H), 2.90 (s, 3H), 1.93 (s, 3H), 1.11 (t, 3H); (M+1): 395.7
77.	N'-(2,5-dimethyl-4-(methyl(o-tolyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.57 (s, 1H), 7.14-7.10 (m, 1H), 7.06-7.05 (m, 1H), 6.94-6.92 (m, 1H), 6.87 (td, 1H), 6.58 (s, 1H), 6.52 (s, 1H), 3.53-3.33 (m, 2H), 2.96 (s, 3H), 2.89 (s, 3H), 2.02 (s, 6H), 1.86 (s, 3H), 1.10 (t, 3H); (M+1): 310.25
78.	N'-(2-chloro-4-((2-methoxyphenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.71 (s, 1H), 6.98 (s, 1H), 6.94-6.91 (m, 1H), 6.84 (s, 1H), 6.76-6.69 (m, 2H), 6.54 (s, 1H), 6.46 (dd, 1H), 3.81 (s, 3H), 3.34 (q, 2H), 2.94 (s, 3H), 2.07 (s, 3H), 1.12 (t, 3H); (M+1): 332.1
79.	N'-(2-chloro-5-methyl-4-((2-	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.70 (d, 1H), 7.50 (dd,

	(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H), 7.32 (t, 1H), 7.09 (d, 2H), 6.90 (d, 1H), 6.81 (t, 1H), 6.40 (d, 1H), 3.44-3.35 (m, 2H), 2.96 (s, 3H), 1.98 (s, 3H), 1.12 (t, 3H); (M+1): 370.15
80.	N'-(2-chloro-5-methyl-4-(methyl(2-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.70-7.57 (m, 3H), 7.26-7.22 (m, 2H), 6.80-6.77 (m, 2H), 3.40-3.26 (m, 2H), 3.08 (s, 3H), 2.93 (s, 3H), 1.96 (s, 3H), 1.11 (t, 3H); (M+1): 384.20
81.	N'-(2-chloro-5-methyl-4-((4-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 8.03 (s, 1H), 7.69 (d, 1H), 7.43 (d, 2H), 7.11 (s, 1H), 6.90 (d, 1H), 6.71 (d, 2H), 3.44-3.35 (m, 2H), 2.95 (s, 3H), 2.08 (s, 3H), 1.13 (t, 3H); (M+1): 370.05
82.	N'-(2-chloro-4-((3-fluorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.61 (s, 2H), 7.13 (dd, 1H), 7.08 (s, 1H), 6.88 (s, 1H), 6.48 (dd, 1H), 6.45-6.40 (m, 1H), 6.34 (dt, 1H), 3.43-3.36 (m, 2H), 2.95 (s, 3H), 2.08 (s, 3H), 1.14 (t, 3H); (M+1): 320.10
83.	N'-(2-chloro-4-((4-fluorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.64 (s, 1H), 7.27 (s, 1H), 7.02-6.96 (m, 3H), 6.84 (s, 1H), 6.76-6.72 (m, 2H), 3.40-3.32 (m, 2H), 2.93 (s, 3H), 2.09 (s, 3H), 1.16 (t, 3H); (M+1): 320.05
84.	N'-(2-chloro-4-((3-fluorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.72 (s, 1H), 7.14-7.08 (m, 2H), 6.94 (d, 1H), 6.43-6.38 (m, 1H), 6.21-6.17 (m, 2H), 3.45-3.36 (m, 2H), 3.12 (s, 3H), 3.00 (s, 3H), 1.98 (s, 3H), 1.14 (t, 3H); (M+1): 334.15
85.	N'-(2-chloro-4-((4-fluorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.71 (s, 1H), 7.07 (s, 1H), 6.99-6.90 (m, 3H), 6.45-6.42 (m, 2H), 3.40-3.25 (m, 2H), 3.10 (s, 3H), 2.96 (s, 3H), 1.98 (s, 3H), 1.13 (t, 3H); (M+1): 334.20
86.	N'-(2,5-dimethyl-4-((3-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.71 (s, 1H), 7.63 (s, 1H), 7.27 (t, 1H), 6.88-6.80 (m, 4H), 6.67 (s, 1H), 3.40-3.34 (m, 2H), 2.92 (s, 3H), 2.11 (s, 3H), 2.05 (s, 3H), 1.12 (t, 3H); (M+1): 350.15
87.	N'-(2-chloro-5-methyl-4-((3-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.85 (s, 1H), 7.69 (d, 1H), 7.33 (t, 1H), 7.08 (d, 1H), 6.96-6.87 (m, 4H), 3.46-3.35 (m, 2H), 2.95 (s, 3H), 2.08 (s, 3H), 1.11 (t, 3H); (M+1): 370.10
88.	N'-(2-chloro-5-methyl-4-(methyl(3-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.74 (s, 1H), 7.33 (t, 1H), 7.15 (s, 1H), 6.97-6.93 (m, 2H), 6.69-6.64 (m, 2H), 3.46-3.33 (m, 2H), 3.18 (s, 3H), 2.97 (s, 3H), 1.97 (s, 3H), 1.14 (t, 3H); (M+1): 384.15
89.	N'-(2,5-dimethyl-4-(methyl(3-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.68 (s, 1H), 7.29 (t, 1H), 6.88-6.85 (m, 2H), 6.72 (s, 1H), 6.66-6.60 (m, 2H), 3.41-3.39 (m, 2H), 3.16 (s, 3H), 2.95 (s, 3H), 2.11 (s, 3H), 1.94 (s, 3H), 1.12 (t, 3H); (M+1): 364.30
90.	N'-(4-((2,6-difluorophenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.55 (s, 1H), 7.07-6.95 (m, 3H), 6.56 (d, 2H), 6.31 (s, 1H), 3.35-3.29 (m, 1H), 2.89 (s, 3H), 2.16 (s, 3H), 2.00 (s, 3H), 1.10 (t, 3H); (M+1): 318.35
91.	N'-(2-chloro-4-((2,6-difluorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.61 (s, 1H), 7.15-7.05 (m, 3H), 6.80 (d, 2H), 6.39 (s, 1H), 3.35-3.31 (m, 2H), 2.88 (s, 3H), 2.18 (s, 3H), 1.10 (t, 3H); (M+1): 338.1
92.	N'-(4-((2,6-difluorophenyl)(methyl)amino)-2,5-	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.55-7.49 (m, 1H), 7.10-6.96 (m, 3H), 6.84 (s, 1H), 6.49 (s, 1H), 3.35-

	dimethylphenyl)-N-ethyl-N-methylformimidamide	3.24 (m, 2H), 3.18 (s, 3H), 2.89 (s, 3H), 2.15 (s, 3H), 1.86 (s, 3H), 1.10 (t, 3H); (M+1): 332.35
93.	N'-(2-chloro-4-((2,6-difluorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.62 (s, 1H), 7.16-7.11 (m, 1H), 7.07-7.02 (m, 3H), 6.70 (s, 1H), 3.47-3.34 (m, 2H), 3.17 (s, 3H), 2.92 (s, 3H), 1.79 (s, 3H), 1.10 (t, 3H); (M+1): 352.15
94.	N'-(4-((2-chloro-6-fluorophenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.55 (s, 1H), 7.30-7.28 (m, 1H), 7.18 (d, 1H), 7.01 (td, 1H), 6.55 (s, 1H), 6.47 (s, 1H), 6.22 (s, 1H), 3.35-3.28 (d, 2H), 2.89 (s, 3H), 2.16 (s, 3H), 1.99 (s, 3H), 1.10 (t, 3H); (M+1): 334.7
95.	N'-(2-chloro-4-((2-chloro-6-fluorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.66 (s, 1H), 7.35 (d, 1H), 7.28-7.23 (m, 1H), 7.13 (td, 1H), 6.78 (d, 2H), 6.27 (s, 1H), 3.39-3.34 (m, 2H), 2.91 (s, 3H), 2.18 (s, 3H), 1.11 (t, 3H); (M+1): 354.1
96.	N'-(4-((2-chloro-6-fluorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.55 (s, 1H), 7.31-7.28 (m, 1H), 7.18-7.14 (m, 2H), 6.81 (s, 1H), 6.46 (s, 1H), 3.35-3.28 (d, 2H), 3.14 (s, 3H), 2.89 (s, 3H), 2.11 (s, 3H), 1.76 (s, 3H), 1.09 (t, 3H); (M+1): 348.65
97.	N'-(2,5-dimethyl-4-((4-(pentafluoro-16-sulfanyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 8.05 (s, 1H), 7.64-7.53 (m, 3H), 6.89 (s, 1H), 6.68 (s, 1H), 6.59 (d, 2H), 3.49-3.32 (m, 2H), 2.92 (s, 3H), 2.11 (s, 3H), 2.05 (s, 3H), 1.12 (t, 3H); (M+1): 408.15
98.	N'-(4-((2,6-dichloro-4-(trifluoromethyl)phenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.73 (s, 2H), 7.61-7.59 (m, 1H), 7.16 (s, 1H), 6.58 (s, 1H), 6.35 (s, 1H), 3.41-3.35 (m, 2H), 2.88 (s, 3H), 2.11 (s, 3H), 1.99 (s, 3H), 1.08 (t, 3H); (M+1): 418.10
99.	N'-(2,5-dimethyl-4-((2-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.63 (s, 1H), 7.21-7.17 (m, 2H), 7.05-7.01 (m, 1H), 6.83 (s, 1H), 6.67-6.61 (m, 2H), 6.35 (dd, 1H), 3.35 (s, 2H), 2.92 (s, 3H), 2.11 (s, 3H), 2.02 (s, 3H), 1.12 (t, 3H); (M+1): 366.1
100.	N'-(2-chloro-5-methyl-4-((2-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.69 (s, 1H), 7.39 (s, 1H), 7.23-7.21 (m, 1H), 7.11-7.07 (m, 1H), 7.01 (s, 1H), 6.90 (s, 1H), 6.77-6.70 (m, 1H), 6.42 (dd, 1H), 3.43-3.34 (m, 2H), 2.96 (s, 3H), 2.04 (s, 3H), 1.13 (t, 3H); (M+1): 386.65
101.	N'-(2-chloro-5-methyl-4-((3-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.79-7.62 (m, 2H), 7.21 (t, 1H), 7.09 (s, 1H), 6.89 (s, 1H), 6.65-6.51 (m, 3H), 3.44-3.35 (m, 2H), 2.95 (s, 3H), 2.08 (s, 3H), 1.13 (t, 3H); (M+1): 386.40
102.	N'-(2,5-dimethyl-4-((4-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.60 (s, 1H), 7.45 (s, 1H), 7.06 (d, 2H), 6.87 (s, 1H), 6.64-6.61 (m, 3H), 3.35-3.31 (m, 2H), 2.91 (s, 3H), 2.10 (s, 3H), 1.98 (s, 3H), 1.11 (t, 3H); (M+1): 366.05
103.	N'-(2-chloro-5-methyl-4-((4-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.66 (d, 2H), 7.12 (d, 2H), 7.08 (s, 1H), 6.87 (s, 1H), 6.73-6.69 (m, 2H), 3.42-3.33 (m, 2H), 2.95 (s, 3H), 2.10 (s, 3H), 1.13 (t, 3H); (M+1): 386.35
104.	N'-(2,5-dimethyl-4-(methyl(2-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.59 (s, 1H), 7.26-7.22 (m, 1H), 7.17-7.15 (m, 1H), 7.00 (dd, 1H), 6.94-6.90 (m, 1H), 6.60 (d, 2H), 3.35-3.31 (m, 2H), 3.07 (s, 3H), 2.91 (s, 3H), 2.04 (s, 3H), 1.98 (s, 3H), 1.10 (t, 3H); (M+1): 380.15
105.	N'-(2-chloro-5-methyl-4-(methyl(2-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.65 (s, 1H), 7.31-7.27 (m, 1H), 7.21-7.19 (m, 1H), 7.10 (dd, 1H), 7.02-6.97 (m, 1H), 6.87 (s, 1H), 6.73-6.69 (m, 2H), 3.42-3.33 (m, 2H), 2.95 (s, 3H), 2.10 (s, 3H), 1.13 (t, 3H); (M+1): 386.35

	yl)-N-ethyl-N-methylformimidamide	¹ H), 6.85 (s, 1H), 6.79 (s, 1H), 3.42-3.32 (m, 2H), 3.06 (s, 3H), 2.98 (s, 3H), 2.06 (s, 3H), 1.12 (t, 3H); (M+1): 400.65
106.	N'-(2,5-dimethyl-4-(methyl(4-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.66 (s, 1H), 7.08 (d, 2H), 6.83 (s, 1H), 6.70 (s, 1H), 6.43 (dd, 2H), 3.34-3.29 (m, 2H), 3.12 (s, 3H), 2.92 (s, 3H), 2.11 (s, 3H), 1.96 (s, 3H), 1.12 (t, 3H); (M+1): 380.10
107.	N'-(2-chloro-5-methyl-4-(methyl(4-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.71 (s, 1H), 7.12-7.10 (m, 3H), 6.94 (d, 1H), 6.49-6.45 (m, 2H), 3.45-3.32 (m, 2H), 3.13 (s, 3H), 2.93 (s, 3H), 1.98 (s, 3H), 1.14 (t, 3H); (M+1): 400.70
108.	N'-(2-chloro-5-methyl-4-(methyl(3-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.73 (s, 1H), 7.21 (t, 1H), 7.14 (s, 1H), 6.95 (d, 1H), 6.57 (d, 1H), 6.42 (dd, 1H), 6.28 (s, 1H), 3.45-3.33 (m, 2H), 3.15 (s, 3H), 2.97 (s, 3H), 1.97 (s, 3H), 1.14 (t, 3H); (M+1): 400.60
109.	N'-(2-chloro-5-methyl-4-(N-phenylethylsulfonamido)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.71 (s, 1H), 7.57 (s, 1H), 7.36-7.34 (m, 4H), 7.23-7.16 (m, 1H), 6.90 (d, 1H), 3.33 (m, 4H), 2.96 (s, 3H), 2.18 (s, 3H), 1.22 (s, 3H), 1.13 (t, 3H); (M+1): 394.35
110.	N'-(2-chloro-4-((2,4-dichloro-6-(trifluoromethyl)phenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.82 (s, 2H), 7.71 (s, 1H), 7.36 (s, 1H), 6.82 (s, 1H), 6.50 (s, 1H), 3.34 (q, 2H), 2.94 (s, 3H), 2.16 (s, 3H), 1.12 (t, 3H); (M+1): 439.95
111.	N'-(2-chloro-5-methyl-4-((4-(pentafluoro-l6-sulfanyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 8.17 (s, 1H), 7.69 (d, 1H), 7.59 (d, 2H), 7.12 (s, 1H), 6.92 (s, 1H), 6.65 (d, 2H), 3.43-3.34 (m, 2H), 2.96 (s, 3H), 2.08 (s, 3H), 1.13 (t, 3H); (M+1): 428.0
112.	N'-(2-chloro-4-((2-chloro-6-fluorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.61 (s, 1H), 7.34 (dd, 1H), 7.26-7.24 (m, 2H), 7.03 (s, 1H), 6.68 (s, 1H), 3.39-3.24 (m, 2H), 3.16 (s, 3H), 2.92 (s, 3H), 1.69 (s, 3H), 1.11 (t, 3H); (M+1): 368.95
113.	N'-(2,5-dimethyl-4-(methyl(4-(pentafluoro-l6-sulfanyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.68 (s, 1H), 7.57 (d, 2H), 6.85 (s, 1H), 6.73 (s, 1H), 6.45 (d, 2H), 3.40-3.24 (m, 2H), 3.19 (s, 3H), 2.96 (s, 3H), 2.12 (s, 3H), 1.96 (s, 3H), 1.12 (t, 3H); (M+1): 422.2.
114.	N'-(2-chloro-5-methyl-4-(methyl(4-(pentafluoro-l6-sulfanyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.70 (s, 1H), 7.57 (d, 2H), 7.13 (s, 1H), 6.94 (d, 1H), 6.45 (d, 2H), 3.43-3.30 (m, 2H), 3.17 (s, 3H), 2.94 (s, 3H), 1.95 (s, 3H), 1.13 (t, 3H); (M+1): 442.15
115.	N'-(2-chloro-5-methyl-4-(methyl(3-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.72 (s, 1H), 7.08-7.03 (m, 2H), 6.92 (d, 1H), 6.54 (dd, 1H), 6.31 (t, 1H), 6.20 (dd, 1H), 3.32-3.26 (m, 2H), 3.12 (s, 3H), 2.96 (s, 3H), 2.36 (s, 3H), 1.98 (s, 3H), 1.14 (t, 3H); (M+1): 362.15
116.	N'-(2,5-dimethyl-4-((2-((trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.65 (s, 1H), 7.47 (dd, 1H), 7.39 (s, 1H), 7.21-7.15 (m, 1H), 6.84 (s, 1H), 6.64-6.60 (m, 2H), 6.33 (dd, 1H), 3.34-3.30 (m, 2H), 2.92 (s, 3H), 2.12 (s, 3H), 2.02 (s, 3H), 1.12 (t, 3H); (M+1): 382.10
117.	N'-(2-chloro-5-methyl-4-((2-((trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.70 (s, 1H), 7.56 (s, 1H), 7.51 (dd, 1H), 7.30-7.26 (m, 1H), 7.04 (s, 1H), 6.92 (d, 1H), 6.73 (td, 1H), 6.37 (dd, 1H), 3.45-3.34 (m, 2H), 2.96 (s, 3H), 2.04 (s, 3H), 1.14 (t, 3H); (M+1): 402.15

118.	N'-(4-((3-(difluoromethyl)thio)phenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.62-7.12 (m, 4H), 6.87 (s, 1H), 6.77-6.76 (m, 2H), 6.70-6.65 (m, 2H), 3.34-3.40 (m, 2H), 2.92 (s, 3H), 2.11 (s, 3H), 2.06 (s, 3H), 1.12 (t, 3H); (M+1): 364.15
119.	N'-(2,5-dimethyl-4-((4-(trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.91 (s, 1H), 7.62 (s, 1H), 7.37 (d, 2H), 6.89 (s, 1H), 6.67-6.62 (m, 3H), 3.48-3.33 (m, 2H), 2.92 (s, 3H), 2.11 (s, 3H), 2.07 (s, 3H), 1.15 (t, 3H); (M+1): 382.20
120.	N'-(2-chloro-5-methyl-4-((4-(trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 8.03 (s, 1H), 7.74-7.65 (m, 1H), 7.42 (d, 2H), 7.11 (s, 1H), 6.91 (s, 1H), 6.69 (d, 2H), 3.44-3.33 (m, 2H), 2.96 (s, 3H), 2.09 (s, 3H), 1.13 (t, 3H); (M+1): 402.10
121.	N'-(2,5-dimethyl-4-(methyl(2-(trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.63-7.43 (m, 3H), 7.22 (dd, 1H), 7.02 (td, 1H), 6.66 (s, 1H), 6.33 (s, 1H), 3.46-3.33 (m, 2H), 3.01 (s, 3H), 2.90 (s, 3H), 2.18 (s, 3H), 1.98 (s, 3H), 1.10 (t, 3H); (M+1): 396.40
122.	N'-(2-chloro-5-methyl-4-(methyl(2-(trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.68 (s, 1H), 7.54-7.49 (m, 2H), 7.27 (dd, 1H), 7.10 (td, 1H), 6.88 (d, 1H), 6.55 (s, 1H), 3.38-3.32 (m, 2H), 3.02 (s, 3H), 2.94 (s, 3H), 2.17 (s, 3H), 1.12 (t, 3H); (M+1): 416.15
123.	N'-(2,5-dimethyl-4-(methyl(4-(trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.67 (s, 1H), 7.39 (d, 2H), 6.85 (s, 1H), 6.72 (s, 1H), 6.48 (d, 2H), 3.34-3.26 (m, 2H), 3.16 (s, 3H), 2.93 (s, 3H), 2.12 (s, 3H), 1.95 (s, 3H), 1.12 (t, 3H); (M+1): 396.40
124.	N'-(2-chloro-5-methyl-4-(methyl(4-(trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.72 (s, 1H), 7.43 (d, 2H), 7.15 (s, 1H), 6.96 (d, 1H), 6.51 (d, 2H), 3.46-3.33 (m, 2H), 3.18 (s, 3H), 2.97 (s, 3H), 1.97 (s, 3H), 1.14 (t, 3H); (M+1): 416.15
125.	N'-(4-((3-(difluoromethyl)thio)phenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.67 (s, 1H), 7.40 (t, 1H), 7.17 (t, 1H), 6.84 (s, 1H), 6.78 (d, 1H), 6.71 (s, 1H), 6.56 (s, 1H), 6.50 (d, 1H), 3.50-3.34 (m, 2H), 3.11 (s, 3H), 2.93 (s, 3H), 2.11 (s, 3H), 1.95 (s, 3H), 1.12 (t, 3H); (M+1): 378.35
126.	N'-(2,5-dimethyl-4-((3-(trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.65 (d, 2H), 7.21 (t, 1H), 6.88-6.78 (m, 4H), 6.66 (s, 1H), 3.50-3.23 (m, 2H), 2.92 (s, 3H), 2.10 (s, 3H), 2.05 (s, 3H), 1.11 (t, 3H); (M+1): 382.30
127.	N'-(2,5-dimethyl-4-((4-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.59 (s, 1H), 7.26 (s, 1H), 7.10 (d, 2H), 6.85 (s, 1H), 6.62-6.59 (m, 3H), 3.48-3.33 (m, 2H), 2.91 (s, 3H), 2.34 (s, 3H), 2.07 (s, 6H), 1.11 (t, 3H); (M+1): 328.30
128.	N'-(2-chloro-5-methyl-4-((4-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.65 (s, 1H), 7.39 (s, 1H), 7.14 (d, 2H), 7.04 (s, 1H), 6.84 (s, 1H), 6.69 (d, 2H), 3.41-3.34 (m, 2H), 2.94 (s, 3H), 2.37 (s, 3H), 2.09 (s, 3H), 1.12 (t, 3H); (M+1): 348.10
129.	N'-(2,5-dimethyl-4-(methyl(3-(trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.68 (s, 1H), 7.25 (t, 1H), 6.85-6.81 (m, 2H), 6.72 (s, 1H), 6.61-6.55 (m, 2H), 3.34-3.31 (m, 2H), 3.14 (s, 3H), 2.92 (s, 3H), 2.12 (s, 3H), 1.94 (s, 3H), 1.12 (t, 3H); (M+1): 396.40
130.	N'-(2-chloro-5-methyl-4-(methyl(3-(trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.73 (s, 1H), 7.28 (t, 1H), 7.14 (s, 1H), 6.96-6.93 (m, 2H), 6.68 (d, 1H), 6.63 (s, 1H), 3.46-3.33 (m, 2H), 3.17 (s, 3H), 2.97 (s, 3H), 1.96 (s, 3H), 1.13 (t, 3H); (M+1): 416.15

131.	N'-(2,5-dimethyl-4-(methyl(4-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.65 (s, 1H), 7.11 (d, 2H), 6.80 (s, 1H), 6.68 (s, 1H), 6.39 (d, 2H), 3.38-3.34 (m, 2H), 3.09 (s, 3H), 2.92 (s, 3H), 2.33 (s, 3H), 2.10 (s, 3H), 1.95 (s, 3H), 1.12 (t, 3H); (M+1): 342.25
132.	N'-(2-chloro-5-methyl-4-(methyl(4-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.71 (s, 1H), 7.13 (d, 2H), 7.07 (s, 1H), 6.92 (s, 1H), 6.42 (d, 2H), 3.34-3.25 (m, 2H), 3.11 (s, 3H), 2.96 (s, 3H), 2.34 (s, 3H), 1.98 (s, 3H), 1.14 (t, 3H); (M+1): 362.15
133.	N'-(2,5-dimethyl-4-((3-(pentafluoro-l6-sulfanyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.82 (s, 1H), 7.64 (s, 1H), 7.27 (t, 1H), 7.04-7.01 (m, 2H), 6.88 (s, 1H), 6.78-6.76 (m, 1H), 6.68 (s, 1H), 3.46-3.28 (m, 2H), 2.92 (s, 3H), 2.11 (s, 3H), 2.03 (s, 3H), 1.12 (t, 3H); (M+1): 408.15
134.	N'-(2-chloro-5-methyl-4-((3-(pentafluoro-l6-sulfanyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.95 (s, 1H), 7.69 (d, 1H), 7.33 (t, 1H), 7.10-7.07 (m, 3H), 6.91 (s, 1H), 6.84 (d, 1H), 3.46-3.43 (m, 2H), 2.95 (s, 3H), 2.08 (s, 3H), 1.13 (t, 3H); (M+1): 428.65
135.	N'-(2,5-dimethyl-4-(methyl(3-(pentafluoro-l6-sulfanyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.65 (s, 1H), 7.31 (t, 1H), 7.04 (dd, 1H), 6.87 (s, 1H), 6.73 (s, 2H), 6.67 (d, 1H), 3.35-3.33 (m, 2H), 3.17 (s, 3H), 2.92 (s, 3H), 2.12 (s, 3H), 1.95 (s, 3H), 1.12 (t, 3H); (M+1): 422.3
136.	N'-(2-chloro-5-methyl-4-(methyl(3-(pentafluoro-l6-sulfanyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.74 (s, 1H), 7.34 (t, 1H), 7.18 (s, 1H), 7.10 (d, 1H), 6.97 (d, 1H), 6.75 (s, 1H), 6.69 (d, 1H), 3.46-3.40 (m, 2H), 3.20 (s, 3H), 2.97 (s, 3H), 1.97 (s, 3H), 1.13-1.16 (m, 3H); (M+1): 442.15
137.	N'-(4-((3,5-bis(trifluoromethyl)phenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 8.27 (s, 1H), 7.67 (s, 1H), 7.12 (s, 1H), 7.00 (s, 2H), 6.91 (s, 1H), 6.72 (s, 1H), 3.34-3.30 (m, 2H), 2.92 (s, 3H), 2.12 (s, 3H), 2.04 (s, 3H), 1.12 (t, 3H); (M+1): 418.35
138.	N'-(4-((3,5-bis(trifluoromethyl)phenyl)amino)-2-chloro-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 8.38 (s, 1H), 7.72 (d, 1H), 7.20 (s, 1H), 7.17 (s, 1H), 7.05 (s, 2H), 6.96 (s, 1H), 3.45-3.34 (m, 2H), 2.96 (s, 3H), 2.07 (s, 3H), 1.14 (t, 3H); (M+1): 438.15
139.	N'-(2-chloro-5-methyl-4-((3-((trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.79 (s, 1H), 7.68 (d, 1H), 7.27 (t, 1H), 7.09 (s, 1H), 6.95 (d, 1H), 6.90-6.85 (m, 3H), 3.42-3.33 (m, 2H), 2.95 (s, 3H), 2.08 (s, 3H), 1.13 (t, 3H); (M+1): 402.15
140.	N'-(2-chloro-4-((4-(dimethylamino)phenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.64 (s, 1H), 6.83-6.79 (m, 3H), 6.75-6.68 (m, 4H), 3.48-3.23 (m, 2H), 2.89 (s, 3H), 2.79 (s, 6H), 2.11 (s, 3H), 1.11 (t, 3H); (M+1): 345.20
141.	N'-(4-((4-(dimethylamino)phenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.55 (s, 1H), 6.71 (d, 3H), 6.66-6.63 (m, 2H), 6.54 (d, 2H), 3.35-3.31 (m, 2H), 2.90 (s, 3H), 2.76 (s, 6H), 2.10 (s, 3H), 2.02 (s, 3H), 1.10 (t, 3H); (M+1): 325.25
142.	N'-(2-chloro-4-((3-((difluoromethyl)thio)phenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.73-7.63 (m, 2H), 7.42 (t, 1H), 7.20 (t, 1H), 7.08 (s, 1H), 6.88-6.83 (m, 3H), 6.75 (dd, 1H), 3.42-3.33 (m, 2H), 2.98 (s, 3H), 2.09 (s, 3H), 1.13 (t, 3H); (M+1): 384.20
143.	N'-(2-chloro-4-((3-((difluoromethyl)thio)phenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.73 (s, 1H), 7.41 (t, 1H), 7.20 (t, 1H), 7.12 (s, 1H), 6.94 (d, 1H), 6.83 (d, 1H), 6.58 (t, 1H), 6.54 (dd, 1H), 3.45-3.33 (m, 2H), 3.14 (s, 3H), 3.00 (s, 3H), 1.97 (s, 3H), 1.14 (t, 3H); (M+1): 398.95

144.	N'-(4-((3-(difluoromethoxy)phenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.62 (s, 1H), 7.51 (s, 1H), 7.27-6.90 (m, 2H), 6.87 (s, 1H), 6.65 (s, 1H), 6.45 (dd, 1H), 6.35 (dd, 1H), 6.31 (t, 1H), 3.35 (q, 2H), 2.92 (s, 3H), 2.10 (s, 3H), 2.07 (s, 3H), 1.11 (t, 3H); (M+1): 348.40
145.	N'-(4-((3-(difluoromethoxy)phenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.67 (s, 1H), 7.30-6.93 (m, 2H), 6.83 (s, 1H), 6.70 (s, 1H), 6.37 (dd, 1H), 6.24 (dd, 1H), 6.14 (t, 1H), 3.34 (q, 2H), 3.13 (s, 3H), 2.93 (s, 3H), 2.11 (s, 3H), 1.96 (s, 3H), 1.12 (t, 3H); (M+1): 362.50
146.	N'-(2-chloro-4-((3-(difluoromethoxy)phenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.69 (s, 2H), 7.30-6.93 (m, 3H), 6.87 (s, 1H), 6.52 (dd, 1H), 6.44 (dd, 1H), 6.39 (t, 1H), 3.42-3.34 (m, 2H), 2.95 (s, 3H), 2.09 (s, 3H), 1.08 (t, 3H); (M+1): 368.35
147.	N'-(2,5-dimethyl-4-((2-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.59 (s, 1H), 7.24 (s, 1H), 7.15-6.77 (m, 4H), 6.64-6.60 (m, 3H), 3.35 (q, 2H), 2.91 (s, 3H), 2.11 (s, 3H), 2.02 (s, 3H), 1.15 (t, 3H); (M+1): 348.40
148.	N'-(2,5-dimethyl-4-((2-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.47 (s, 1H), 7.17-6.73 (m, 4H), 6.74-6.64 (m, 1H), 6.47-6.35 (m, 2H), 3.52-3.31 (m, 2H), 3.05 (s, 3H), 2.81 (s, 3H), 2.14 (s, 3H), 2.00 (s, 3H), 1.06 (t, 3H); (M+1): 362.50
149.	N'-(2,5-dimethyl-4-((2-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.65 (s, 1H), 7.38 (s, 1H), 7.19-6.81 (m, 5H), 6.74-6.70 (m, 2H), 3.41-3.34 (m, 2H), 2.94 (s, 3H), 2.09 (s, 3H), 1.12 (t, 3H); (M+1): 368.35
150.	N'-(2-chloro-4-((4-(difluoromethoxy)phenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.71 (s, 1H), 7.16-6.79 (m, 5H), 6.47-6.43 (m, 2H), 3.45-3.32 (m, 2H), 3.11 (s, 3H), 2.96 (s, 3H), 1.99 (s, 3H), 1.14 (t, 3H); (M+1): 382.0
151.	N'-(4-((2,5-difluorophenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.64-7.51 (m, 1H), 7.40 (s, 1H), 7.12-7.05 (m, 1H), 6.84 (s, 1H), 6.68 (s, 1H), 6.37-6.32 (m, 1H), 6.02-5.97 (m, 1H), 3.35-3.30 (m, 2H), 2.92 (s, 3H), 2.11 (s, 3H), 2.04 (s, 3H), 1.12 (t, 3H); (M+1): 318.3
152.	N'-(2-chloro-4-((2,5-difluorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.69 (s, 1H), 7.55 (s, 1H), 7.16-7.10 (m, 1H), 7.04 (s, 1H), 6.90 (s, 1H), 6.45 (tt, 1H), 6.18-6.14 (m, 1H), 3.44-3.33 (m, 2H), 2.95 (s, 3H), 2.07 (s, 3H), 1.13 (t, 3H); (M+1): 338.15
153.	N'-(4-((3,5-bis(trifluoromethyl)phenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.72 (s, 1H), 7.15 (s, 1H), 6.91 (s, 1H), 6.85 (s, 2H), 6.77 (s, 1H), 3.46-3.35 (m, 2H), 3.25 (s, 3H), 2.93 (s, 3H), 2.12 (s, 3H), 1.95 (s, 3H), 1.13 (t, 3H); (M+1): 432.45
154.	N'-(4-((3,5-bis(trifluoromethyl)phenyl)(methyl)amino)-2-chloro-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.76 (s, 1H), 7.24 (s, 1H), 7.21 (s, 1H), 7.00 (d, 1H), 6.87 (s, 2H), 3.41 (q, 2H), 3.27 (s, 3H), 2.98 (s, 3H), 1.98 (s, 3H), 1.15 (t, 3H); (M+1): 452.20
155.	N'-(2,5-dimethyl-4-((5-methyl-2-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.63 (s, 1H), 7.30 (d, 1H), 6.83 (s, 1H), 6.77 (s, 1H), 6.66 (s, 1H), 6.51 (d, 1H), 6.14 (s, 1H), 3.36 (q, 2H), 2.90 (s, 3H), 2.07 (s, 3H), 2.10 (s, 3H), 1.96 (s, 3H), 1.09 (t, 3H); (M+1): 364.4
156.	N'-(4-((2,5-difluorophenyl)(methyl)amino)-2,5-	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.54 (s, 1H), 7.04-6.97 (m, 1H), 6.73 (s, 1H), 6.63-6.53 (m, 3H), 3.35-3.27 (m,

	dimethylphenyl)-N-ethyl-N-methylformimidamide	2H), 3.10 (s, 3H), 2.91 (s, 3H), 2.06 (s, 6H), 1.15 (t, 3H); (M+1): 332.15
157.	N'-(2-chloro-4-((2,5-difluorophenyl)(methylamino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.68 (bs, 1H), 7.08-7.01 (m, 1H), 6.96 (s, 1H), 6.85 (d, 1H), 6.75-6.69 (m, 1H), 6.67-6.61 (m, 1H), 3.43-3.33 (m, 2H), 3.07 (s, 3H), 2.95 (s, 3H), 2.08 (s, 3H), 1.13 (t, 3H); (M+1): 352.7
158.	N'-(2,5-dimethyl-4-(methyl(5-methyl-2-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.58 (s, 1H), 7.49 (d, 1H), 6.96 (d, 2H), 6.64 (s, 1H), 6.55 (s, 1H), 3.35-3.27 (m, 2H), 3.06 (s, 3H), 2.90 (s, 3H), 2.28 (s, 3H), 2.06 (s, 3H), 1.97 (s, 3H), 1.10 (t, 3H); (M+1): 378.2
159.	N'-(4-((4-chloro-2-(trifluoromethyl)phenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.65 (bs, 1H), 7.46 (d, 1H), 7.32 (dd, 1H), 7.19 (s, 1H), 6.86 (s, 1H), 6.70 (s, 1H), 6.32 (d, 1H), 3.35-3.30 (m, 2H), 2.92 (s, 3H), 2.12 (s, 3H), 1.98 (s, 3H), 1.12 (t, 3H); (M+1): 384.6
160.	N'-(2-chloro-4-((4-chloro-2-(trifluoromethyl)phenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.70 (s, 1H), 7.50 (d, 1H), 7.37 (dd, 1H), 7.32 (s, 1H), 7.09 (s, 1H), 6.91 (d, 1H), 6.36 (d, 1H), 3.44-3.34 (m, 2H), 2.96 (s, 3H), 1.98 (s, 3H), 1.13 (t, 3H); (M+1): 405.2
161.	N'-(4-((4-chloro-2-(trifluoromethyl)phenyl)(methylamino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.63-7.57 (m, 3H), 7.14 (d, 1H), 6.64 (s, 1H), 6.57 (s, 1H), 3.35-3.27 (m, 2H), 3.07 (s, 3H), 2.89 (s, 3H), 2.05 (s, 3H), 1.97 (s, 3H), 1.11-1.07 (m, 3H) (M+1): 398.2
162.	N'-(2-chloro-4-((4-chloro-2-(trifluoromethyl)phenyl)(methylamino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.59-7.70 (m, 3H), 7.26 (d, 1H), 6.82 (s, 2H), 3.42-3.33 (m, 2H), 3.08 (s, 3H), 2.93 (s, 3H), 1.98 (s, 3H), 1.10-1.16 (m, 3H); (M+1): 419
163.	N'-(2-chloro-5-methyl-4-(methyl(2-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.63 (s, 1H), 7.18 (dd, 1H), 7.10 (td, 1H), 7.06 (td, 1H), 6.88 (s, 1H), 6.82 (dd, 1H), 6.74 (s, 1H), 3.30-3.28 (m, 2H), 2.98 (s, 3H), 2.96 (s, 3H), 2.37 (s, 3H), 1.86 (s, 3H), 1.11 (t, 3H); (M+1): 363.15
164.	N'-(2-chloro-4-((3-(difluoromethoxy)phenyl)(methylamino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.72 (s, 1H), 7.13 (s, 1H), 7.10 (s, 1H), 6.94 (d, 1H), 6.42 (dd, 2H), 6.26 (dd, 1H), 6.18 (t, 1H), 3.45-3.34 (m, 2H), 3.13 (s, 3H), 2.95 (s, 3H), 1.98 (s, 3H), 1.12 (t, 3H); (M+1): 383.00
165.	N'-(2-chloro-5-methyl-4-((2-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.66 (s, 1H), 7.30 (dd, 1H), 7.07-7.03 (m, 1H), 6.90 (s, 1H), 6.85 (s, 1H), 6.81 (td, 1H), 6.77 (s, 1H), 6.49 (dd, 1H), 3.42-3.34 (m, 2H), 2.94 (s, 3H), 2.38 (s, 3H), 2.05 (s, 3H), 1.13 (t, 3H); (M+1): 349.10
166.	N'-(4-((2-chloro-4-(trifluoromethyl)phenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.68-7.62 (m, 3H), 7.34 (dd, 1H), 6.89 (s, 1H), 6.72 (s, 1H), 6.32 (d, 1H), 3.36 (q, 2H), 2.93 (s, 3H), 2.11 (s, 3H), 2.01 (s, 3H), 1.11-1.16 (m, 3H); (M+1): 384.55
167.	N'-(2-chloro-4-((2-chloro-4-(trifluoromethyl)phenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.77-7.66 (m, 3H), 7.40-7.37 (m, 1H), 7.14 (s, 1H), 6.95 (d, 1H), 6.35 (d, 1H), 3.46-3.35 (m, 2H), 2.97 (s, 3H), 2.02 (s, 3H), 1.14 (t, 3H); (M+1): 404.15
168.	N'-(4-((2-chloro-4-(trifluoromethyl)phenyl)(methylamino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.60-7.62 (m, 3H), 7.24 (d, 1H), 6.64 (s, 1H), 6.56 (s, 1H), 3.35 (q, 2H), 3.09 (s, 3H), 2.91 (s, 3H), 2.10 (s, 3H), 2.04 (s, 3H), 1.11 (t, 3H); (M+1): 398.60
169.	N'-(2-chloro-4-((2-chloro-4-	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.74-7.63 (m, 3H),

	(trifluoromethyl)phenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.29 (d, 1H), 6.88 (s, 1H), 6.78 (s, 1H), 3.43-3.35 (m, 2H), 3.09 (s, 3H), 2.95 (s, 3H), 2.10 (s, 3H), 1.11-1.14 (m, 3H); (M+1): 418.20
170.	N'-(2,5-dimethyl-4-((2-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.61 (s, 1H), 7.30 (dd, 1H), 7.02-6.98 (m, 1H), 6.83 (s, 1H), 6.69-6.65 (m, 2H), 6.60 (s, 1H), 6.37 (dd, 1H), 3.35-3.29 (m, 2H), 2.92 (s, 3H), 2.38 (s, 3H), 2.12 (s, 3H), 2.01 (s, 3H), 1.12 (t, 3H); (M+1): 328.45
171.	N-ethyl-N'-(4-((4-fluoro-3-(1,1,2,2-tetrafluoroethoxy)phenyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.63 (s, 1H), 7.49 (s, 1H), 7.18-7.13 (m, 1H), 6.98-6.91 (m, 2H), 6.65 (s, 1H), 6.58-6.54 (m, 2H), 3.35-3.23 (m, 2H), 2.91 (s, 3H), 2.08 (s, 3H), 2.06 (s, 3H), 1.11 (t, 3H); (M+1): 416.25
172.	N'-(2-chloro-4-((4-fluoro-3-(1,1,2,2-tetrafluoroethoxy)phenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.68 (d, 2H), 7.24-7.19 (m, 1H), 7.07 (s, 1H), 6.96-6.70 (m, 2H), 6.66-6.62 (m, 2H), 3.43-3.34 (m, 2H), 2.95 (s, 3H), 2.08 (s, 3H), 1.13 (t, 3H); (M+1): 436.10
173.	5-chloro-N-(2-fluorophenyl)-N,2-dimethyl-4-((morpholinomethylene)amino)aniline	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.63 (s, 1H), 7.21-7.16 (m, 1H), 6.93-6.66 (m, 3H), 6.38 (dt, 1H), 6.27 (dd, 1H), 3.39 (s, 2H), 3.12 (s, 3H), 2.92 (s, 3H), 2.11 (s, 3H), 1.97 (s, 3H), 1.14-1.07 (t, 3H); (M+1): 430.1
174.	N'-(2-chloro-4-(N-(2-fluorophenyl)methylsulfonamido)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.74-7.65 (m, 3H), 7.42-7.36 (m, 1H), 7.35-7.29 (m, 1H), 7.26-7.22 (m, 1H), 6.88 (d, 1H), 3.44-3.32 (m, 2H), 3.20 (d, 3H), 2.95 (s, 3H), 2.29 (s, 3H), 1.12 (t, 3H); (M+1): 398.15
175.	N-(5-chloro-4-(((ethyl(methyl)amino)methylene)amino)-2-methylphenyl)-N-(2-fluorophenyl)acetamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.84-7.77 (m, 6H), 6.86-6.74 (m, 1H), 3.34-3.32 (m, 2H), 2.95 (s, 3H), 2.13 (s, 3H), 1.98 (s, 3H), 1.16 (t, 3H); (M+1): 362.20
176.	N'-(2-chloro-4-((2-fluorophenyl)(methyl)amino)-5-methylphenyl)-N,N-dimethylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.67 (s, 1H), 7.03-7.01 (m, 2H), 6.94 (s, 1H), 6.87-6.82 (m, 2H), 6.82 (s, 1H), 3.07 (s, 3H), 3.00 (s, 3H), 2.92 (s, 3H), 2.01 (s, 3H); (M+1): 320.50
177.	N'-(2-chloro-4-(ethyl(2-fluorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.67 (s, 1H), 7.08-7.00 (m, 3H), 6.88-6.80 (m, 3H), 3.52 (q, 2H), 3.37 (q, 2H), 2.94 (s, 3H), 1.98 (s, 3H), 1.14-1.07 (m, 6H); (M+1): 348.10
178.	5-chloro-N-(2-fluorophenyl)-N,2-dimethyl-4-((morpholinomethylene)amino)aniline	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.73 (s, 1H), 7.08-7.01 (m, 2H), 6.96 (s, 1H), 6.92-6.79 (m, 2H), 5.74 (s, 1H), 3.63-3.60 (m, 4H), 3.54-3.50 (m, 4H), 3.07 (s, 3H), 2.02 (s, 3H); (M+1): 362.10
179.	5-chloro-N-(2-fluorophenyl)-N,2-dimethyl-4-((thiomorpholinomethylene)amino)aniline	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.71 (s, 1H), 7.08-7.03 (m, 2H), 6.95 (s, 1H), 6.93-6.87 (m, 3H), 3.84-3.80 (m, 2H), 3.64-3.60 (m, 2H), 3.07 (s, 3H), 2.62-2.60 (m, 4H), 2.02 (s, 3H); (M+1): 379.00
180.	N-ethyl-N'-(5-fluoro-4-((4-fluoro-3-(1,1,2,2-tetrafluoroethoxy)phenyl)amino)-2-methylphenyl)-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.80 (s, 1H), 7.68 (d, 1H), 7.22-7.17 (m, 1H), 6.99-6.66 (m, 5H), 3.41-3.36 (m, 2H), 2.94 (s, 3H), 2.11 (s, 3H), 1.12 (t, 3H) (M+1): 420.50
181.	N-ethyl-N'-(5-fluoro-4-((4-fluoro-3-(1,1,2,2-tetrafluoroethoxy)phenyl)(methyl)amino)-2-methylphenyl)-N-	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.72 (s, 1H), 7.22 (t, 1H), 7.05 (d, 1H), 6.95-6.67 (m, 2H), 6.53 (dt, 1H), 6.46 (q, 1H), 3.43-3.33 (m, 2H), 3.16 (s, 3H), 2.95 (s, 3H), 2.13 (s, 3H), 1.16-1.08 (m, 3H); (M+1): 434.1

	methyleformimidamide	
182.	N-(5-chloro-4-(((ethyl(methyl)amino)methylene)amino)-2-methylphenyl)-N-(2-chlorophenyl)acetamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.70 (s, 1H), 6.95-7.66 (m, 5H), 6.90 (s, 1H), 3.39 (q, 2H), 2.96 (s, 3H), 2.24 (s, 3H), 1.93 (s, 3H), 1.15 (t, 3H); (M+1): 378.05
183.	N'-(2-chloro-4-(N-(2-chlorophenyl)methylsulfonamido)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.87 (dd, 1H), 7.65-7.76 (m, 2H), 7.54 (dd, 1H), 7.42 (td, 1H), 7.39-7.35 (m, 1H), 6.87 (d, 1H), 3.43-3.44 (m, 2H), 3.24 (s, 3H), 2.95 (s, 3H), 2.33 (s, 3H), 1.12 (t, 3H); (M+1): 414.10
184.	N'-(4-((4-((difluoromethyl)thio)phenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.71 (s, 1H), 7.62 (s, 1H), 7.36-7.08 (m, 3H), 6.88 (s, 1H), 6.66 (s, 1H), 6.63-6.59 (m, 2H), 3.36-3.21 (m, 2H), 2.92 (s, 3H), 2.11 (s, 3H), 2.06 (s, 3H), 1.11 (t, 3H); (M+1): 364.50
185.	N'-(2-chloro-4-((4-((difluoromethyl)thio)phenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.83 (s, 1H), 7.68 (d, 1H), 7.39-7.10 (m, 3H), 7.09 (s, 1H), 6.89-6.83 (m, 1H), 6.67 (d, 2H), 3.44-3.35 (m, 2H), 2.95 (s, 3H), 2.08 (s, 3H), 1.13 (t, 3H); (M+1): 384.35
186.	N'-(4-((4-((difluoromethyl)thio)phenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.62 (s, 1H), 7.35-7.07 (m, 3H), 6.83 (s, 1H), 6.69 (d, 1H), 6.48-6.43 (m, 2H), 3.40-3.38 (m, 2H), 3.18 (s, 3H), 2.99 (s, 3H), 2.15 (s, 3H), 2.01 (s, 3H), 1.16 (t, 3H); (M+1): 378.55
187.	N'-(2-chloro-4-((4-((difluoromethyl)thio)phenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.72 (s, 1H), 7.37-7.09 (m, 4H), 6.95 (d, 1H), 6.49-6.46 (m, 2H), 3.40-3.35 (m, 2H), 3.17 (s, 3H), 2.93 (s, 3H), 2.00 (s, 3H), 1.14 (t, 3H); (M+1): 399.0
188.	N'-(2-chloro-4-(ethyl(phenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.72 (s, 1H), 7.12-7.06 (m, 2H), 7.05 (d, 1H), 6.93 (d, 1H), 6.59 (t, 1H), 6.42 (d, 2H), 3.56 (q, 2H), 3.45-3.34 (m, 2H), 2.96 (s, 3H), 1.99 (s, 3H), 1.15 (m, 3H), 1.06 (t, 3H); (M+1): 330.35
189.	N-(5-chloro-4-(((ethyl(methyl)amino)methylene)amino)-2-methylphenyl)-N-phenylacetamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.71 (s, 1H), 7.38-7.16 (m, 6H), 6.92 (d, 1H), 3.39 (q, 2H), 2.95 (s, 3H), 2.10 (s, 3H), 1.88 (s, 3H), 1.13 (t, 3H); (M+1): 344.15
190.	N'-(2-chloro-4-((2-((difluoromethyl)thio)phenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.71 (s, 1H), 7.49-7.09 (m, 5H), 6.93 (s, 1H), 6.75 (td, 1H), 6.43 (dd, 1H), 3.34-3.26 (m, 2H), 2.97 (s, 3H), 2.07 (s, 3H), 1.34 (t, 3H); (M+1): 385.00
191.	N'-(2-chloro-4-((2-((difluoromethyl)thio)phenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.66 (s, 1H), 7.53-7.23 (m, 3H), 7.13-7.07 (m, 2H), 6.83 (d, 1H), 6.67 (s, 1H), 3.45-3.41 (m, 2H), 3.00 (s, 3H), 2.93 (s, 3H), 2.06 (s, 3H), 1.13 (t, 3H); (M+1): 398.35
192.	N'-(2-chloro-4-(ethyl(3-methoxyphenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.87 (s, 1H), 7.10-6.77 (m, 3H), 6.28-6.20 (m, 1H), 6.07-5.91 (m, 2H), 3.69 (s, 3H), 3.60-3.50 (m, 2H), 3.43-3.23 (m, 2H), 3.08 (s, 3H), 1.76 (s, 3H), 1.35 (t, 3H), 0.98 (t, 3H); (M+1): 361.45
193.	N'-(2-chloro-4-((3-(difluoromethoxy)-4-fluorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.96-7.52 (m, 2H), 7.39-6.77 (m, 4H), 6.63-6.53 (m, 2H), 3.43-3.33 (m, 2H), 3.00 (s, 3H), 1.92 (s, 3H), 1.13 (t, 3H); (M+1): 386.15
194.	N'-(2-chloro-4-(N-(3-methoxyphenyl)methylsulfonamido)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.79-7.61 (m, 2H), 7.29 (t, 1H), 6.94-6.81 (m, 4H), 3.84-3.74 (m, 5H), 3.47 (s, 3H), 2.98 (s, 3H), 2.22 (s, 3H), 1.12 (t, 3H); (M+1): 411.00

195.	N'-(4-((3-(difluoromethoxy)-4-fluorophenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) 7.62 (s, 1H), 7.39 (d, 1H), 7.17-6.84 (m, 2H), 6.53 (dd, 1H), 6.60-6.36 (m, 2H), 6.46 (dd, 1H), 3.28-3.13 (m, 2H), 2.50 (s, 3H), 1.91 (s, 6H), 1.62 (t, 3H); (M+1): 366.55
196.	N'-(2-chloro-4-((3-(difluoromethoxy)-4-fluorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.79 (s, 1H), 7.34-7.12 (m, 1H), 7.18-7.12 (m, 2H), 6.97 (d, 1H), 6.39-6.25 (m, 1H), 6.28-6.25 (m, 1H), 3.38-3.34 (m, 2H), 2.90 (s, 3H), 2.50 (s, 6H), 1.14 (t, 3H); (M+1): 401.00
197.	N'-(4-((3-(difluoromethoxy)-4-fluorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.68 (s, 1H), 7.29-6.92 (m, 2H), 6.81 (s, 1H), 6.68 (s, 1H), 6.35-6.29 (m, 1H), 6.18 (dt, 1H), 3.52-3.30 (m, 2H), 3.12 (s, 3H), 2.90 (s, 3H), 2.17 (s, 3H), 1.99 (s, 3H), 1.25 (t, 3H); (M+1): 380.55
198.	N'-(4-((2,5-dimethylphenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.62 (s, 1H), 6.90 (d, 1H), 6.70 (s, 1H), 6.63 (s, 1H), 6.41 (d, 1H), 6.34 (s, 1H), 6.12 (s, 1H), 3.36 (q, 2H), 2.92 (s, 3H), 2.07 (s, 3H), 2.12 (s, 6H), 2.01 (s, 3H), 1.11 (t, 3H) (M+1): 310.45
199.	N'-(2-chloro-4-((2,5-dimethylphenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.72 (s, 1H), 6.97 (d, 1H), 6.83 (s, 1H), 6.76 (s, 1H), 6.55 (d, 2H), 6.28 (s, 1H), 3.41-3.36 (m, 2H), 2.94 (s, 3H), 2.10 (s, 3H), 2.15 (s, 3H), 2.06 (s, 3H), 1.12 (t, 3H); (M+1): 331.1
200.	N-(5-chloro-4-(((ethyl(methyl)amino)methylene)amino)-2-methylphenyl)-N-(2-chlorophenyl)propionamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.69 (s, 1H), 7.57-5.31 (5H), 6.90 (s, 1H), 3.38 (q, 2H), 2.96 (s, 3H), 2.30-2.20 (m, 5H), 1.15 (t, 3H), 1.04 (t, 3H); (M+1): 393.45
201.	N-ethyl-N'-(5-fluoro-4-((4-methoxyphenyl)amino)-2-methylphenyl)-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.69-7.52 (m, 1H), 7.20 (s, 1H), 6.91-6.69 (m, 6H), 3.72-3.50 (m, 2H), 3.42 (s, 3H), 2.92 (s, 3H), 2.25 (s, 3H), 1.11 (t, 3H); (M+1): 316.55
202.	N-ethyl-N'-(5-fluoro-4-((4-methoxyphenyl)(methyl)amino)-2-methylphenyl)-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.76 (s, 1H), 6.98-6.95 (m, 1H), 6.79-6.75 (m, 3H), 6.60-6.57 (m, 2H), 3.67 (s, 3H), 3.39 (q, 2H), 3.12 (s, 3H), 2.96 (s, 3H), 2.13 (s, 3H), 1.20 (t, 3H); (M+1): 330.40
203.	N-(5-chloro-4-(((ethyl(methyl)amino)methylene)amino)-2-methylphenyl)-N-(2-fluorophenyl)propionamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.64 (s, 1H), 7.57-7.04 (m, 5H), 7.00-6.57 (m, 1H), 3.35-3.29 (m, 2H), 3.04 (s, 3H), 2.27-1.90 (m, 5H), 1.18 (t, 3H), 1.05 (t, 3H); (M+1): 376.55
204.	N'-(2-chloro-4-(N-(4-fluoro-3-(1,1,2,2-tetrafluoroethoxy)phenyl)methylsulfonamido)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.78-7.67 (m, 2H), 7.52-7.45 (m, 2H), 7.41-7.37 (m, 1H), 7.02-6.74 (m, 2H), 3.46-3.34 (m, 2H), 3.29 (s, 3H), 2.96 (s, 3H), 2.19 (s, 3H), 1.10-1.15 (m, 3H); (M+1): 514.95
205.	N'-(2,5-dimethyl-4-((3-(1,1,2,2-tetrafluoroethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) 7.61 (s, 1H), 7.17-6.39 (m, 8H), 3.36 (q, 2H), 2.93 (s, 3H), 2.00 (s, 3H); 2.28 (s, 3H), 1.27 (t, 3H); (M+1): 398.55
206.	N'-(2,5-dimethyl-4-(methyl(3-(1,1,2,2-tetrafluoroethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.60 (s, 1H), 7.16 (t, 1H), 6.83 (t, 1H), 6.70 (d, 1H), 6.46 (d, 1H), 6.41-6.39 (m, 1H), 6.14 (s, 1H), 3.39-3.31 (m, 2H), 3.12 (s, 3H), 2.90 (s, 3H), 2.11 (s, 3H), 1.97 (s, 3H), 1.12 (t, 3H); (M+1): 412.1
207.	N-ethyl-N'-(4-((2-fluoro-5-methylphenyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.62 (s, 1H), 6.96-6.91 (m, 2H), 6.79 (s, 1H), 6.64 (s, 1H), 6.42-6.39 (m, 1H), 6.21 (dd, 1H), 3.35 (q, 2H), 2.92 (s, 3H), 2.10-2.03 (m, 9H), 1.13-1.10 (m, 3H); (M+1): 313.6
208.	N-ethyl-N'-(5-fluoro-4-((2-fluorophenyl)amino)-2-methylphenyl)-	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.68 (s, 1H), 7.30 (s, 1H), 7.09 (d, 1H), 6.89-6.96 (m, 2H), 6.75-6.69 (m, 2H),


	N-methylformimidamide	6.63 (t, 1H), 3.38 (q, 2H), 2.93 (s, 3H), 2.11 (s, 3H), 1.12 (t, 3H); (M+1): 304.5
209.	N-ethyl-N'-(4-((2-fluoro-5-methylphenyl)(methylamino)-2,5-dimethylphenyl)-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.60 (s, 1H), 6.87 (dd, 1H), 6.71 (s, 1H), 6.64-6.59 (m, 3H), 3.39 (q, 2H), 3.04 (s, 3H), 2.90 (s, 3H), 2.19 (s, 3H), 2.06 (s, 3H), 2.02 (s, 3H), 1.10 (t, 3H); (M+1): 328.60
210.	N'-(2-chloro-4-((2-fluoro-5-methylphenyl)(methylamino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.67 (s, 1H), 6.90-6.95 (m, 2H), 6.82 (s, 1H), 6.71-6.68 (m, 2H), 3.35-3.25 (m, 2H), 3.07 (s, 3H), 2.91 (s, 3H), 2.21 (s, 3H), 2.00 (s, 3H), 1.10 (t, 3H); (M+1): 349.05
211.	N-ethyl-N'-(5-fluoro-2-methyl-4-(phenylamino)phenyl)-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.73-7.68 (m, 2H), 7.15-6.99 (m, 3H), 6.77-6.66 (m, 4H), 3.39-3.27 (m, 2H), 2.93 (s, 3H), 2.33 (s, 3H), 1.12-1.36 (m, 3H); (M+1): 286.35
212.	N'-(4-((2-chlorophenyl)amino)-5-fluoro-2-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.70 (s, 1H), 7.31 (dd, 1H), 7.09-7.05 (m, 2H), 6.98 (d, 1H), 6.78-6.72 (m, 2H), 6.52 (d, 1H), 3.43-3.34 (m, 2H), 2.95 (s, 3H), 2.14 (s, 3H), 1.13 (t, 3H); (M+1): 320.1
213.	N'-(4-((4-(tert-butyl)phenyl)amino)-5-fluoro-2-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.72 (s, 1H), 7.37- 6.71 (m, 7H), 3.49-3.28 (m, 2H), 2.93 (s, 3H), 2.28 (s, 3H), 1.39 (s, 9H), 0.86 (t, 3H); (M+1): 342.7
214.	N-ethyl-N'-(5-fluoro-2-methyl-4-(m-tolylamino)phenyl)-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.79 (s, 1H), 7.43-7.34 (m, 1H), 7.03-6.96 (m, 2H), 6.74 (d, 1H), 6.55-6.49 (m, 3H), 3.43-3.30 (m, 2H), 2.95 (s, 3H), 2.03 (s, 3H), 2.19 (s, 3H), 1.24 (t, 3H); (M+1): 300.4
215.	N-(5-chloro-4-(((ethyl(methyl)amino)methylene)amino)-2-methylphenyl)-N-phenylpropionamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.85 (s, 1H), 7.55-7.04 (m, 6H), 6.99-6.84 (m, 1H), 3.40-3.19 (m, 2H), 3.07 (s, 3H), 2.30-1.88 (m, 5H), 1.18 (s, 3H), 1.04 (t, 3H); (M+1): 358.25
216.	N-(5-chloro-4-(((ethyl(methyl)amino)methylene)amino)-2-methylphenyl)-N-(3-methoxyphenyl)acetamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.81 (s, 1H), 7.51-7.08 (m, 2H), 7.12-6.69 (m, 4H), 3.64 (s, 3H), 3.45-3.30 (m, 2H), 2.84 (s, 3H), 2.18 (s, 3H), 1.81 (s, 3H), 1.08 (t, 3H); (M+1): 375.05
217.	N'-(2-chloro-4-((4-fluoro-3-methoxyphenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.78 (s, 1H), 7.32 (s, 1H), 7.12-6.91 (m, 2H), 6.88-6.74 (m, 1H), 6.59-6.51 (m, 1H), 6.26-6.11 (m, 1H), 3.76 (s, 3H), 3.54-3.27 (m, 2H), 3.03 (s, 3H), 2.13 (s, 3H), 1.28 (t, 3H); (M+1): 351.05
218.	N-ethyl-N'-(4-((4-fluoro-3-methoxyphenyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.61 (s, 1H), 7.14 (s, 1H), 6.94-6.88 (m, 2H), 6.63 (s, 1H), 6.48 (dd, 1H), 6.10 (dt, 1H), 3.85 (s, 3H), 3.39-3.32 (m, 2H), 2.93 (s, 3H), 2.18 (s, 3H), 2.00 (s, 3H), 1.11 (t, 3H); (M+1): 330.55
219.	N-ethyl-N'-(4-((4-fluoro-3-methoxyphenyl)(methylamino)-2,5-dimethylphenyl)-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.72 (s, 1H), 6.97-6.91 (m, 1H), 6.85-6.66 (m, 1H), 6.25-6.20 (m, 1H), 5.87-5.84 (m, 1H), 5.78-5.75 (m, 1H), 3.64 (s, 3H), 3.39-3.30 (m, 2H), 3.12 (s, 3H), 2.92 (s, 3H), 2.12 (s, 3H), 1.96 (s, 3H), 1.12 (t, 3H); (M+1): 344.60
220.	N'-(4-((2-((difluoromethyl)thio)phenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.64 (s, 1H), 7.84-6.47 (m, 5H), 6.70-6.54 (m, 2H), 6.39 (dd, 1H), 3.40-3.34 (m, 2H), 2.94 (s, 3H), 2.31 (s, 3H), 1.89 (s, 3H), 1.24 (t, 3H); (M+1): 364.45
221.	N'-(4-((2-((difluoromethyl)thio)phenyl)(methylamino)-2,5-dimethylphenyl)-N-ethyl-	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.63 (s, 1H), 7.42-7.27 (m, 2H), 7.13-6.97 (m, 3H), 6.62 (d, 1H), 6.45 (d, 1H), 3.34-3.29 (m, 2H), 3.00 (s, 3H), 2.93 (s, 3H), 2.22 (s, 3H),

	N-methylformimidamide	1.96 (s, 3H), 1.10 (t, 3H); (M+1): 378.50
222.	N'-(2-chloro-4-((4-fluoro-3-methoxyphenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.72 (s, 1H), 6.89-7.69 (m, 3H), 6.25 (dd, 1H), 5.88 (td, 1H), 3.75 (s, 3H), 3.30-3.26 (m, 2H), 3.10 (s, 3H), 2.98 (s, 3H), 2.33 (s, 3H), 1.13 (t, 3H); (M+1): 365.05
223.	N'-(2-bromo-6-fluoro-3-methyl-4-(phenylamino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.62 (d, 2H), 7.14-7.11 (m, 2H), 6.95 (d, 1H), 6.71-6.67 (m, 3H), 3.29-3.24 (m, 2H), 2.96 (s, 3H), 2.22 (s, 3H), 1.34 (t, 3H); (M+1): 365.35
224.	N'-(2-chloro-5-methyl-4-((5-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 8.16 (s, 1H), 7.82-7.65 (m, 2H), 7.16-7.05 (m, 1H), 6.95-6.87 (m, 1H), 6.59-6.51 (m, 1H), 6.40-6.20 (m, 1H), 3.48-3.28 (m, 2H), 3.06 (m, 3H), 2.80-2.73 (m, 2H), 2.48-2.42 (m, 2H), 2.13 (s, 3H), 1.98-1.91 (m, 2H), 1.24-1.10 (t, 3H); (M+1): 370.15
225.	N'-(2-bromo-6-fluoro-3-methyl-4-(methyl(phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.74 (s, 1H), 7.31-7.04 (m, 3H), 6.70-6.66 (m, 1H), 6.48 (dd, 2H), 3.51-3.31 (m, 2H), 3.15 (s, 3H), 2.98 (s, 3H), 2.33 (s, 3H), 1.12 (t, 3H); (M+1): 379.50
226.	N'-(2-chloro-5-methyl-4-((1-methylindolin-5-yl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.69-7.49 (m, 1H), 6.81-6.69 (m, 3H), 6.67-6.59 (m, 2H), 6.47-6.40 (m, 1H), 3.38-3.24 (m, 2H), 3.26-3.05 (m, 2H), 3.01-2.85 (m, 3H), 2.85-2.73 (m, 2H), 2.66 (s, 3H), 2.16 (s, 3H), 1.22 (t, 3H); (M+1): 357.15
227.	N'-(2,5-dimethyl-4-((5-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 8.07 (s, 1H), 7.63 (d, 2H), 6.87 (s, 1H), 6.68 (s, 1H), 6.48 (dd, 1H), 6.31 (d, 1H), 3.35-3.30 (m, 2H), 2.92 (s, 3H), 2.72 (t, 2H), 2.42-2.39 (m, 2H), 2.12 (m, 2H), 2.05 (s, 3H), 1.92 (s, 3H), 1.14 (t, 3H); (M+1): 350.35
228.	N-ethyl-N'-(5-fluoro-2-methyl-4-(methyl(phenyl)amino)phenyl)-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.73 (s, 1H), 7.16-7.00 (m, 3H), 6.80-6.56 (m, 4H), 3.46-3.33 (m, 2H), 3.17 (s, 3H), 2.97 (s, 3H), 2.14 (s, 3H), 1.24-1.13 (m, 3H); (M+1): 300.01
229.	N'-(4-((4-(tert-butyl)phenyl)(methyl)amino)-5-fluoro-2-methylphenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.70 (s, 1H), 7.16 (d, 3H), 6.98 (d, 2H), 6.75 (d, 1H), 6.51 (d, 1H), 3.46-3.35 (m, 2H), 3.10 (s, 3H), 2.92 (s, 3H), 2.15 (s, 3H), 1.25 (s, 9H), 1.14 (t, 3H); (M+1): 356.5
230.	N-ethyl-N'-(5-fluoro-2-methyl-4-(methyl(m-tolyl)amino)phenyl)-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.73 (s, 1H), 7.03-6.99 (m, 2H), 6.78 (d, 1H), 6.51-6.37 (m, 3H), 3.34 (s, 3H), 3.15 (q, 2H), 2.94 (s, 3H), 2.50 (s, 3H), 1.98 (s, 3H), 1.24-1.13 (m, 3H); (M+1): 314.1
231.	N-ethyl-N'-(7-((2-methoxyphenyl)amino)-2,3-dihydro-1H-inden-4-yl)-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.65 (s, 1H), 6.90 (dd, 1H), 6.83-6.79 (m, 1H), 6.72 (td, 1H), 6.66 (td, 1H), 6.62-6.58 (m, 2H), 6.38 (s, 1H), 3.81 (2, 3H), 3.44-3.32 (m, 2H), 2.86 (s, 3H), 2.75-2.81 (m, 2H), 2.66 (t, 2H), 1.88-1.95 (m, 2H), 1.10 (t, 3H); (M+1): 324.30
232.	N-ethyl-N-methyl-N'-(7-(p-tolylamino)-2,3-dihydro-1H-inden-4-yl)formimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.73-7.52 (m, 1H), 7.25-6.56 (m, 6H), 6.59 (dd, 1H), 3.34 (q, 2H), 2.68-2.91 (m, 6H), 2.33-1.89 (m, 6H), 1.34-1.10 (m, 3H); (M+1): 308.1
233.	N'-(7-((4-chlorophenyl)amino)-2,3-dihydro-1H-inden-4-yl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.68-7.55 (m, 2H), 7.17-7.12 (m, 2H), 6.92-6.60 (m, 4H), 3.34-3.42 (m, 2H), 2.92-2.67 (m, 5H), 2.52-2.50 (m, 2H), 2.08-1.89 (m, 2H), 1.34-0.80 (m, 3H); (M+1): 328.15

234.	N-ethyl-N-methyl-N'-(4-(phenylamino)naphthalen-1-yl)formimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 8.39 (s, 1H), 7.97-7.80 (m, 3H), 7.44 (td, 2H), 7.26-6.63 (m, 7H), 3.58-3.22 (m, 2H), 3.07 (s, 3H), 1.40 (t, 3H); (M+1): 304.55
235.	N'-(2,5-dimethyl-4-(pyridin-2-ylamino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 7.96 (s, 1H), 7.88 (s, 1H), 7.60-7.58 (m, 1H), 7.42-7.31 (m, 1H), 7.03 (s, 1H), 6.62 (s, 1H), 6.55 (d, 1H), 6.42 (d, 1H), 3.35-3.31 (m, 2H), 2.92 (s, 3H), 2.11 (s, 3H), 2.06 (s, 3H), 1.12 (t, 3H); (M+1): 283.30
236.	N'-(2,5-dimethyl-4-(methyl(pyridin-2-yl)amino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 8.08 (s, 1H), 7.73-7.47 (m, 1H), 7.33-7.28 (m, 1H), 6.87 (s, 1H), 6.71 (s, 1H), 6.52 (dd, 1H), 5.97 (d, 1H), 3.41-3.40 (m, 2H), 3.24 (s, 3H), 2.93 (s, 3H), 2.12 (s, 3H), 1.95 (s, 3H), 1.12 (t, 3H); (M+1): 297.40
237.	N'-(2-chloro-5-methyl-4-(pyridin-2-ylamino)phenyl)-N-ethyl-N-methylformimidamide	¹ H-NMR (400 MHz, DMSO-d ₆) δ 8.03-8.02 (m, 2H), 7.65 (d, 1H), 7.50 (s, 1H), 7.49-7.45 (m, 1H), 6.82 (s, 1H), 6.64-6.61 (m, 2H), 3.42-3.34 (m, 2H), 2.94 (s, 3H), 2.12 (s, 3H), 1.13 (t, 3H); (M+1): 303.30

* Compound names generated using Chemdraw Professional 16.0

Table 2 provides compounds of general formula (Ia)




(Ia)

Sr. No	Compound Name	Analytical Data
238.	N1-(4-chlorophenyl)-2,5-dimethylbenzene-1,4-diamine	(M+1): 247
239.	N'-(2-chloro-4-((2-fluorophenyl)(methyl)amino)-5-methylphenyl)-N-isopropylformimidamide	¹ H-NMR, DMSO-d ₆) δ 7.47 (s, 1H), 7.15 (s, 1H), 7.08-7.02 (m, 2H), 6.93-6.87 (m, 3H), 6.76 (s, 1H), 4.00-3.85 (m, 1H), 3.09 (s, 3H), 2.01 (s, 3H), 1.15 (d, 3H), 1.22 (d, 3H); (M+1): 335.80


* Compound names generated using Chemdraw Professional 16.0

Compounds of the present invention as defined by general formula (I) and/or in table 1 and 2 may be prepared, in known manner, in a variety of ways as described in Schemes 1-2.




The compound of formula 1a can be synthesised by treating compound 2 with triemethylorthoformate in the presence of catalytic pTSA followed by reacting with a secondary amine of formula HNR_2R_3 as described in US20110130282.

- 5 The compound 1 is a critical intermediate where Y is a nitro group or a protected amine functionality and can be synthesised by reacting compound of formula 3



where X is a halogen and Y is a nitro group or a protected amine functionality with the corresponding aniline derivatives as mentioned in European Journal of Organic Chemistry, 2016(10), page no.1908-1914; Green Chemistry, 2016, 16(7), page no. 3494-3500; and Tetrahedron Letters, 2014, 55(30), page no. 4098-4101.

Scheme 2



- 15 The compound of formula 1a can also be synthesised by treating compound 4 with appropriately substituted anilines using Buchwald conditions as mentioned in J.Med.Chem 2012,vol.55,19, page no. 8538-48; Synlett 2012, vol.23,13, page no. 2504-10; and Journal of Organic Chemistry, 2010,vol.75, 19, page no. 6477-88.

Compound of formula 4 can be synthesised by using corresponding aniline derivatives and converting them into amidine by using the known literature methods.

The present invention is further illustrated in the following non-limiting examples. Structures of novel compounds were confirmed by NMR and/or other appropriate analysis as given below.

EXAMPLE 1

5 Preparation of N'-[2, 5-dimethyl-4-(phenyl amino) phenyl]-N-ethyl-N-methylimidoforamide

Step A: 2, 5-dimethyl-N-phenylbenzene-1, 4-diamine

To a stirred solution of 4-Anilino-2, 5-dimethyl nitrobenzene (1.3 g, 5.365 mmol) in 1, 4-dioxane and conc HCl (1:1) (30 ml), Tin (II) chloride (3.62 g, 16.097 mmol) was added. The reaction mixture was heated at 100°C for 3-4 hours. After completion of the reaction, the reaction mixture was cooled to room temperature and cautiously basified with sodium bicarbonate to pH 7-8. The aqueous layer was extracted with 5% methanol/dichloromethane (3x100ml). The combined organic layer was washed with water (1x100ml), brine solution (1x100ml). The organic layer was dried over anhydrous sodium sulphate. The organic layer was filtered and evaporated under high vacuum to get the residue, which was then purified by flash chromatography using 0-80% Ethyl acetate: hexane as eluent to give 2,5-dimethyl-N-phenylbenzene-1,4-diamine (0.9 g) as solid. LCMS (M+H) 249.75

Step B: N'-[2, 5-dimethyl-4-(phenylamino) phenyl]-N-ethyl-N-methylimidoforamide

To a stirred solution of 4-anilino-2, 5-dimethyl aniline (0.8g, 3.791 mmol) in trimethylorthoformate (80 ml), PTSA (0.02 g, 0.113 mmol) was added and the reaction mixture was heated at 100°C for 6 hours. After the complete disappearance of the amine, the reaction mixture was cooled and evaporated the volatiles. 1, 4-dioxane (20 ml) was added to the residue followed by addition of N-ethylmethylamine (0.45 g, 7.582 mmol). The reaction mixture was heated at 100°C for 1-2 hours. After completion of the reaction, the volatiles were evaporated to get the residue which was then purified by flash chromatography eluting with 0-60% ethyl acetate: hexane as eluent to give N'-[2,5-dimethyl-4-(phenylamino)phenyl]-N-ethyl-N-methylimidoforamide (0.25 g) as a gum. ¹H-NMR (400 MHz, DMSO-d₆) δ 7.60 (bs, 1H), 7.17 (s, 1H), 7.08 (t, J = 7.8 Hz, 2H), 6.88 (s, 1H), 6.64 (d, J = 7.3 Hz, 3H), 6.60 (t, J = 7.3 Hz, 1H), 3.51-3.35 (m, 2H), 3.02-2.84 (bs, 3H), 2.10 (s, 3H), 2.07 (s, 3H), 1.12 (t, J = 7.1 Hz, 3H)

EXAMPLE 2

30 Preparation of N'-{2, 5-dimethyl-4-[methyl (phenyl) amino] phenyl}-N-ethyl-N-methylimidoforamide

Step A: Preparation of 4-N-methylanilino-2, 5-dimethyl aniline

To a stirred solution of 4-N-methylanilino-2, 5-dimethyl nitrobenzene (2.0 g, 7.80 mmol), in 1, 4-dioxane and conc HCl (1:1) (50 ml), Tin (II) chloride (3.62 g, 16.097 mmol) was added. The reaction mixture was heated at 100°C for 3-4 hours. After completion of the reaction, the reaction mixture was cooled to room temperature and cautiously basified with sodium bicarbonate to pH 7-8. The aqueous

layer was extracted with 5% methanol/dichloromethane (3x100ml). The combined organic layer as washed with water (1x100ml), brine solution (1x100ml). The organic layer was dried over anhydrous sodium sulphate. The organic layer was filtered and evaporated under high vacuum to get the residue, which was then purified by flash chromatography using 0-80% ethyl acetate: hexane as eluent to give

5 4-N-methylanilino-2, 5-dimethyl aniline (1.5 g) as solid. LCMS (M+H) 227.40

Step B: Preparation of N'-{2, 5-dimethyl-4-[methyl (phenyl) amino] phenyl}-N-ethyl-N-methylimidoforamamide

To a stirred solution of 4-N-methylanilino-2,5-dimethyl aniline (0.7g, 3.317 mmol) in trimethylorthoformate (80 ml) was added PTSA (0.02 g, 0.099 mmol). The reaction mixture was
10 heated at 100°C for 6 hours. After completion of the reaction, the reaction mixture was cooled and evaporated. To the residue was added 1, 4-dioxane followed by addition of N-ethylmethyl amine (0.392 g, 6.635 mmol). The reaction mixture was heated at 100°C for 2 hours. After the completion of the reaction, the volatiles were evaporated. The residue was purified by flash chromatography eluting with 0-60% ethyl acetate: hexane to get N'-{2, 5-dimethyl-4-[methyl (phenyl) amino] phenyl}-N-ethyl-N-methylimidoforamamide (0.25) as a gum. ¹H-NMR (400 MHz, DMSO-d₆) δ 7.73-7.51 (bs, 1H), 7.09 (t, J = 8.0 Hz, 2H), 6.82 (s, 1H), 6.69 (s, 1H), 6.61-6.54 (m, 1H), 6.42 (d, J = 7.8 Hz, 2H), 3.49-3.34 (m, 2H), 3.11 (s, 3H), 2.93 (s, 3H), 2.12 (s, 3H), 1.97 (s, 3H), 1.13 (t, J = 7.1 Hz, 3H)
15

EXAMPLE 3

20 Preparation of N'-[2-chloro-5-methyl-4-(phenyl amino) phenyl]-N-ethyl-N-methylimidoforamamide

Step A: Preparation of 4-anilino-2-chloro-5-methyl aniline

To a stirred solution of 4-anilino-2-chloro-5-methylnitrobenzene (2g, 7.61 mmol), iron (2.12 g, 3.80 mmol) and ammonium chloride (2.1 g, 3.80 mmol) in ethanol-water (1:1.50ml) mixture was heated at 9°C for 2 hours. After completion of the reaction, the contents were filtered through celite. Filtrate was
25 concentrated and diluted with ethyl acetate (300 ml) then washed with saturated sodium bicarbonate solution. The organic layer was separated, dried over anhydrous sodium sulphate and concentrated to obtain the crude compound which was purified by flash column chromatography to get 4-anilino-2-chloro-5-methyl aniline (1.6 g) as a gum. LCMS (M+H) 233.74

Step B: Preparation of N'-[2-chloro-5-methyl-4-(phenyl amino) phenyl]-N-ethyl-N-methylimidoforamamide
30

To a stirred solution of 4-anilino-2-chloro-5-methyl aniline (0.8g, 3.791 mmol) in trimethylorthoformate (80 ml), PTSA (0.02 g, 0.1137 mmol) was added and reaction mixture was heated at 100°C for 6 hours. After completion of the reaction, the reaction mixture was cooled and evaporated the volatiles. 1, 4- dioxane was added to the residue followed by addition of N-ethyl
35 methyl amine (0.45 g, 0.65 ml, 7.582 mmol). The reaction mixture was heated at 100°C for 2 hours. After completion of the reaction the volatiles were evaporated under reduced pressure. The crude

compound was purified by flash chromatography eluting with 0-60% ethyl acetate: hexane to give N'-[2-chloro-5-methyl-4-(phenyl amino) phenyl]-N-ethyl-N-methylimidoforamide (0.25 g). ¹H-NMR (400 MHz, DMSO-d₆) δ 7.76-7.56 (br, 1H), 7.32 (s, 1H), 7.14 (t, J = 7.8 Hz, 2H), 7.06 (s, 1H), 6.85 (s, 1H), 6.72 (d, J = 8.2 Hz, 2H), 6.68 (t, J = 7.3 Hz, 1H), 3.42 (m, 2H), 3.04-2.85 (br, 3H), 2.11 (s, 3H), 1.13 (t, J = 6.9 Hz, 3H)

EXAMPLE 4

Preparation of N'-{2-chloro-5-methyl-4-[methyl (phenyl) amino] phenyl}-N-ethyl-N-methylimidoforamide

10 Step A: Preparation of 5-chloro-N-2-dimethyl-N-phenylbenzene-1, 4-diamine

To a stirred solution of 5-chloro-N, 2-dimethyl-4-nitro-N-phenylaniline (2 g, 7.24 mmol), iron (2.02 g, 36.17 mmol) and ammonium chloride (1.93g, 36.17 mmol) in ethanol-water (1:1,50ml) mixture was heated at 90°C for 2 hours. After completion of the reaction, the contents were filtered through celite. Filtrate was concentrated and diluted with ethyl acetate (300 ml) and then washed with saturated sodium bicarbonate solution. The organic layer was separated, dried over anhydrous sodium sulphate and concentrated to obtain the crude compound which was purified by flash column chromatography to get 5-chloro-N-2-dimethyl-N-phenylbenzene-1,4-diamine (1.7 g) as a solid. LCMS (M+H) 227.32

Step B: Preparation of N'-{2-chloro-5-methyl-4-[methyl (phenyl) amino] phenyl}-N-ethyl-N-methylimidoforamide

20 To a stirred solution of 5-chloro-N-2-dimethyl-N-phenylbenzene-1, 4-diamine (0.9 g, 3.6 mmol) in trimethylorthoformate (50 ml), PTSA (0.02 g, 0.11 mmol) was added and the reaction mixture was heated at 100°C for 6 hours. After the completion of the reaction the volatiles were evaporated. To the residue was added 1,4-dioxane followed by the addition of N-ethylmethyl amine (0.45 g, 0.65 ml, 7.582 mmol). The reaction was heated at 100°C for 2 hours. After completion of the reaction
25 evaporated the volatiles and the residue was purified by flash chromatography eluting with 0-60% ethyl acetate: hexane to give N'-{2-chloro-5-methyl-4-[methyl (phenyl) amino] phenyl}-N-ethyl-N-methylimidoforamide (0.8 g). ¹H-NMR (400 MHz, DMSO-d₆) δ 7.79-7.63 (br, 1H), 7.13 (td, J = 7.0, 1.6 Hz, 2H), 7.08 (s, 1H), 6.97-6.88 (br, 1H), 6.64 (t, J = 7.1 Hz, 1H), 6.46 (d, J = 7.7 Hz, 2H), 3.51-3.36 (m, 2H), 3.13 (s, 3H), 3.05-2.91 (br, 3H), 1.99 (s, 3H), 1.15 (t, J = 6.9 Hz, 3H)

EXAMPLE 5

Preparation of N-[4-([ethyl (methyl) amino] methylidene) amino]-2, 5-dimethylphenyl]-N-phenylmethanesulfonamide Step A was carried out as described in above examples.

Step B: Preparation of N-[4-([ethyl (methyl) amino] methylidene) amino]-2, 5-dimethylphenyl]-N-phenylmethanesulfonamide

To a stirred solution of (N-(4-amino-2, 5-dimethylphenyl)-N-phenylmethanesulfonamide (0.5 g, 1.722 mmol) in trimethyl orthoformate (20.00 ml) p-toluenesulfonic acid monohydrate (0.016 g, 0.086 mmol) was added. Reaction mixture was stirred at 103°C for 3 hours. After 3 hours, the volatiles were evaporated and 1, 4-dioxane (20 ml) was added to the residue under nitrogen atmosphere. N-methylethanamine (1.018 g, 17.22 mmol) was added and stirred for 3 hours at 103°C. After the completion of the reaction was the volatiles were evaporated to get the crude compound which was then purified by flash column chromatography to get desired N'-(2, 5-dimethyl-4-(N-phenylmethylsulfonamido) phenyl)-N-ethyl-N-methylformimidamide (0.294 g). ¹H-NMR (400 MHz, DMSO-d₆) δ 7.73-7.53 (br, 1H), 7.35 (m, 4H), 7.28 (s, 1H), 7.23-7.14 (m, 1H), 6.69 (s, 1H), 3.49-3.36 (bs, 1H), 3.32-3.28 (bs, 1H), 3.24 (s, 3H), 3.02-2.87 (br, 3H), 2.19 (s, 3H), 2.16 (s, 3H), 1.12 (t, J = 7.1 Hz, 3H)

EXAMPLE 6

Preparation of N'-{4-[(4-chlorophenyl) (methyl) amino]-2, 5-dimethylphenyl}-N-ethyl-N-methylimidoforamide

Step A: Preparation of N-1-(4-chlorophenyl)-N'-1, 2, 5-trimethylbenzene-1, 4-diamine

To a solution of N-(4-chlorophenyl)-N, 2, 5-trimethyl-4-nitroaniline (0.6 g, 2.064 mmol) in ethanol (16 ml) and water (4.00 ml) were added ammonium chloride (0.442 g, 8.25 mmol) and iron (1.152 g, 20.64 mmol). The reaction mixture was stirred for 2 hours at 65°C. After completion of the reaction, the reaction was cooled to room temperature and filtered through celite. The filtrate was evaporated to get residue which was taken in water and extracted with ethyl acetate. The ethyl acetate layer was washed with water (2x100ml), brine solution (1x 100ml). The organic layer was collected, dried over anhydrous sodium sulphate. The organic layer was filtered, evaporated to get the residue, which was purified by flash chromatography to get desired N1-(4-chlorophenyl)-N1, 2, 5-trimethylbenzene-1, 4-diamine (0.5 g). LCMS (M+H) 261.77

Step B: Preparation of N'-{4-[(4-chlorophenyl) (methyl) amino]-2, 5-dimethylphenyl}-N-ethyl-N-methylimidoforamide

To a stirred solution of N-1-(4-chlorophenyl)-N'-1, 2, 5-trimethylbenzene-1, 4-diamine (0.5 g, 1.917 mmol) in Trimethyl ortho formate (20 ml) added a p-toluenesulfonic acid monohydrate (0.036 g, 0.192 mmol). Reaction mass was stirred at 105°C for 3 hours. After completion of the reaction, the volatiles were evaporated. Dioxane (20.00 ml) was added to the residue followed by N-methylethanamine (1.133 g, 19.17 mmol) and stirred the reaction mixture for 3 hours. After the completion of the reaction, the volatiles were evaporated to get the crude product which was purified by preparative HPLC to get desired N'-(4-((4-chlorophenyl) (methyl) amino)-2, 5-dimethylphenyl)-N-ethyl-N-methylformimidamide (0.35 g). ¹H-NMR (400 MHz, DMSO-d₆) δ 7.71-7.55 (br, 1H), 7.12

(dd, $J = 7.1, 2.1$ Hz, 2H), 6.83 (s, 1H), 6.70 (s, 1H), 6.40 (dd, $J = 6.9, 2.3$ Hz, 2H), 3.48-3.34 (bs, 1H), 3.31-3.25 (bs, 1H), 3.11 (s, 3H), 3.02-2.86 (br, 3H), 2.12 (s, 3H), 1.95 (s, 3H), 1.13 (t, $J = 7.1$ Hz, 3H).

EXAMPLE 7

- 5 Preparation of *N'*-{4-[(3-chlorophenyl) (methyl) amino]-2, 5-dimethylphenyl}-*N*-ethyl-*N*-methylimidoforamide Step A: Preparation of *N*-1-(3-chlorophenyl)-*N'*-1, 2, 5-trimethylbenzene-1, 4-diamine

To a solution of *N*-(3-chlorophenyl)-*N*, 2, 5-trimethyl-4-nitroaniline (0.5 g, 1.720 mmol) in ethanol (15 ml) and water (3.00 ml) were added ammonium chloride (0.46g, 8.6 mmol) and iron (0.960 g, 10 17.20 mmol). The reaction mixture was stirred for 2 hours at 65°C. After the completion of the reaction, the reaction mixture was cooled to room temperature, filtered through celite. The filtrate was evaporated to get the residue, which was taken in water and extracted with ethyl acetate. The ethyl acetate layer was dried over anhydrous sodium sulphate, evaporated to get the residue, which was purified by flash chromatography to get desired *N*-1-(3-chlorophenyl)-*N*1, 2, 5-trimethylbenzene-1, 4-
15 diamine (0.4 g). LCMS ($M+H$) 262.77

Step B: Preparation of *N'*-{4-[(3-chlorophenyl) (methyl) amino]-2, 5-dimethylphenyl}-*N*-ethyl-*N*-methylimidoforamide

To a stirred solution of *N*-1-(3-chlorophenyl)-*N'*-1, 2, 5-trimethylbenzene-1, 4-diamine (0.4 g, 1.534 mmol) in trimethyl orthoformate (16 ml) added a *p*-toluenesulfonic acid monohydrate (0.029 g, 0.153 20 mmol). Reaction mixture was stirred at 105°C for 3 hours. After completion of the reaction the volatiles were evaporated. To the residue was added dioxane (16.00 ml) followed by *N*-methylethanamine (0.907 g, 15.34 mmol) and stirred at room temperature for 3 hours. After the completion of the reaction, the volatiles were evaporated to get the crude compound which was then purified by flash column chromatography to get desired *N'*-(4-[(3-chlorophenyl) (methyl) amino]-2, 5-
25 dimethylphenyl)-*N*-ethyl-*N*-methylformimidamide (0.23 g). $^1\text{H-NMR}$ (400 MHz, DMSO-d_6) δ 7.74-7.55 (br, 1H), 7.10 (t, $J = 8.5$ Hz, 1H), 6.84 (s, 1H), 6.72 (s, 1H), 6.60 (dot, $J = 7.3, 1.1$ Hz, 1H), 6.36 (m, 2H), 3.50-3.34 (m, 2H), 3.12 (s, 3H), 3.03-2.87 (bs, 3H), 2.13 (s, 3H), 1.96 (s, 3H), 1.13 (t, $J = 7.1$ Hz, 3H)

30 EXAMPLE 8

Preparation of *N'*-{4-[(3, 4-dichlorophenyl) (methyl) amino]-2, 5-dimethylphenyl}-*N*-ethyl-*N*-methylimidoforamide

Step A: Preparation of *N*-1-(3, 4-dichlorophenyl)-*N*-1, 2, 5-trimethylbenzene-1, 4-diamine

To a stirred solution of *N*-(3, 4-dichlorophenyl)-*N'*-1, 2, 5-trimethyl-4-nitroaniline (0.6 g, 1.845 35 mmol) in ethanol (15 ml) and water (3.75 ml) added ammonium chloride (0.395 g, 7.38 mmol) and iron (1.030 g, 18.45 mmol) in it. Then reaction was stirred for 2 hours at 65°C. After completion of the

reaction, the reaction mixture was filtered through celite. The filtrate was evaporated to get the residue, which was partitioned between ethyl acetate and water. The ethyl acetate layer was separated, dried over anhydrous sodium sulphate and evaporated to get the residue which was purified by flash chromatography to get desired N-1-(3,4-dichlorophenyl)-N'-1,2,5-trimethylbenzene-1,4-diamine

5 (0.5g). LCMS (M+H) 296.31

Step B: Preparation of N'-{4-[(3, 4-dichlorophenyl) (methyl) amino]-2, 5-dimethylphenyl}-N-ethyl-N-methylimidoforamide

To a stirred solution of N-1-(3,4-dichlorophenyl)-N'-1,2,5-trimethylbenzene-1,4-diamine (0.5 g, 1.694 mmol) in Trimethyl orthoformate (20 ml) was added a p-toluenesulfonic acid monohydrate (0.016 g, 0.085 mmol). After stirring the reaction mixture at 105°C for 3 hours. The volatiles were evaporated and then dioxane (20.00 ml) was added to the residue followed by the addition of N-methylethanamine (1.001 g, 16.94 mmol). Reaction mixture was stirred for 3 hours. After completion of the reaction, evaporate the volatiles and the crude was purified by column chromatography to get the desired N'-(4-((3, 4-dichlorophenyl) (methyl) amino)-2, 5-dimethylphenyl)-N-ethyl-N-methylformimidamide

10 (270mg). ¹H-NMR (400 MHz, DMSO-d₆) δ 7.77-7.52 (br, 1H), 7.29 (d, J = 9.2 Hz, 1H), 6.85 (s, 1H), 6.73 (s, 1H), 6.55 (d, J = 2.3 Hz, 1H), 6.35 (dd, J = 9.2, 2.3 Hz, 1H), 3.52-3.35 (m, 2H), 3.13 (s, 3H), 3.03-2.87 (bs, 3H), 2.12 (s, 3H), 1.96 (s, 3H), 1.13 (t, J = 6.9 Hz, 3H)

EXAMPLE 9

20 Preparation of N'-{2-chloro-5-methyl-4-[methyl (3, 4, 5-trifluorophenyl) amino] phenyl}-N-ethyl-N-methylimidoforamide

Step A: 5-chloro-N, 2-dimethyl-N-(3, 4, 5-trifluorophenyl) benzene-1, 4-diamine

To a stirred solution of 5-chloro-N,2-dimethyl-4-nitro-N-(3,4,5-trifluorophenyl)aniline (0.53 g, 1.603 mmol) in ethanol-water mixture were added iron (0.895 g, 16.03 mmol) and ammonium chloride (0.857 g, 16.03 mmol). The reaction mixture was heated at 90°C for 2 hours. After completion of the reaction, the reaction mixture was filtered through celite, concentrated and diluted with ethyl acetate (30 ml), washed with saturated sodium bicarbonate, organic layer separated, dried over anhydrous sodium sulphate and concentrated to get the crude compound which was purified by flash chromatography to get 5-chloro-N-1,2-dimethyl-N1-(3,4,5-trifluorophenyl)benzene-1,4-diamine (0.35 g) as pale brown gum. LCMS (M+H) 301.71

25 30

Step B: Preparation of N'-{2-chloro-5-methyl-4-[methyl (3, 4, 5-trifluorophenyl) amino] phenyl}-N-ethyl-N-methylimidoforamide

To a stirred solution of 5-chloro-N-1,2-dimethyl-N'-1-(3,4,5-trifluorophenyl)benzene-1,4-diamine (0.3 g, 0.998 mmol) in trimethyl orthoformate (10 ml), catalytic amount of p-toluenesulfonic acid monohydrate (0.019 g, 0.100 mmol) was added and heated the reaction contents at 105°C under nitrogen atmosphere for 2 hours. After the completion of the reaction, the volatiles were evaporated

35

under high vacuum, contents were diluted with 1, 4-dioxane (8 ml), N-ethyl methylamine (0.139 ml, 1.596 mmol) was added slowly at room temperature. The contents were heated at 75°C for 4 hours. After completion of the reaction the dioxane evaporated at high vacuum and purified by flash column chromatography using 35-90% ethyl acetate: hexane to get N'-(2-chloro-5-methyl-4-(methyl(3,4,5-trifluorophenyl)amino)phenyl)-N-ethyl-N-methylformimidamide (0.299 g) as a gum. ¹H-NMR (400 MHz, DMSO-d₆) δ 7.83-7.64 (br, 1H), 7.14 (s, 1H), 7.00-6.92 (br, 1H), 6.20 (dd, J = 12.0, 6.0 Hz, 2H), 3.49-3.34 (m, 2H), 3.13 (s, 3H), 3.05-2.92 (br, 3H), 1.99 (s, 3H), 1.15 (t, J = 6.9 Hz, 3H)

EXAMPLE 10

10 Preparation of N'-(2-chloro-5-methyl-4-[methyl (3-methylphenyl) amino] phenyl)-N-ethyl-N-methylimidoforamide

Step A: 5-chloro-N, 2-dimethyl-N-(3-methylphenyl) benzene-1, 4-diamine

To a stirred solution of 5-chloro-N, 2-dimethyl-4-nitro-N-(m-tolyl) aniline (0.55 g, 1.892 mmol), iron (1.056 g, 18.92 mmol), and ammonium chloride (1.012 g, 18.92 mmol) in ethanol-water mixture was heated at 90°C for 2 hours. After completion of the reaction, the reaction mixture was filtered through celite, concentrated and diluted with ethyl acetate (30 ml), washed with saturated sodium bicarbonate, organic layer separated, dried over anhydrous sodium sulphate and concentrated to obtain the residue which was purified by flash column chromatography to get 5-chloro-N-1,2-dimethyl-N1-(m-tolyl)benzene-1,4-diamine (0.34 g) as pale brown gum. LCMS (M+H) 261.77

20 Step B: Preparation of N'-(2-chloro-5-methyl-4-[methyl (3-methylphenyl) amino] phenyl)-N-ethyl-N-methylimidoforamide

To a stirred solution of 5-chloro-N-1,2-dimethyl-N-1-(m-tolyl)benzene-1,4-diamine (0.34 g, 1.304 mmol) in trimethyl orthoformate (10 ml), catalytic amount of p-toluenesulfonic acid monohydrate (0.025 g, 0.130 mmol) was added and heated the reaction contents at 105°C under nitrogen atmosphere for 2 hours. After the completion of reaction the volatiles were evaporated under vacuum, the residue was diluted with 1, 4-dioxane (10 ml), N-ethyl methylamine (0.181 ml, 2.086 mmol) was added slowly at room temperature. The contents were heated at 75°C for 4 hours. After completion of the reaction the dioxane was evaporated and purified by the residue by flash column chromatography using 35-90% ethyl acetate: hexane to get N'-(2-chloro-5-methyl-4-(methyl(m-tolyl)amino)phenyl)-N-ethyl-N-methylformimidamide (0.155 g) as gum. ¹H-NMR (400 MHz, DMSO-d₆) δ 7.83-7.61 (br, 1H), 7.07 (s, 1H), 7.02 (t, J = 8.0 Hz, 1H), 6.98-6.87 (br, 1H), 6.25 (dd, J = 8.0, 2.1 Hz, 1H), 6.08-5.94 (m, 2H), 3.65 (s, 3H), 3.51-3.35 (m, 2H), 3.11 (s, 3H), 3.04-2.90 (br, 3H), 1.99 (s, 3H), 1.15 (t, J = 6.9 Hz, 3H)

35 EXAMPLE 11

Preparation of *N'*-{2-chloro-4-[(3, 4-dichlorophenyl) (methyl) amino]-5-methylphenyl}-*N*-ethyl-*N*-methylimidoforamide

Step A was carried out as described in above examples.

Step B: Preparation of *N'*-{2-chloro-4-[(3, 4-dichlorophenyl) (methyl) amino]-5-methylphenyl}-*N*-ethyl-*N*-methylimidoforamide

To a stirred solution of 5-chloro-*N*-1-(3,4-dichlorophenyl)-*N*-1,2-dimethylbenzene-1,4-diamine (0.32 g, 1.014 mmol) in trimethyl orthoformate (10 ml), catalytic amount of *p*-toluenesulfonic acid monohydrate (0.019 g, 0.101 mmol) was added and heated the reaction contents at 105°C under nitrogen atmosphere for 2 hours. After the completion of reaction the contents were evaporated, the residue was diluted with 1, 4-dioxane (10 ml), *N*-ethyl methylamine (0.141 ml, 1.622 mmol) was added slowly at room temperature. The contents were heated at 75°C for 4 hours. After completion of the reaction, the dioxane was evaporated and the residue was purified by flash column chromatography using 35-90% ethyl acetate: hexane to get *N'*-(2-chloro-4-[(3, 4-dichlorophenyl) (methyl) amino]-5-methylphenyl)-*N*-ethyl-*N*-methylformimidamide (0.302 g) as gum. ¹H-NMR (400 MHz, DMSO-d₆) δ 7.83-7.64 (br, 1H), 7.32 (d, *J* = 9.2 Hz, 1H), 7.14 (s, 1H), 7.02-6.89 (br, 1H), 6.60 (d, *J* = 2.7 Hz, 1H), 6.36 (dd, *J* = 8.9, 3.0 Hz, 1H), 3.50-3.34 (m, 2H), 3.14 (s, 3H), 3.05-2.89 (br, 3H), 1.98 (s, 3H), 1.15 (t, *J* = 6.9 Hz, 3H)

EXAMPLE 12

N'-{2-chloro-4-[(3-methoxyphenyl)(methyl)amino]-5-methylphenyl}-*N*-ethyl-*N*-methylimidoforamide

Step A was carried out as described in above examples.

Step B: Preparation of *N'*-{2-chloro-4-[(3-methoxyphenyl) (methyl) amino]-5-methylphenyl}-*N*-ethyl-*N*-methylimidoforamide

To a stirred solution of 5-chloro-*N*-1-(3-methoxyphenyl)-*N*-1,2-dimethylbenzene-1,4-diamine (0.3 g, 1.084 mmol) in trimethyl orthoformate (12 ml), catalytic amount of *p*-toluenesulfonic acid monohydrate (0.021 g, 0.108 mmol) was added and heated the reaction contents at 105°C for 3 hours. After the completion of the reaction the volatiles were evaporated under high vacuum to get the residue which was taken in 1, 4-dioxane (12 ml). Added *N*-ethyl methylamine (0.151 ml, 1.734 mmol) was added and the contents were heated at 75°C for 4 hours. After completion of the reaction the volatiles were evaporated and the residue was purified by flash column chromatography using 35-90% ethyl acetate: hexane to get *N'*-(2-chloro-4-[(3-methoxyphenyl) (methyl) amino]-5-methylphenyl)-*N*-ethyl-*N*-methylformimidamide (0.347 g) as gum. ¹H-NMR (400 MHz, DMSO-d₆) δ 7.81-7.62 (br, 1H), 7.06 (s, 1H), 7.00 (t, *J* = 7.8 Hz, 1H), 6.97-6.88 (br, 1H), 6.47 (d, *J* = 7.3 Hz, 1H), 6.29 (s, 1H), 6.25 (dd, 8.0, 2.0 Hz, 1H), 3.51-3.35 (m, 2H), 3.11 (s, 3H), 3.05-2.91 (br, 3H), 2.18 (s, 3H), 1.98 (s, 3H), 1.15 (t, *J* = 7.1 Hz, 3H)

EXAMPLE 13

N'-(2-chloro-5-methyl-4-{methyl[4-(trifluoromethyl)phenyl]amino}phenyl)-*N*-ethyl-*N*-methylimidiformamide

5 Step A was carried out as described in above examples.

Step B: Preparation of *N'*-(2-chloro-5-methyl-4-{methyl [4-(trifluoromethyl) phenyl] amino} phenyl)-*N*-ethyl-*N*-methylimidiformamide

To a stirred solution of 5-chloro-*N*-1,2-dimethyl-*N*1-(4-(trifluoromethyl)phenyl)benzene-1,4-diamine (0.35 g, 1.112 mmol) in trimethyl orthoformate (10 ml), catalytic amount of *p*-toluenesulfonic acid monohydrate (0.021 g, 0.111 mmol) was added and heated the reaction contents at 105°C under nitrogen atmosphere for 2 hours. After the complete conversion of the starting material, evaporated the volatiles and diluted the residue with 1, 4-dioxane (10 ml). *N*-ethyl methylamine (0.155 ml, 1.779 mmol) was added slowly at room temperature. The contents were heated at 75°C for 4 hours. After completion of the reaction, dioxane was evaporated and the crude compound was purified by preparative HPLC to get *N'*-(2-chloro-5-methyl-4-(methyl(4-(trifluoromethyl)phenyl)amino)phenyl)-*N*-ethyl-*N*-methylformimidamide (0.359 g) as pale yellow gum. ¹H-NMR (400 MHz, DMSO-d₆) δ 7.83-7.66 (br, 1H), 7.45 (d, *J* = 8.7 Hz, 2H), 7.16 (s, 1H), 7.03-6.92 (br, 1H), 6.55 (d, *J* = 8.7 Hz, 2H), 3.51-3.35 (m, 2H), 3.20 (s, 3H), 3.05-2.90 (br, 3H), 1.98 (s, 3H), 1.16 (t, *J* = 6.9 Hz, 3H)

20 EXAMPLE 14

N'-(2-chloro-5-methyl-4-[methyl (4-methylphenyl) amino] phenyl)-*N*-ethyl-*N*-methylimidiformamide

Step A was carried out as described in above examples.

Step B: Preparation of *N'*-(2-chloro-5-methyl-4-[methyl (4-methylphenyl) amino] phenyl)-*N*-ethyl-*N*-methylimidiformamide

To a stirred solution of 5-chloro-*N*-1,2-dimethyl-*N*1-(*p*-tolyl)benzene-1,4-diamine (0.35 g, 1.342 mmol) in trimethyl orthoformate (10 ml), catalytic amount of *p*-toluenesulfonic acid monohydrate (0.026 g, 0.134 mmol) was added and heated the reaction contents at 105°C under nitrogen atmosphere for 2 hours. After the completion of the reaction, the volatiles were evaporated under vacuum, the contents were diluted with 1,4-dioxane (10 ml). *N*-ethyl methylamine (0.187 ml, 2.148 mmol) was added slowly at room temperature. The contents were heated at 75°C for 4 hours. After completion of the reaction, dioxane was evaporated to get the residue, which was purified by preparative HPLC to get *N'*-(2-chloro-5-methyl-4-(methyl (*p*-tolyl) amino) phenyl)-*N*-ethyl-*N*-methylformimidamide (0.317 g) as gum. ¹H-NMR (400 MHz, DMSO-d₆) δ 7.82-7.62 (br, 1H), 7.05 (s, 1H), 6.94 (m, 3H), 6.38 (dd, *J* = 11.4, 2.7 Hz, 2H), 3.50-3.34 (m, 2H), 3.10 (s, 3H), 3.05-2.91 (br, 3H), 2.17 (s, 3H), 1.98 (s, 3H), 1.15 (t, *J* = 6.9 Hz, 3H)

EXAMPLE 15

N'-(2-chloro-4-[(2-methoxyphenyl)(methyl)amino]-5-methylphenyl)-*N*-ethyl-*N*-methylimidoforamide

5 Step A was carried out as described in above examples.

Step B: Preparation of *N'*-(2-chloro-4-[(2-methoxyphenyl) (methyl) amino]-5-methylphenyl)-*N*-ethyl-*N*-methylimidoforamide

To a stirred solution of 5-chloro-*N*1-(2-methoxyphenyl)-*N*-1,2-dimethylbenzene-1,4-diamine (0.35 g, 1.265 mmol) in trimethyl orthoformate (10 ml), catalytic amount of *p*-toluenesulfonic acid monohydrate (0.024 g, 0.126 mmol) was added and heated the reaction contents at 105°C under nitrogen atmosphere for 2 hours. After the completion of the reaction, the volatiles were evaporated. The residue was diluted with 1, 4-dioxane (10 ml). *N*-ethyl methylamine (0.176 ml, 2.023 mmol) was added slowly at room temperature. The contents were heated at 75°C for 4 hours. After completion of the reaction, dioxane was evaporated under high vacuum and the residue was purified by preparative HPLC to get *N'*-(2-chloro-4-[(2-methoxyphenyl) (methyl) amino]-5-methylphenyl)-*N*-ethyl-*N*-methylformimidamide (0.310 g) as gum. ¹H-NMR (400 MHz, DMSO-*d*₆) δ 7.76-7.56 (br, 1H), 7.03-6.89 (m, 3H), 6.81 (m, 1H), 6.79-6.72 (br, 1H), 6.73-6.61 (m, 1H), 3.70 (s, 3H), 3.47-3.34 (2H), 3.01 (s, 3H), 2.99-2.88 (br, 3H), 1.84 (s, 3H), 1.12 (t, *J* = 7.1 Hz, 3H)

20 EXAMPLE 16

N-[5-chloro-4-({-[ethyl(methyl)amino]methylidene} amino)-2-methylphenyl]-*N*-phenylmethane sulfonamide

Step A was carried out as described in above examples.

Step B: Preparation of *N*-[5-chloro-4-({-[ethyl (methyl) amino] methylidene} amino)-2-methylphenyl]-*N*-phenylmethanesulfonamide

To a stirred solution of *N*-(4-amino-5-chloro-2-methylphenyl)-*N*-phenylmethanesulfonamide (0.32 g, 1.030 mmol) in Trimethyl orthoformate (10 ml), catalytic amount of *p*-toluenesulfonic acid monohydrate (0.020 g, 0.103 mmol) was added and heated the reaction contents at 105°C under nitrogen atmosphere for 2 hours. After the complete conversion of the amine derivative the volatiles were evaporated under high vacuum to get the residue. 1, 4-dioxane (10 ml) was added to this residue followed by the addition of *N*-ethyl methylamine (0.233 ml, 2.68 mmol) room temperature. The contents were heated at 75°C for 4 hours. After completion of the reaction, the dioxane was evaporated under high vacuum and purified the residue by preparative HPLC to get *N'*-(2-chloro-5-methyl-4-(*N*-phenylmethylsulfonamido) phenyl)-*N*-ethyl-*N*-methyl formimidamide (0.07 g) as gum. ¹H-NMR (400 MHz, DMSO-*d*₆) δ 7.81-7.65 (br, 1H), 7.61 (s, 1H), 7.43-7.33 (m, 4H), 7.23 (td, *J* =

5.6, 2.9 Hz, 1H), 6.95-6.87 (br, 1H), 3.54-3.34 (m, 2H), 3.27 (s, 3H), 3.03-2.91 (br, 3H), 2.20 (s, 3H), 1.14 (t, J = 6.9 Hz, 3H)

EXAMPLE 17

- 5 N'-{2-chloro-4-[(2-chlorophenyl)(methyl)amino]-5-methylphenyl}-N-ethyl-N-methylimidoformamide

Step A was carried out as described in above examples.

Step B: Preparation of N'-{2-chloro-4-[(2-chlorophenyl) (methyl) amino]-5-methylphenyl}-N-ethyl-N-methylimidoformamide

- 10 To a stirred solution of 5-chloro-N1-(2-chlorophenyl)-N-1,2-dimethylbenzene-1,4-diamine (0.31 g, 1.102 mmol) in trimethyl orthoformate (10 ml), catalytic amount of *p*-toluenesulfonic acid monohydrate (0.021 g, 0.110 mmol) was added and heated the reaction contents at 105°C under nitrogen atmosphere for 2 hours. The volatiles were evaporated under high vacuum. The residue was diluted with 1, 4-dioxane (10 ml). N-ethyl methylamine (0.192 ml, 2.205 mmol) was added slowly at
- 15 room temperature. The contents were heated at 75°C for 4 hours. After completion of the reaction, dioxane was evaporated under reduced pressure, the residue was purified by preparative HPLC to get -N'-(2-chloro-4-((2-chlorophenyl) (methyl) amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide (0.359 g) as pale yellow gum. ¹H-NMR (400 MHz, DMSO-d₆) δ 7.80-7.59 (br, 1H), 7.40 (dd, J = 7.8, 1.4 Hz, 1H), 7.32-7.23 (m, 1H), 7.11-6.99 (m, 2H), 6.84 (s, 2H), 3.47-3.35 (m, 2H), 3.04 (s, 3H), 3.02-
- 20 2.87 (br, 3H), 1.98 (s, 3H), 1.13 (t, J = 6.9 Hz, 3H)

EXAMPLE 18

N'-{2-chloro-4-[(4-chlorophenyl)(methyl)amino]-5-methylphenyl}-N-ethyl-N-methylimidoformamide
Step A was carried out as described in above examples.

- 25 Step B: Preparation of N'-{2-chloro-4-[(4-chlorophenyl) (methyl) amino]-5-methylphenyl}-N-ethyl-N-methylimidoformamide

- To a stirred solution of 5-chloro-N1-(4-chlorophenyl)-N-1,2-dimethylbenzene-1,4-diamine (0.32 g, 1.138 mmol) in trimethyl orthoformate (10 ml), catalytic amount of *p*-toluenesulfonic acid monohydrate (0.022 g, 0.114 mmol) was added and heated the reaction contents at 105°C under
- 30 nitrogen atmosphere for 2 hours. After the complete conversion of the amine, the volatiles were removed under vacuum, contents were diluted with 1, 4-dioxane (10 ml), N-ethyl methylamine (0.198 ml, 2.276 mmol) was added slowly at room temperature. The contents were heated at 75°C for 4 hours. After completion of the reaction, the dioxane was removed and the residue was purified by preparative HPLC to get -N'-(2-chloro-4-((4-chlorophenyl) (methyl) amino)-5-methylphenyl)-N-ethyl-
- 35 N-methylformimidamide (0.360 g) as gum. ¹H-NMR (400 MHz, DMSO-d₆) δ 7.86-7.64 (br, 1H), 7.16

(dd, J = 6.9, 2.3 Hz, 2H), 7.11 (s, 1H), 7.01-6.90 (br, 1H), 6.44 (dd, J = 6.9, 2.3 Hz, 2H), 3.51-3.34 (m, 2H), 3.13 (s, 3H), 3.04-2.92 (br, 3H), 1.98 (s, 3H), 1.15 (t, J = 6.9 Hz, 3H)

EXAMPLE 19

- 5 N'-(2-chloro-4-[(4-methoxyphenyl)(methyl)amino]-5-methylphenyl)-N-ethyl-N-methylimidoforamamide

Step A was carried out as described in above examples.

Step B: Preparation of N'-(2-chloro-4-[(4-methoxyphenyl) (methyl) amino]-5-methylphenyl)-N-ethyl-N-methylimidoforamamide

- 10 To a stirred solution of 5-chloro-N1-(4-methoxyphenyl)-N-1,2-dimethylbenzene-1,4-diamine (0.3 g, 1.084 mmol) in trimethyl orthoformate (10 ml), catalytic amount of *p*-toluenesulfonic acid monohydrate (0.021 g, 0.108 mmol) was added and heated the reaction contents at 105°C under nitrogen atmosphere for 2 hours. After the completion of the reaction the volatiles were evaporated under high vacuum. The residue was diluted with 1, 4-dioxane (10 ml). N-ethyl methylamine (0.188
- 15 ml, 2.168 mmol) was added slowly at room temperature. The contents were heated at 75°C for 4 hours, monitored by TLC. After completion of the reaction, dioxane was evaporated and the residue was purified by preparative HPLC to get N'-(2-chloro-4-[(4-methoxyphenyl) (methyl) amino]-5-methylphenyl)-N-ethyl-N-methylformimidamide (0.079 g) as gum. ¹H-NMR (400 MHz, DMSO-d₆) δ
- 20 7.82-7.62 (br, 1H), 7.03 (s, 1H), 6.96-6.85 (br, 1H), 6.77 (dd, J = 6.9, 2.3 Hz, 2H), 6.46 (dd, J = 6.9, 2.3 Hz, 2H), 3.65 (s, 3H), 3.49-3.35 (m, 2H), 3.08 (s, 3H), 3.04-2.92 (br, 3H), 1.99 (s, 3H), 1.15 (t, J = 6.9 Hz, 3H)

EXAMPLE 20

- 25 N'-(2-chloro-4-[(4-methoxy-3-methylphenyl) (methyl) amino]-5-methylphenyl)-N-ethyl-N-methylformimidamide

Step A was carried out as described in above examples.

Step B: Preparation of N'-(2-chloro-4-[(4-methoxy-3-methylphenyl) (methyl) amino]-5-methylphenyl)-N-ethyl-N-methylformimidamide

- 30 To a stirred solution of 5-chloro-N1-(4-methoxy-3-methylphenyl)-N-1,2-dimethylbenzene-1,4-diamine (0.3 g, 1.032 mmol) in Trimethyl orthoformate (10 ml), catalytic amount of *p*-toluenesulfonic acid monohydrate (0.196 g, 1.032 mmol) was added and heated the reaction contents at 105°C under nitrogen atmosphere for 2 hours. After completion of the reaction, the volatiles were evaporated to get the residue which was diluted with 1, 4 dioxane (10 ml). N-ethyl methylamine (0.090 ml, 1.032 mmol) was added slowly at room temperature. The contents were heated at 75°C for 4 hours. After
- 35 completion of the reaction the dioxane was evaporated and the crude compound was purified by preparative HPLC to get N'-(2-chloro-4-[(4-methoxy-3-methylphenyl) (methyl) amino]-5-

methylphenyl)-N-ethyl-N-methylformimidamide (0.124 g) as gum. ¹H-NMR (400 MHz, DMSO-d₆) δ 7.91-7.57 (br, 1H), 7.03 (s, 1H), 6.98-6.83 (br, 1H), 6.75 (d, J = 8.7 Hz, 1H), 6.37 (d, J = 2.7 Hz, 1H), 6.31 (dd, J = 8.7, 2.7 Hz, 1H), 3.68 (s, 3H), 3.51-3.37 (m, 2H), 3.07 (s, 3H), 3.05-2.90 (br, 3H), 2.05 (s, 3H), 1.98 (s, 3H), 1.15 (t, J = 6.9 Hz, 3H)

5

EXAMPLE 21

N'-(2-chloro-4-((3, 4-dimethoxyphenyl) (methyl) amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide

Step A was carried out as described in above examples.

10 Step B: Preparation of N'-(2-chloro-4-((3, 4-dimethoxyphenyl) (methyl) amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide

To a stirred solution of 5-chloro-N1-(3,4-dimethoxyphenyl)-N-1,2-dimethylbenzene-1,4-diamine (0.24 g, 0.782 mmol) in trimethyl orthoformate (10 ml), catalytic amount of *p*-toluenesulfonic acid monohydrate (0.015 g, 0.078 mmol) was added and heated the reaction contents at 105°C under
15 nitrogen atmosphere for 2 hours. After the completion of the reaction the volatiles were evaporated under vacuum. The residue was diluted with 1, 4-dioxane (10 ml). N-ethyl methylamine (0.122 ml, 1.408 mmol) was added slowly at room temperature. The contents were heated at 75°C for 4 hours. After completion of the reaction, dioxane was evaporated and the residue was purified by preparative HPLC to get N'-(2-chloro-4-((3, 4-dimethoxyphenyl) (methyl) amino)-5-methylphenyl)-N-ethyl-N-
20 methylformimidamide (0.192 g) as gum. ¹H-NMR (400 MHz, DMSO-d₆) δ 7.82-7.59 (br, 1H), 7.05 (s, 1H), 6.95-6.84 (br, 1H), 6.75 (d, J = 8.7 Hz, 1H), 6.19 (d, J = 2.7 Hz, 1H), 5.95 (dd, J = 8.7, 2.7 Hz, 1H), 3.64 (s, 3H), 3.63 (s, 3H), 3.50-3.34 (br, 2H), 3.10 (s, 3H), 3.04-2.88 (br, 3H), 1.99 (s, 3H), 1.14 (t, J = 6.9 Hz, 3H)

25 EXAMPLE 22

N'-(2-chloro-4-((3, 5-dimethoxyphenyl) (methyl) amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide

Step A was carried out as described in above examples.

30 Step B: Preparation of N'-(2-chloro-4-((3, 5-dimethoxyphenyl) (methyl) amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide

To a stirred solution of 5-chloro-N1-(3,5-dimethoxyphenyl)-N-1,2-dimethylbenzene-1,4-diamine (0.28 g, 0.913 mmol) in Trimethyl orthoformate (10 ml), catalytic amount of *p*-toluenesulfonic acid monohydrate (0.017 g, 0.091 mmol) was added and heated the reaction contents at 105°C under
35 nitrogen atmosphere for 2 hours. After the completion of reaction the volatiles were evaporated under vacuum. The residue was diluted with 1, 4-dioxane (10 ml). N-ethyl methylamine (0.143 ml, 1.643 mmol) was added slowly at room temperature. The contents were heated at 75°C for 4 hours. After

completion of the reaction, the dioxane was evaporated and purified by preparative HPLC to get N'-(2-chloro-4-((3, 5-dimethoxyphenyl) (methyl) amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide (0.267 g) as gum. ¹H-NMR (400 MHz, DMSO-d₆) δ 7.83-7.61 (br, 1H), 7.06 (s, 1H), 6.96-6.86 (1H), 5.87 (s, 1H), 5.58 (s, 2H), 3.63 (s, 6H), 3.51-3.34 (m, 2H), 3.10 (s, 3H), 3.04-2.87 (br, 3H), 1.99 (s, 3H), 1.14 (t, J = 6.6 Hz, 3H)

EXAMPLE 23

N-ethyl-N'-(4-((3-methoxyphenyl) amino)-2, 5-dimethylphenyl)-N-methylformimidamide

Step A was carried out as described in above examples.

10 Step B: Preparation of N-ethyl-N'-(4-((3-methoxyphenyl) amino)-2, 5-dimethylphenyl)-N-methylformimidamide

To a stirred solution of N1-(3-methoxyphenyl)-2,5-dimethylbenzene-1,4-diamine (0.22 g, 0.908 mmol) in trimethyl orthoformate (10 ml), catalytic amount of *p*-toluenesulfonic acid monohydrate (0.017 g, 0.091 mmol) was added and heated the reaction contents at 105°C under nitrogen atmosphere for 2 hours. After the completion of reaction, the volatiles were evaporated under vacuum.

15 The residue was diluted with 1, 4-dioxane (10 ml). N-ethyl methylamine (0.158 ml, 1.816 mmol) was added slowly at room temperature. The contents were heated at 90°C for 4 hours. After completion of the reaction, dioxane was evaporated and purified the crude compound by preparative HPLC to get N-ethyl-N'-(4-((3-methoxyphenyl) amino)-2, 5-dimethylphenyl)-N-methylformimidamide (0.235 g) as gum. ¹H-NMR (400 MHz, DMSO-d₆) δ 7.70-7.49 (bs, 1H), 6.77 (s, 1H), 6.72 (d, J = 9.0 Hz, 2H), 6.64 (s, 1H), 6.39 (d, J = 9.2 Hz, 2H), 3.63 (s, 3H), 3.54-3.19 (bs, 2H), 3.05 (s, 3H), 2.91 (s, 3H), 2.09 (s, 3H), 1.96 (s, 3H), 1.11 (t, J = 7.1 Hz, 3H)

EXAMPLE 24

25 N-ethyl-N'-(4-((4-methoxyphenyl) (methyl) amino)-2, 5-dimethylphenyl)-N-methylformimidamide

Step A was carried out as described in above examples.

Step B: Preparation of N-ethyl-N'-(4-((4-methoxyphenyl) (methyl) amino)-2, 5-dimethylphenyl)-N-methylformimidamide

To a stirred solution of N-1-(4-methoxyphenyl)-N-1,2,5-trimethylbenzene-1,4-diamine (0.31 g, 1.209 mmol) in trimethyl orthoformate (10 ml), catalytic amount of *p*-toluenesulfonic acid monohydrate (0.023 g, 0.121 mmol) was added and heated the reaction contents at 105°C under nitrogen atmosphere for 2 hours. After completion of the reaction, the volatiles were evaporated under vacuum contents were diluted with 1, 4-dioxane (10 ml), N-ethyl methylamine (0.210 ml, 2.419 mmol) was added slowly at room temperature. The contents were heated at 90°C for 4 hours. After completion dioxane was removed and purified the residue by preparative HPLC using ammonium formate buffer to get N-ethyl-N'-(4-((4-methoxyphenyl)(methyl)amino)-2,5-dimethylphenyl)-N-

methylformimidamide (0.177 g) as pale yellow gum. ¹H-NMR (400 MHz, DMSO-d₆) δ 7.70-7.49 (bs, 1H), 6.77 (s, 1H), 6.72 (d, J = 9.0 Hz, 2H), 6.64 (s, 1H), 6.39 (d, J = 9.2 Hz, 2H), 3.63 (s, 3H), 3.54-3.19 (bs, 2H), 3.05 (s, 3H), 2.91 (s, 3H), 2.09 (s, 3H), 1.96 (s, 3H), 1.11 (t, J = 7.1 Hz, 3H)

5 EXAMPLE 25

N'-(2-Chloro-4-((2-fluorophenyl) amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide

Step A: Preparation of N'-(4-Bromo-2-chloro-5-methylphenyl)-N-ethyl-N-methylformimidamide

To a stirred solution of 4-bromo-2-chloro-5-methylaniline (2g, 9.07 mmol) in trimethyl orthoformate, catalytic amount of *p*-toluenesulfonic acid monohydrate (0.173 g, 0.907 mmol) was added and heated
10 the reaction contents at 105°C under nitrogen atmosphere for 2 hours. After the completion of reaction, the volatiles were removed under vacuum, contents were diluted with 1, 4-dioxane (15 ml), N-ethyl methylamine (2.365 ml, 27.2 mmol) was added slowly at room temperature. The contents were heated at 90°C for 4 hours. After completion of the reaction, dioxane was removed and purified by flash column chromatography using ethyl acetate: hexane as eluent to get N'-(4-bromo-2-chloro-5-
15 methylphenyl)-N-ethyl-N-methylformimidamide (2.2 g) as pale brown gum. LCMS (M+H) 289.60

Step B: N'-(2-Chloro-4-((2-fluorophenyl) amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide

To a stirred solution of N'-(4-bromo-2-chloro-5-methylphenyl)-N-ethyl-N-methylformimidamide (0.521 g, 1.800 mmol), 2-fluoroaniline (0.2 g, 1.800 mmol), BINAP (0.112 g, 0.180 mmol), caesium carbonate (1.290 g, 3.96 mmol) in toluene was degassed for 15 minutes and Palladium (II) acetate
20 (0.061 g, 0.090 mmol) was added and further degassed for 15 more minutes and the contents were heated at 110°C for 8 hours. After completion of the reaction contents were filtered through celite, purified by flash column chromatography to get N'-(2-chloro-4-((2-fluorophenyl) amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide (0.1318 g) as a gum. ¹H-NMR (400 MHz,
25 CHLOROFORM-D) δ 7.60-7.36 (br, 1H), 7.23 (s, 1H), 7.11-7.01 (m, 1H), 6.96 (t, J = 7.6 Hz, 1H), 6.73-6.85 (m, 3H), 5.38 (s, 1H), 3.68-3.22 (2H), 3.08 (s, 3H), 2.19 (s, 3H), 1.25 (t, J = 7.2 Hz, 3H)

EXAMPLE 26

N'-(2-Chloro-4-((3-chlorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide

30 Step A was carried out as described in examples.

Step B: N'-(2-Chloro-4-((3-chlorophenyl) amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide

To a stirred solution of 3-chloroaniline (1 g, 7.84 mmol) N'-(4-bromo-2-chloro-5-methylphenyl)-N-ethyl-N-methylformimidamide (2.270 g, 7.84 mmol), BINAP (0.488 g, 0.784 mmol), caesium carbonate (7.66 g, 23.52 mmol) in toluene was degassed for 15 minutes and Palladium (II) acetate
35 (0.264 g, 0.392 mmol) was added and further degassed for 15 more minutes and the contents were heated at 110°C for 8 hours. After completion of the reaction contents were filtered through celite,

purified by flash column chromatography to obtain the N'-(2-chloro-4-((3-chlorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide (0.8 g) as gum. ¹H-NMR (400 MHz, DMSO-d₆) δ 7.73 (bs, 1H), 7.66 (s, 1H), 7.10-7.14 (m, 1H), 7.07 (s, 1H), 6.88 (s, 1H), 6.70-6.63 (m, 1H), 6.58-6.60 (m, 2H), 3.50-3.33 (2H), 3.04-2.86 (3H), 2.08 (s, 3H), 1.13 (t, J = 7.0 Hz, 3H)

5

EXAMPLE 27

N'-(2-Chloro-4-((3-chlorophenyl) (methyl) amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide
Step A: Preparation of N'-(2-Chloro-4-((3-chlorophenyl) (methyl) amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide (compound 53)

- 10 To a stirred solution of compound 52 from example 26 (0.3 g, 0.892 mmol), sodium hydride (0.043 g, 1.784 mmol) in DMF at 0°C, iodomethane (0.112 ml, 1.784 mmol) was added and stirred at room temperature for 2 hours. After completion of the reaction, the reaction mixture was poured into crushed ice and diluted with ethyl acetate. The separated organic layer was washed with brine, dried over anhydrous sodium sulphate. Evaporated under high vacuum to obtain the residue, which was
- 15 purified by preparative HPLC to get N'-(2-chloro-4-((3-chlorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide (0.249 g) as pale yellow gum. ¹H-NMR (400 MHz, DMSO-d₆) δ 7.83-7.61 (1H), 7.10-7.14 (m, 2H), 6.95 (s, 1H), 6.63-6.66 (m, 1H), 6.35-6.40 (m, 2H), 3.34-3.45 (m, 2H), 3.13 (s, 3H), 3.05-2.87 (3H), 1.97 (s, 3H), 1.14 (t, J = 6.9 Hz, 3H)

20 EXAMPLE 28

N-(3-Chlorophenyl)-N, 2, 5-trimethyl-4-((morpholinomethylene) amino) aniline

Step A was carried out as described in example 1.

Step B: Preparation of N-(3-Chlorophenyl)-N, 2, 5-trimethyl-4-((morpholinomethylene) amino) aniline

- 25 To a stirred solution of N1-(3-chlorophenyl)-N-1,2,5-trimethylbenzene-1,4-diamine (0.3 g, 1.150 mmol) in trimethyl orthoformate, catalytic amount of *p*-toluenesulfonic acid monohydrate (0.010 g, 0.053 mmol) was added and heated the reaction contents at 105°C under nitrogen atmosphere for 2 hours. After completion of reaction, the volatiles were removed under vacuum. The residue was diluted with 1, 4-dioxane (10 ml), morphine (0.200 ml, 2.301 mmol) was added slowly at room
- 30 temperature. The contents were heated at 90°C for 4 hours. After completion of the reaction, dioxane was removed and purified by preparative HPLC to get N-(3-chlorophenyl)-N,2,5-trimethyl-4-((morpholinomethylene)amino)aniline (0.277 g) as pale yellow gum. ¹H-NMR (400 MHz, DMSO-d₆) δ 7.69 (s, 1H), 7.07-7.11 (m, 1H), 6.85 (s, 1H), 6.75 (s, 1H), 6.65-6.54 (1H), 6.34-6.36 (m, 2H), 3.61-3.63 (m, 4H), 3.59-3.38 (m, 4H), 3.11 (s, 3H), 2.11 (s, 3H), 1.96 (s, 3H)

35

EXAMPLE 29

N-(3-Chlorophenyl)-N, 2, 5-trimethyl-4-((piperidin-1-ylmethylene) amino) aniline

Step A was carried out as described in example 1.

Step B: N-(3-Chlorophenyl)-N, 2, 5-trimethyl-4-((piperidin-1-ylmethylene) amino) aniline

To a stirred solution of N1-(3-chlorophenyl)-N-1,2,5-trimethylbenzene-1,4-diamine (0.3 g, 1.150 mmol) in trimethyl orthoformate, catalytic amount of *p*-toluenesulfonic acid monohydrate (0.015 g, 0.079 mmol) was added and heated the reaction contents at 105°C under nitrogen atmosphere for 2 hours. After completion of reaction, the volatiles were removed under vacuum contents were diluted with 1, 4- dioxane (10 ml), piperidine (0.228 ml, 2.301 mmol) was added slowly at room temperature. The contents were heated at 90°C for 4 hours, monitored by TLC. After completion dioxane was removed and purified by preparative HPLC using ammonium formate buffer to get N-(3-chlorophenyl)-N,2,5-trimethyl-4-((piperidin-1-ylmethylene)amino)aniline (0.231 g) as off-white gum. ¹H-NMR (400 MHz, DMSO-d₆) δ 7.61 (s, 1H), 7.12-7.04 (m, 1H), 6.83 (s, 1H), 6.71 (s, 1H), 6.58-6.60 (m, 1H), 6.34-6.36 (m, 2H), 3.64-3.33 (4H), 3.11 (s, 3H), 2.11 (s, 3H), 1.95 (s, 3H), 1.59-1.62 (m, 2H), 1.48-1.54 (m, 4H)

EXAMPLE 30

N'-(4-((3-Chlorophenyl) (methyl) amino)-2, 5-dimethylphenyl)-N-cyanoformimidamide

Step A was carried out as described in example 1.

Step B: N'-(4-((3-Chlorophenyl) (methyl) amino)-2, 5-dimethylphenyl)-N-cyanoformimidamide

To a stirred solution of N1-(3-chlorophenyl)-N-1,2,5-trimethylbenzene-1,4-diamine (0.3 g, 1.150 mmol) in trimethyl orthoformate, catalytic amount of *p*-toluenesulfonic acid monohydrate (0.02 g, 0.105 mmol) was added and heated the reaction contents at 105°C under nitrogen atmosphere for 2 hours. After completion of reaction, solvent was removed under vacuum, contents were diluted with 1, 4-dioxane (10 ml). Cyanamide (0.1 g, 2.379 mmol) was added slowly at room temperature. The contents were heated at 90°C for 4 hours. After completion of the reaction, dioxane was removed and purified by preparative HPLC using ammonium formate buffer to get N'-(4-((3-chlorophenyl) (methyl) amino)-2, 5-dimethylphenyl)-N-cyanoformimidamide as off-white solid (0.172g). ¹H-NMR (400 MHz, DMSO-d₆) δ 11.09-10.13 (1H), 8.81-8.49 (1H), 7.38 (d, J = 41.7 Hz, 1H), 7.10-7.14 (m, 1H), 7.05 (d, J = 13.8 Hz, 1H), 6.66 (d, J = 7.3 Hz, 1H), 6.46-6.39 (1H), 6.39-6.31 (1H), 3.14 (3H), 2.19 (3H), 2.01 (s 3H)

EXAMPLE 31

N-Allyl-N'-(4-((3-chlorophenyl) (methyl) amino)-2, 5-dimethylphenyl)-N-methylformimidamide

Step A was carried out as described in example 1.

Step B: N-Allyl-N'-(4-((3-chlorophenyl) (methyl) amino)-2, 5-dimethylphenyl)-N-methylformimidamide

To a stirred solution of N1-(3-chlorophenyl)-N-1,2,5-trimethylbenzene-1,4-diamine (0.3 g, 1.150 mmol) in trimethyl orthoformate, catalytic amount of *p*-toluenesulfonic acid monohydrate (0.02 g, 0.105 mmol) was added and heated the reaction contents at 105°C under nitrogen atmosphere for 2 hours. After completion of the reaction, the solvent was removed under vacuum contents were diluted
 5 with 1, 4-dioxane (10 ml), N-Allyl methylamine (0.205 g, 2.88 mmol) was added slowly at room temperature. The contents were heated at 90°C for 4 hours. After completion dioxane was removed and purified by preparative HPLC using ammonium format buffer to get N-allyl-N'-(4-((3-chlorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide as pale brown gum (0.227g). ¹H-NMR (400 MHz, DMSO-d₆) δ 7.69 (s, 1H), 7.07-7.11 (m, 1H), 6.84 (s, 1H), 6.72 (s,
 10 1H), 6.58-6.61 (m, 1H), 6.35 (t, J = 2.3 Hz, 2H), 5.94-5.77 (1H), 5.18-5.23 (m, 2H), 4.13-3.78 (2H), 3.11 (s, 3H), 2.90 (bs, 3H), 2.11 (s, 3H), 1.96 (s, 3H).

As described herein the compounds of general formula (I) shows an extremely high fungicidal activity which is exerted with respect to numerous phytopathogenic fungi which attacks on important
 15 agricultural crops. Compounds of present invention were assessed for activity against one or more of the following:

Biological Test Examples (IN VITRO TEST)

Example 1: *Pyricularia oryzae* (Rice blast): Compounds were dissolved in 0.3% DMSO and & then added to Potato Dextrose Agar medium just prior to dispensing it into Petri dishes. 5ml medium with
 20 compound was dispensed into 60mm sterile petri-plates. After solidification each plate was seeded with 5mm size mycelial disc taken from periphery of actively growing virulent culture plate. Plates were incubated in growth chambers at 25°C temperature and 60% relative humidity for seven days and radial growth was measured. Compounds 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 13, 16, 18, 20, 24, 25, 26, 27, 28,
 25 29, 30, 31, 33, 34, 35, 36, 38, 39, 40, 42, 43, 44, 45, 46, 47, 48, 50, 51, 52, 53, 54, 55, 56, 57, 58,
 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 82, 83, 84, 85,
 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 110,
 111, 112, 113, 115, 116, 117, 118, 119, 121, 122, 123, 125, 126, 129, 130, 131, 133, 134, 135, 139,
 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 155, 156, 157, 158, 159, 160, 161,
 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 176, 177, 178, 180, 181, 182, 184, 185,
 30 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 205, 206,
 207, 208, 209, 210, 211, 212, 213, 214, 215, 217, 218, 219, 220, 221, 222, 223, 224, 227, 228, 229 &
 230 at 300ppm gave 70 to 100% control in these tests when compared to untreated check which showed extensive disease development.

Example 2: *Rhizoctonia solani* (Rice sheath blight/Potato black scurf): Compounds were dissolved in 0.3% DMSO and then added to Potato Dextrose Agar medium just prior to dispensing it into Petri dishes. 5ml medium with compound was dispensed into 60mm sterile petri-plates. After solidification each plate was seeded with 5mm size mycelial disc taken from periphery of actively growing virulent culture plate. Plates were incubated in growth chambers at 25°C temperature and 60% relative humidity for seven days and radial growth was measured. Compounds 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 13, 14, 15, 16, 18, 19, 20, 21, 24, 25, 26, 27, 29, 30, 31, 33, 34, 35, 36, 38, 39, 40, 42, 43, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 70, 71, 72, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 135, 137, 139, 140, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 173, 176, 177, 180, 181, 184, 185, 186, 187, 188, 190, 191, 192, 195, 197, 198, 199, 201, 202, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 219, 220, 221, 222, 228, 229 & 230 at 300ppm gave 70 to 100% control in these tests when compared to untreated check which showed extensive disease development.

Example 3: *Botrytis cinerea* (Gray mold): Compounds were dissolved in 0.3% DMSO and then added to Potato Dextrose Agar medium just prior to dispensing it into Petri dishes. 5ml medium with compound was dispensed into 60mm sterile petri-plates. After solidification each plate was seeded with 5mm size mycelial disc taken from periphery of actively growing virulent culture plate. Plates were incubated in growth chambers at 22°C temperature and 90% relative humidity for seven days and radial growth was measured. Compounds 1, 2, 3, 4, 8, 9, 18, 19, 33, 34, 35, 38, 40, 46, 47, 48, 52, 53, 54, 55, 57, 58, 59, 60, 61, 62, 63, 64, 70, 72, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 86, 87, 88, 89, 93, 94, 95, 97, 98, 99, 100, 101, 103, 104, 105, 106, 107, 108, 110, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 129, 130, 133, 135, 142, 143, 144, 145, 146, 148, 149, 150, 151, 152, 153, 155, 156, 157, 158, 159, 160, 161, 162, 166, 167, 168, 169, 173, 177, 181, 186, 187, 197, 199, 206, 207, 209, 210, 211, 212, 213, 214, 217, 218, 219, 220, 221, 223, 225, 229 & 230 at 300ppm gave 70 to 100% in these tests when compared to untreated check which showed extensive disease development.

Example 4: *Alternaria solani* (early blight of tomato/potato): Compounds were dissolved in 0.3% DMSO and then added to Potato Dextrose Agar medium just prior to dispensing it into Petri dishes. 5ml medium with compound was dispensed into 60mm sterile petri-plates. After solidification each plate was seeded with 5mm size mycelial disc taken from periphery of actively growing virulent culture plate. Plates were incubated in growth chambers at 25°C temperature and 60% relative humidity for seven days and radial growth was measured. Compounds 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,

12, 13, 15, 16, 18, 19, 20, 21, 22, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 110, 112, 115, 116, 117, 118, 119, 121, 123, 125, 126, 127, 128, 129, 130, 131, 132, 133, 135, 137, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 155, 156, 157, 158, 159, 160, 161, 163, 164, 165, 166, 167, 168, 169, 170, 171, 173, 176, 177, 180, 181, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 195, 196, 197, 198, 199, 200, 201, 202, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229 & 230 at 300ppm gave 70 to 100% control in these tests when compared to untreated check which showed extensive disease development.

Example 5: *Colletotrichum capsici* (anthracnose): Compounds were dissolved in 0.3% DMSO and then added to Potato Dextrose Agar medium just prior to dispensing it into Petri dishes. 5ml medium with compound was dispensed into 60mm sterile petri-plates. After solidification each plate was seeded with 5mm size mycelial disc taken from periphery of actively growing virulent culture plate. Plates were incubated in growth chambers at 25°C temperature and 60% relative humidity for seven days and radial growth was measured. Compounds 2, 3, 4, 7, 8, 9, 11, 15, 18, 19, 24, 25, 26, 27, 29, 31, 32, 33, 34, 35, 36, 38, 39, 40, 43, 44, 46, 48, 51, 52, 53, 54, 55, 57, 58, 59, 60, 61, 62, 63, 64, 66, 71, 72, 74, 75, 76, 77, 79, 80, 82, 83, 85, 86, 88, 89, 92, 93, 95, 96, 97, 98, 99, 100, 102, 104, 106, 110, 111, 112, 113, 116, 117, 118, 119, 121, 123, 125, 126, 127, 129, 131, 133, 135, 141, 142, 144, 145, 146, 147, 148, 149, 151, 152, 155, 156, 157, 158, 159, 160, 161, 162, 166, 167, 168, 169, 170, 171, 173, 176, 180, 181, 184, 185, 186, 190, 191, 195, 197, 198, 199, 202, 205, 206, 207, 209, 210, 211, 212, 213, 217, 218, 219, 220, 221, 222, 225 & 230 at 300ppm gave 70 to 100% control in these tests when compared to untreated check which showed extensive disease development.

Example 6: *Septoria lycopersici* (Leaf spot of tomato): Compounds were dissolved in 0.3% DMSO and then added to Potato Dextrose Agar medium just prior to dispensing it into Petri dishes. 5ml medium with compound was dispensed into 60mm sterile petri-plates. After solidification each plate was seeded with 5mm size mycelial disc taken from periphery of actively growing virulent culture plate. Plates were incubated in growth chambers at 25°C temperature and 70% relative humidity for seven days and radial growth was measured. Compounds 1, 2, 3, 4, 6, 7, 8, 9, 11, 13, 15, 16, 18, 19, 20, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 43, 44, 45, 46, 47, 48, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 66, 72, 77, 86, 89, 98, 99, 102, 106, 110, 112, 116, 119, 123, 125, 126, 129, 135, 145, 148, 155, 166, 158, 159, 160, 161, 166, 167, 168, 169, 171, 173, 180, 184, 186, 188, 190, 191, 194, 195, 197, 198, 199, 202, 205, 206, 207, 208, 209, 211, 212, 213, 214, 217, 218, 219, 220, 221, 222, 223, 224, 225 & 230 at 300ppm gave 80 -100% control in these tests when

compared to untreated check which showed extensive disease development.

Example 7: *Fusarium culmorum* Foot rot of cereals): Compounds were dissolved in 0.3% DMSO and then added to Potato Dextrose Agar medium just prior to dispensing it into petri dishes. 5ml medium with compound was dispensed into 60mm sterile petri-plates. After solidification each plate was seeded with 5mm size mycelial disc taken from periphery of actively growing virulent culture plate. Plates were incubated in growth chambers at 25°C temperature and 60% relative humidity for seven days and radial growth was measured. Compounds 1, 7, 8, 26, 27, 29, 31, 35, 38, 39, 40, 45, 52, 53, 54, 55, 57, 58, 59, 60, 61, 62, 64, 66, 71, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 89, 102, 104, 106, 116, 117, 119, 121, 123, 125, 126, 129, 145, 147, 148, 151, 153, 155, 156, 158, 159, 160, 161, 166, 168, 170, 172, 181, 197, 205, 206, 209, 210, 213, 220 & 221 at 300ppm gave 70 -100% control in these tests when compared to untreated check which showed extensive disease development.

Biological Test Examples (GREENHOUSE)

Example A: *Pyricularia oryzae* test in Rice

Compounds were dissolved in 2% DMSO/Acetone and then mixed with water to calibrated spray volume of 50ml. This 50ml spray solution was poured into the spray bottles for further applications.

To test the preventive activity of compounds, healthy young rice seedlings/ plants raised in the greenhouse were sprayed with active compound preparation at the stated application rates inside the spray cabinets using hallowcone nozzles. One day after treatment, the plants were inoculated with spore suspension (sterile water) containing 1.4×10^6 *Pyricularia oryzae* inoculum. The inoculated plants were then kept in greenhouse chamber at 24°C temperature and 95% relative humidity for disease expression.

visual assessment of compound's performance was carried by rating the disease severity (0-100% scale) on treated plants on 3, 7, 10 and 15 days after application. Efficacy (% control) of the compounds was calculated by comparing the disease rating in the treatment with untreated control. The sprayed plants were also assessed for compound's phytotoxic effects by recording symptoms like necrosis, chlorosis & stunting. Compounds 54, 58, 80, 129, 138 & 152 at 500ppm gave 70 -100% control in these tests when compared to untreated check which showed extensive disease development. . None of these compounds showed any phytotoxicity to rice crop.

Example B: *Fusarium culmorum* test in Wheat

Compounds were dissolved in 2% DMSO/Acetone and then mixed with water to calibrated spray volume of 50ml. This 50ml spray solution was poured into the spray bottles for further applications.

To test the preventive activity of compounds, healthy young wheat plants raised in the greenhouse

were sprayed with active compound preparation at the stated application rates inside the spray cabinets using hallowcone nozzles. One day after treatment, the plants were inoculated with spore suspension (2% Malt) containing 2×10^6 *Fusarium culmorum* inoculum. The inoculated plants were then kept in greenhouse chamber at 24°C temperature and 80-90 % relative humidity for disease expression.

- 5 A visual assessment of compound's performance was carried by rating the disease severity (0-100% scale) on treated plants on 3, 7, 10 and 15 days after application. Efficacy (% control) of the compounds was calculated by comparing the disease rating in the treatment with untreated control. The sprayed plants were also assessed for compound's phytotoxic effects by recording symptoms like necrosis, chlorosis and stunting. Compounds 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 20, 21, 27, 28, 31,
10 35, 36, 82, 112, 139, 151, 152, & 158 at 500ppm gave 70 -100% control in these tests when compared to untreated check which showed extensive disease development. None of these compounds showed any phytotoxicity to wheat crop.

Example H: *Botrytis cinera* test in Tomato

- 15 Compounds were dissolved in 2% DMSO/Acetone and then mixed with water to calibrated spray volume of 50ml. This 50ml spray solution was poured into the spray bottles for further applications. To test the preventive activity of compounds, healthy young bean/chilli plants raised in the greenhouse were sprayed with active compound preparation at the stated application rates inside the spray cabinets using hallowcone nozzles. One day after treatment, the plants were inoculated with spore suspension
20 (2% Malt) containing 1.2×10^6 *Botrytis cinera* inoculum. The inoculated plants were then kept in greenhouse chamber at 18-20°C temperature and 90-100 % Relative Humidity for disease expression. A visual assessment of compound's performance was carried by rating the disease severity (0-100% scale) on treated plants on 3, 7, 10 and 15 days after application. Efficacy (% control) of the
25 The sprayed plants were also assessed for compound's phytotoxic effects by recording symptoms like necrosis, chlorosis and stunting. Compounds 1, 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 43, 44, 45, 46, 85, 86, 87, 88, 90, 96, 97, 99, 100, 102, 103, 123, 127, 128, 129, 133, 134, 135, 136, 137, 138, 150, 161, 162, 163, & 164 at 500ppm gave 70 -100% control in these tests when compared to untreated. None of these
30 compounds showed any phytotoxicity to tomato crop.

Example D: *Alternaria solani* test in Tomato

- Compounds were dissolved in 2% DMSO/ Acetone and then mixed with water to calibrated spray volume of 50ml. This 50ml spray solution was poured into the spray bottles for further applications.
35 To test the preventive activity of compounds, healthy young Tomato plants raised in the greenhouse

were sprayed with active compound preparation at the stated application rates inside the spray cabinets using hallowcone nozzles. One day after treatment, the plants were inoculated with spore suspension (2% Malt) containing 0.24×10^6 *Alternaria solani* inoculum. The inoculated plants were then kept in greenhouse chamber at 22-24°C temperature and 90-95% relative humidity for disease expression.

- 5 A visual assessment of compound's performance was carried by rating the disease severity (0-100% scale) on treated plants on 3, 7, 10 and 15 days after application. Efficacy (% control) of the compounds was calculated by comparing the disease rating in the treatment with untreated control. The sprayed plants were also assessed for compound's phytotoxic effects by recording symptoms like necrosis, chlorosis and stunting. Compounds 1, 2, 3, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 23, 10 24, 25, 26, 28, 29, 30, 31, 32, 33, 35, 37, 40, 43, 44, 54, 66, 67, 75, 88, 89, 116, 117, 118, 119, 123, 124, 125, 129, 130, 131, 132, 139, 143, 148, 156, 157 & 158 at 500ppm gave 70 -100% control in these tests when compared to untreated. None of these compounds showed any phytotoxicity to tomato crop.

15 Example E: *Corynespora corrica* test in Tomato

Compounds were dissolved in 2% DMSO/Acetone and then mixed with water to calibrated spray volume of 50ml. This 50ml spray solution was poured into the spray bottles for further applications.

- To test the preventive activity of compounds, healthy young Tomato plants raised in the greenhouse were sprayed with active compound preparation at the stated application rates inside the spray cabinets 20 using hallowcone nozzles. One day after treatment, the plants were inoculated with spore suspension (tween 20 water solution) containing 2.6×10^6 *Corynespora corrica* inoculum. The inoculated plants were then kept in greenhouse chamber at 22-24°C temperature and 90-95 % Relative Humidity for disease expression.


- A visual assessment of compound's performance was carried by rating the disease severity (0-100% 25 scale) on treated plants on 3, 7, 10 and 15 days after application. Efficacy (% control) of the compounds was calculated by comparing the disease rating in the treatment with untreated control. The sprayed plants were also assessed for compound's phytotoxic effects by recording symptoms like necrosis, chlorosis and stunting.

- Compounds 1, 3, 13, 14, 15, 16, 17, 18, 19, 20 & 22 at 500ppm gave 70 -100% control in these tests 30 when compared to untreated. None of these compounds showed any phytotoxicity to tomato crop.

- Having described the invention with reference to certain preferred aspects, other aspects will become apparent to one skilled in the art from consideration of the specification. It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without 35 departing from the scope of the invention.

WE CLAIM

1) A compound of general formula (I)



(I)

wherein

- 10 R¹ is selected from the group consisting of hydrogen, CN, SR'', S(O)_nR'', OR'', C₁₋₁₂-alkyl, C₁₋₁₂-alkoxy, C₁₋₁₂-alkylthio, C₂₋₁₂-alkenyl, C₂₋₁₂-alkynyl, C₁₋₁₂-haloalkyl, C₂₋₁₂-haloalkenyl, C₂₋₁₂-haloalkynyl, C₃₋₈-cycloalkyl, C₄₋₈-cycloalkenyl, C₅₋₈-cycloalkynyl; where in the cyclic ring system one or more carbon atoms may be replaced by heteroatoms selected from the group consisting of N, O, and S(O)_n;
- 15 R² and R³ are independently selected from the group consisting of hydrogen, CN, S(O)_nR'', OR', (C=O)-R'', C₁₋₁₂-alkyl, C₂₋₁₂-alkenyl, C₂₋₁₂-alkynyl, C₁₋₁₂-haloalkyl, C₂₋₁₂-haloalkenyl, C₂₋₁₂-haloalkynyl, C₃₋₈-cycloalkyl, C₄₋₈-cycloalkenyl, C₅₋₈-cycloalkynyl, C₅₋₁₈-aryl, C₇₋₁₉-aralkyl, C₇₋₁₉-alkaryl; where in the cyclic ring system one or more carbon atoms may be replaced by heteroatoms selected from the group consisting of N, O, and S(O)_n;
- 20 R¹ and R², R² and R³ or R¹ and R³ together with the atoms to which they are attached or together with further atoms selected from the group consisting of C, N, O, S and optionally including 1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O)_m and SiR'₂ may form a four to seven membered ring, which for its part may be substituted by one or more X, R', OR', SR', NR'₂, SiR'₃, COOR', CN, and CONR'₂; and wherein all of the groups of R¹, R², and R³ may optionally be
- 25 substituted by one or more groups selected from the group consisting of X, R', OR', SR', NR'₂, SiR'₃, COOR', CN, and CONR'₂;

- R⁴, R⁵, R⁶ and R⁷ are independently selected from the group consisting of hydrogen, X, CN, SCN, SF₅, S(O)_nR'', SiR'₃, OR'', NR'R'', (C=O)-R'', CR'=NR'', C₁₋₁₂-alkyl, C₂₋₁₂-alkenyl, C₂₋₁₂-alkynyl, C₁₋₁₂-haloalkyl, C₂₋₁₂-haloalkenyl, C₂₋₁₂-haloalkynyl, C₁₋₁₂-haloalkoxy, C₁₋₁₂-haloalkylthio, C₃₋₈-cycloalkyl, C₄₋₈-cycloalkenyl, C₅₋₈-cycloalkynyl, C₃₋₈-cycloalkyloxy, C₃₋₈-cycloalkylthio, C₅₋₁₈-aryl, C₇₋₁₉-aralkyl,
- 30

C₇₋₁₉-alkaryl; where in the cyclic ring system one or more carbon atoms may be replaced by heteroatoms selected from the group consisting of N, O, and S(O)_n; and all of the groups mentioned above may optionally be substituted by one or more groups selected from the group consisting of X, R', OR', SR', NR'₂, SiR'₃, COOR', CN, and CONR'₂; or

- 5 wherein R⁴ and R⁷ or R⁵ and R⁶ together with the atom to which they are attached or together with further atoms selected from the group consisting of C, N, O, S and optionally including 1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O)_m and SiR'₂ may form a four to seven membered ring, which for its part may be substituted by one or more X, R', OR', SR', NR'₂, SiR'₃, COOR', CN, and CONR'₂; and wherein all of the groups of R⁴, R⁵, R⁶ and R⁷ may optionally be
 10 substituted by one or more groups selected from the group consisting of X, R', OR', SR', NR'₂, SiR'₃, COOR', CN, and CONR'₂;

- R⁸ is selected from the group consisting of hydrogen, CN, SCN, S(O)_nR'', SiR'₃, NR'R'', (C=O)-R'', CR'=NR'', C₁₋₁₂-alkyl, C₂₋₁₂-alkenyl, C₂₋₁₂-alkynyl, C₁₋₁₂-haloalkyl, C₂₋₁₂-haloalkenyl, C₂₋₁₂-haloalkynyl,
 15 C₃₋₈-cycloalkyl, C₄₋₈-cycloalkenyl, C₅₋₈-cycloalkynyl, C₅₋₁₈-aryl, C₇₋₁₉-aralkyl, C₇₋₁₉-alkaryl, heterocyclyl, C₃₋₈-heterocyclalkyl; where in the cyclic ring system one or more carbon atoms may be replaced by heteroatoms selected from the group consisting of N, O, and S(O)_n; and all of the groups mentioned above may be substituted by one or more groups selected from the group consisting of X, R', OR', SR', NR'₂, SiR'₃, COOR', CN, and CONR'₂; or wherein

- 20 A is selected from the group consisting of fused or non-fused C₆₋₁₈-aryl, C₅₋₁₈-heteroaryl, wherein one or more carbon atoms are replaced by heteroatoms selected from N, O, S and optionally including 1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O)_m and SiR'₂ optionally substituted by one or more groups of R⁹; wherein

- 25 R⁹ is selected from the group consisting of hydrogen, X, CN, SCN, SF₅, R'', OR'', NO₂, NR''₂, SiR'₃, (C=O)-R'', S(O)_nR'', OS(O)_nR'', OSiR'₃, NR'S(O)_nR'', C₁₋₈-alkyl-S(O)_nR'', C₁₋₈-alkyl-(C=O)-R'', CR'=NR'', S(O)_nC₅₋₁₈-aryl, S(O)_nC₇₋₁₉-aralkyl, S(O)_nC₇₋₁₉-alkaryl, C₁₋₁₂-alkyl, C₂₋₁₂-alkenyl, C₂₋₁₂-alkynyl, C₁₋₁₂-haloalkyl, C₂₋₁₂-haloalkenyl, C₂₋₁₂-haloalkynyl, C₁₋₁₂-alkoxy, C₁₋₁₂-alkylthio, C₁₋₁₂-haloalkoxy, C₁₋₁₂-haloalkylthio, C₃₋₁₂-cycloalkyl, C₄₋₈-cycloalkenyl, C₅₋₈-cycloalkynyl, C₃₋₈-cycloalkyloxy, C₃₋₈-cycloalkylthio, C₇₋₁₉-aralkyl, C₇₋₁₉-alkaryl; bicyclic C₅₋₁₂-alkyl, C₇₋₁₂-alkenyl;
 30 where in the cyclic ring system one or more carbon atoms may be replaced by heteroatoms selected from the group consisting of N, O, and S(O)_n; and all of the groups mentioned above may be substituted by one or more groups selected from the group consisting of X, R', OR', SR', NR'₂, SiR'₃, COOR', CN, and CONR'₂; or two R⁹ together with the atom to which they are attached or together
 35 with further atoms selected from the group consisting of C, N, O, S and optionally including 1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O)_m and SiR'₂ may form a four to

ten membered ring, which for its part may be substituted by one or more X, R', OR', SR', NR'₂, SiR'₃, COOR', CN, and CONR'₂;

and wherein all of the groups of R⁸ and R⁹ may optionally be substituted by one or more groups selected from the group consisting of X, R', OR', SR', NR'₂, SiR'₃, COOR', CN, and CONR'₂;

5 wherein

X represents halogen;

wherein

R' represents hydrogen, straight chain or branched chain C₁₋₁₂-alkyl or cyclic C₃₋₁₀-alkyl which are optionally substituted by one or more X;

10

R'' represents hydrogen; NR'₂, OR', straight chain or branched chain C₁₋₁₂-alkyl, C₁₋₁₂-haloalkyl, cyclic C₃₋₈-alkyl which are optionally substituted by one or more groups selected from the group consisting of X, R', OR', SR', NR'₂, SiR'₃, COOR', CN, and CONR'₂, C₅₋₁₈-aryl which is optionally substituted by one or more R';

15 wherein,

m and n represent integers wherein n=0, 1 or 2; and m = 1 or 2;

and agronomically acceptable salts, metallic complexes, isomers/structural isomers, stereo-isomers, diastereoisomers, enantiomers, tautomers, or N-oxides of said compounds.

20

2) A compound of general formula (I) according to claim 1 wherein the each substituent is independently selected from:

R¹ is hydrogen, C₁₋₆-alkyl, C₁₋₆-alkoxy, C₁₋₆-alkylthio, C₁₋₆-haloalkyl, C₃₋₈-cycloalkyl;

R² and R³ are C₁₋₆-alkyl, C₂₋₆-alkenyl, C₂₋₆-alkynyl, C₁₋₆-alkoxy, C₁₋₆-alkylthio, C₁₋₆-haloalkyl, C₃₋₈-cycloalkyl;

25

R¹ and R², R² and R³ or R¹ and R³ together with the atoms to which they are attached or together with further atoms selected from the group consisting of C, N, O, S and optionally including 1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O)_m and SiR'₂ may form a four to seven membered ring, which for its part may be substituted by one or more X, R', OR', SR', NR'₂, SiR'₃, COOR', CN, and CONR'₂;

30

R⁴ and R⁵ are of X, CN, S(O)_nR'', NR'R'', (C=O)-R'', CR'=NR'', C₁₋₆-alkyl, C₂₋₆-alkenyl, C₂₋₆-alkynyl, C₁₋₆-haloalkyl, C₁₋₆-haloalkylthio, C₃₋₈-cycloalkyl, C₃₋₈-cycloalkylthio;

R⁶ and R⁷ are of hydrogen, X, CN, S(O)_nR'', NR'R'', (C=O)-R'', CR'=NR'', C₁₋₆-alkyl, C₂₋₆-alkenyl, C₂₋₆-alkynyl, C₁₋₆-haloalkyl, C₁₋₆-haloalkylthio, C₃₋₈-cycloalkyl, C₃₋₈-cycloalkylthio;

35

R⁴ and R⁷ or R⁵ and R⁶ together with the atom to which they are attached or together with further atoms selected from the group consisting of C, N, O, S and optionally including 1 to 3 ring members selected

from the group consisting of C(=O), C(=S), S(O)_n and SiR'₂ may form a four to seven membered ring, which for its part may be substituted by one or more X, R', OR', SR', NR'₂, SiR'₃, COOR', CN, and CONR'₂;

R⁸ is hydrogen, CN, S(O)_nR'', NR'R'', (C=O)-R'', CR'=NR'', C₁₋₆-alkyl, C₂₋₆-alkenyl, C₂₋₆-alkynyl, C₁₋₆-haloalkyl, C₃₋₈-cycloalkyl, C₃₋₈-heterocyclyl, C₃₋₈-heterocyclalkyl;

R⁹ is X, CN, SCN, SF₅, R'', OR'', NO₂, NR''₂, SiR'₃, (C=O)-R'', S(O)_nR'', OS(O)_nR'', OSiR'₃, NR'S(O)_nR'', C₁₋₈-alkyl-S(O)_nR'', C₁₋₆-alkyl-(C=O)-R'', CR'=NR'', C₂₋₆-alkenyl, C₂₋₆-alkynyl, C₁₋₆-haloalkyl, C₂₋₆-haloalkenyl, C₁₋₁₂-alkoxy, C₁₋₁₂-alkylthio, C₁₋₁₂-haloalkoxy, C₁₋₁₂-haloalkylthio, C₃₋₈-cycloalkyl, C₄₋₈-cycloalkenyl, C₃₋₈-cycloalkyloxy, C₃₋₈-cycloalkylthio or two R⁹ together with the atom to which they are attached or together with further atoms selected from the group consisting of C, N, O, S and optionally including 1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O)_n and SiR'₂ may form a four to ten membered ring, which for its part may be substituted by one or more X, R', OR', SR', NR'₂, SiR'₃, COOR', CN, and CONR'₂;

A is phenyl, naphthalenyl, furyl, thienyl, pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, oxazolyl, imidazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, triazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolyl, benzimidazolyl, indazolyl, benzofuranyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, iquinazolinyl, cinnonyl; substituted with one or more R⁹;

wherein R¹ to R⁹ may further optionally substituted by one or more groups selected from the group consisting of X, R'', OR', SR', NR'₂, SiR'₃, COOR', CN, and CONR'₂;

and agronomically acceptable salts, isomers/structural isomers, stereo-isomers, diastereoisomers, enantiomers, tautomers, or N-oxides of said compounds

3) A compound of general formula (I) according to claim 1, 2 or 4 wherein the each substituent is independently selected from:

R¹ is hydrogen or C₁₋₆-alkyl;

R² and R³ are C₁₋₆-alkyl, C₁₋₆-haloalkyl;

R⁴ and R⁵ are of X, CN, C₁₋₆-alkyl, C₁₋₆-haloalkyl, C₃₋₈-cycloalkyl;

R⁶ and R⁷ are of hydrogen, X, C₁₋₆-alkyl, C₁₋₆-haloalkyl;

R⁸ is hydrogen, CN, S(O)_nR'', (C=O)-R'', C₁₋₆-alkyl, C₁₋₆-haloalkyl, C₂₋₆-alkenyl, C₂₋₆-alkynyl, C₃₋₈-cycloalkyl, C₃₋₆-heterocyclyl, C₃₋₆-heterocyclalkyl;

R⁹ is X, CN, SCN, SF₅, R'', OR'', NO₂, NR''₂, SiR'₃, (C=O)-R'', S(O)_nR'', C₁₋₆-alkyl-S(O)_nR'', OS(O)_nR'', OSiR'₃, NR'S(O)_nR'', C₁₋₆-alkyl-(C=O)-R'', CR'=NR'', SC₁₋₆-alkyl, C₂₋₆-alkenyl, C₂₋₆-alkynyl, C₁₋₆-haloalkyl, C₂₋₆-haloalkenyl, C₁₋₁₂-alkoxy, C₁₋₁₂-alkylthio, C₁₋₁₂-haloalkoxy, C₁₋₁₂-haloalkylthio, C₃₋₈-cycloalkyl, C₄₋₈-cycloalkenyl, C₃₋₈-cycloalkyloxy, C₃₋₈-cycloalkylthio or two R⁹ together with the atom to which they are attached or together with further atoms selected from the

group consisting of C, N, O, S and optionally including 1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O)_m and SiR'₂ may form a four to ten membered ring, which for its part may be substituted by one or more X, R', OR', SR', NR'₂, SiR'₃, COOR', CN, and CONR'₂;

A is phenyl, naphthalenyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl isoxazolyl, oxadiazolyl,

5 pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl and quinolinyl; substituted with one or more R⁹;

wherein R¹ to R⁹ may further optionally substituted by one or more groups selected from the group consisting of X, R'', OR', SR', NR'₂, SiR'₃, COOR', CN, and CONR'₂;

and agronomically acceptable salts, isomers/structural isomers, stereo-isomers, diastereoisomers, enantiomers, tautomers, or N-oxides of said compounds.

10

4) A compound according to any one of claims 1, 2, or 3 wherein compound of general formula (I) are:

N'-(2,5-dimethyl-4-(phenylamino)phenyl)-N-ethyl-N-methylformimidamide;

N'-(2,5-dimethyl-4-(methyl(phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;

15 N'-(2-chloro-5-methyl-4-(phenylamino)phenyl)-N-ethyl-N-methylformimidamide;

N'-(2-chloro-5-methyl-4-(methyl(phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;

N'-(2,5-dimethyl-4-(N-phenylmethylsulfonamido)phenyl)-N-ethyl-N-methylformimidamide;

N'-(2,5-dimethyl-4-(methyl(2-methyl-4-(perfluoropropan-2-yl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;

20 N'-(4-((4-chlorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;

N'-(4-((3-chlorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;

N'-(4-((3,4-dichlorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;

N'-(2-chloro-5-methyl-4-(methyl(3,4,5-trifluorophenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;

25 N'-(2-chloro-5-methyl-4-(methyl(m-tolyl)amino)phenyl)-N-ethyl-N-methylformimidamide;

N'-(2-chloro-4-((3,4-dichlorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;

N'-(2-chloro-4-((3-methoxyphenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;

30 N'-(2-chloro-5-methyl-4-(methyl(4-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;

N'-(2-chloro-5-methyl-4-(methyl(p-tolyl)amino)phenyl)-N-ethyl-N-methylformimidamide;

N'-(2-chloro-4-((2-methoxyphenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;

35 N'-(2-chloro-5-methyl-4-(N-phenylmethylsulfonamido)phenyl)-N-ethyl-N-methylformimidamide;

N'-(2-chloro-4-((2-chlorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;

- N'-(2-chloro-4-((4-chlorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
N'-(2-chloro-4-((4-methoxyphenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
N'-(2-chloro-4-((4-methoxy-3-methylphenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
5 N'-(2-chloro-4-((3,4-dimethoxyphenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
N'-(2-chloro-4-((3,5-dimethoxyphenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
10 N'-(2,5-dimethyl-4-(methyl(m-tolyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
N-ethyl-N'-(4-((3-methoxyphenyl)(methyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
N'-(2,5-dimethyl-4-(methyl(p-tolyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
N-ethyl-N'-(4-((4-methoxyphenyl)(methyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
N-ethyl-N'-(4-((3-methoxyphenyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
15 N'-(2,5-dimethyl-4-(m-tolylamino)phenyl)-N-ethyl-N-methylformimidamide;
N'-(2,5-dimethyl-4-(p-tolylamino)phenyl)-N-ethyl-N-methylformimidamide;
N'-(4-((4-(tert-butyl)phenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
N'-(4-((4-(tert-butyl)phenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
N'-(4-((2-chlorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
20 N'-(2-chloro-4-((2-chlorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
N-ethyl-N'-(4-((2-fluorophenyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
N-ethyl-N'-(4-((2-fluorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
N'-(2-chloro-4-((2-fluorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
N-ethyl-N'-(4-((3-fluorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
25 N-ethyl-N'-(4-((4-fluorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
N'-(4-((2-chlorophenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
N-(4-(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylphenyl)-N-phenylacetamide
N'-(2-chloro-5-methyl-4-(methyl(pyridin-2-yl)amino)phenyl)-N-ethyl-N-methylformimidamide;
N'-(4-((4-chlorophenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
30 N-ethyl-N'-(4-((4-fluorophenyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
N-ethyl-N'-(4-((2-methoxyphenyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
N-ethyl-N'-(4-((3-fluorophenyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
N'-(2-chloro-4-((2-fluorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
N'-(2-chloro-4-((3-chlorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
35 N-(3-chlorophenyl)-N,2,5-trimethyl-4-((morpholinomethylene)amino)aniline
N'-(2-chloro-4-((3-chlorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;

- N-(3-Chlorophenyl)-N, 2, 5-trimethyl-4-((piperidin-1-ylmethylene) amino) aniline
N-allyl-N'-(4-((3-chlorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
N'-(4-((3-chlorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-isopropyl-N-methylformimidamide;
N'-(4-((2-bromophenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
5 N'-(4-((3-chlorophenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
N-ethyl-N'-(4-((4-methoxyphenyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
N'-(2,5-dimethyl-4-((2-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
N'-(2,5-dimethyl-4-(methyl(2-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
10 N'-(2,5-dimethyl-4-((4-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
N'-(2,5-dimethyl-4-((3-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
N'-(2,5-dimethyl-4-(methyl(4-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
N'-(2,5-dimethyl-4-(methyl(3-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
15 N'-(2,5-dimethyl-4-((3-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
N'-(4-((2-bromophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
N-ethyl-N'-(4-((2-methoxyphenyl)(methyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
N'-(2,5-dimethyl-4-(methyl(3-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
20 N'-(2-chloro-5-methyl-4-((3-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
N'-(2-chloro-5-methyl-4-(m-tolylamino)phenyl)-N-ethyl-N-methylformimidamide;
N'-(2-chloro-4-((3-methoxyphenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
N'-(2-chloro-5-methyl-4-(o-tolylamino)phenyl)-N-ethyl-N-methylformimidamide;
N'-(2-chloro-4-((4-chlorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
25 N'-(2,5-dimethyl-4-(o-tolylamino)phenyl)-N-ethyl-N-methylformimidamide;
N'-(2-chloro-4-((4-methoxyphenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
N'-(2-chloro-5-methyl-4-(methyl(o-tolyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
N'-(4-((2-bromophenyl)amino)-2-chloro-5-methylphenyl)-N-ethyl-N-methylformimidamide;
N'-(4-((2-bromophenyl)(methyl)amino)-2-chloro-5-methylphenyl)-N-ethyl-N-methylformimidamide;
30 N'-(2,5-dimethyl-4-(methyl(o-tolyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
N'-(2-chloro-4-((2-methoxyphenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
N'-(2-chloro-5-methyl-4-((2-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
N'-(2-chloro-5-methyl-4-(methyl(2-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
35 methylformimidamide;

- N'-(2-chloro-5-methyl-4-((4-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-4-((3-fluorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-4-((4-fluorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- 5 N'-(2-chloro-4-((3-fluorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-4-((4-fluorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-((3-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-((3-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- 10 N'-(2-chloro-5-methyl-4-(methyl(3-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-(methyl(3-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((2,6-difluorophenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- 15 N'-(2-chloro-4-((2,6-difluorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((2,6-difluorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-4-((2,6-difluorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((2-chloro-6-fluorophenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- 20 N'-(2-chloro-4-((2-chloro-6-fluorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((2-chloro-6-fluorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-((4-(pentafluoro-16-sulfaneyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- 25 N'-(4-((2,6-dichloro-4-(trifluoromethyl)phenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-((2-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-((2-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- 30 N'-(2-chloro-5-methyl-4-((3-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-((4-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-((4-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- 35 N'-(2,5-dimethyl-4-(methyl(2-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;

- N'-(2-chloro-5-methyl-4-(methyl(2-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-(methyl(4-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- 5 N'-(2-chloro-5-methyl-4-(methyl(4-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-(methyl(3-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-(N-phenylethylsulfonamido)phenyl)-N-ethyl-N-methylformimidamide;
- 10 N'-(2-chloro-4-((2,4-dichloro-6-(trifluoromethyl)phenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-((4-(pentafluoro-16-sulfaneyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-4-((2-chloro-6-fluorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-
- 15 methylformimidamide;
- N'-(2,5-dimethyl-4-(methyl(4-(pentafluoro-16-sulfaneyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-(methyl(4-(pentafluoro-16-sulfaneyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- 20 N'-(2-chloro-5-methyl-4-(methyl(3-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-((2-((trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-((2-((trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-
- 25 methylformimidamide;
- N'-(4-((3-((difluoromethyl)thio)phenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-((4-((trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- 30 N'-(2-chloro-5-methyl-4-((4-((trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-(methyl(2-((trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-(methyl(2-((trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-
- 35 methylformimidamide;

- N'-(2,5-dimethyl-4-(methyl(4-((trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-(methyl(4-((trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- 5 N'-(4-((3-((difluoromethyl)thio)phenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-((3-((trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-((4-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- 10 N'-(2-chloro-5-methyl-4-((4-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-(methyl(3-((trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-(methyl(3-((trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- 15 N'-(2,5-dimethyl-4-(methyl(4-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-(methyl(4-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-((3-(pentafluoro-l6-sulfaneyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- 20 N'-(2-chloro-5-methyl-4-((3-(pentafluoro-l6-sulfaneyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-(methyl(3-(pentafluoro-l6-sulfaneyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-(methyl(3-(pentafluoro-l6-sulfaneyl)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- 25 methylformimidamide;
- N'-(4-((3,5-bis(trifluoromethyl)phenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((3,5-bis(trifluoromethyl)phenyl)amino)-2-chloro-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-((3-((trifluoromethyl)thio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- 30 methylformimidamide;
- N'-(2-chloro-4-((4-(dimethylamino)phenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((4-(dimethylamino)phenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-4-((3-((difluoromethyl)thio)phenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- 35 methylformimidamide;

- N'-(2-chloro-4-((3-((difluoromethyl)thio)phenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((3-(difluoromethoxy)phenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((3-(difluoromethoxy)phenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-
- 5 methylformimidamide;
- N'-(2-chloro-4-((3-(difluoromethoxy)phenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-((2-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-((2-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- 10 N'-(2,5-dimethyl-4-((2-(trifluoromethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-4-((4-(difluoromethoxy)phenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((2,5-difluorophenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-4-((2,5-difluorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- 15 N'-(4-((3,5-bis(trifluoromethyl)phenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((3,5-bis(trifluoromethyl)phenyl)(methyl)amino)-2-chloro-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-((5-methyl-2-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-
- 20 methylformimidamide;
- N'-(4-((2,5-difluorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-4-((2,5-difluorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-(methyl(5-methyl-2-(trifluoromethyl)phenyl)amino)phenyl)-N-ethyl-N-
- 25 methylformimidamide;
- N'-(4-((4-chloro-2-(trifluoromethyl)phenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-4-((4-chloro-2-(trifluoromethyl)phenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- 30 N'-(4-((4-chloro-2-(trifluoromethyl)phenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-4-((4-chloro-2-(trifluoromethyl)phenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-(methyl(2-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-
- 35 methylformimidamide;

- N'-(2-chloro-4-((3-(difluoromethoxy)phenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-((2-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((2-chloro-4-(trifluoromethyl)phenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- 5 N'-(2-chloro-4-((2-chloro-4-(trifluoromethyl)phenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((2-chloro-4-(trifluoromethyl)phenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- 10 N'-(2-chloro-4-((2-chloro-4-(trifluoromethyl)phenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-((2-(methylthio)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N-ethyl-N'-(4-((4-fluoro-3-(1,1,2,2-tetrafluoroethoxy)phenyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
- 15 N'-(2-chloro-4-((4-fluoro-3-(1,1,2,2-tetrafluoroethoxy)phenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- 5-chloro-N-(2-fluorophenyl)-N,2-dimethyl-4-((morpholinomethylene)amino)aniline
- N'-(2-chloro-4-(N-(2-fluorophenyl)methylsulfonamido)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- 20 N-(5-chloro-4-(((ethyl(methyl)amino)methylene)amino)-2-methylphenyl)-N-(2-fluorophenyl)acetamide
- N'-(2-chloro-4-((2-fluorophenyl)(methyl)amino)-5-methylphenyl)-N,N-dimethylformimidamide;
- N'-(2-chloro-4-(ethyl(2-fluorophenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- 5-chloro-N-(2-fluorophenyl)-N,2-dimethyl-4-((morpholinomethylene)amino)aniline
- 25 5-chloro-N-(2-fluorophenyl)-N,2-dimethyl-4-((thiomorpholinomethylene)amino)aniline
- N-ethyl-N'-(5-fluoro-4-((4-fluoro-3-(1,1,2,2-tetrafluoroethoxy)phenyl)amino)-2-methylphenyl)-N-methylformimidamide;
- N-ethyl-N'-(5-fluoro-4-((4-fluoro-3-(1,1,2,2-tetrafluoroethoxy)phenyl)(methyl)amino)-2-methylphenyl)-N-methylformimidamide;
- 30 N-(5-chloro-4-(((ethyl(methyl)amino)methylene)amino)-2-methylphenyl)-N-(2-chlorophenyl)acetamide;
- N'-(2-chloro-4-(N-(2-chlorophenyl)methylsulfonamido)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((4-((difluoromethyl)thio)phenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- 35

- N'-(2-chloro-4-((4-((difluoromethyl)thio)phenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((4-((difluoromethyl)thio)phenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- 5 N'-(2-chloro-4-((4-((difluoromethyl)thio)phenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-4-(ethyl(phenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N-(5-chloro-4-(((ethyl(methyl)amino)methylene)amino)-2-methylphenyl)-N-phenylacetamide;
- N'-(2-chloro-4-((2-((difluoromethyl)thio)phenyl)amino)-5-methylphenyl)-N-ethyl-N-
- 10 methylformimidamide;
- N'-(2-chloro-4-((2-((difluoromethyl)thio)phenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-4-(ethyl(3-methoxyphenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-4-((3-(difluoromethoxy)-4-fluorophenyl)amino)-5-methylphenyl)-N-ethyl-N-
- 15 methylformimidamide;
- N'-(2-chloro-4-(N-(3-methoxyphenyl)methylsulfonamido)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((3-(difluoromethoxy)-4-fluorophenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- 20 N'-(2-chloro-4-((3-(difluoromethoxy)-4-fluorophenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((3-(difluoromethoxy)-4-fluorophenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((2,5-dimethylphenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- 25 N'-(2-chloro-4-((2,5-dimethylphenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N-(5-chloro-4-(((ethyl(methyl)amino)methylene)amino)-2-methylphenyl)-N-(2-chlorophenyl)propionamide;
- N-ethyl-N'-(5-fluoro-4-((4-methoxyphenyl)amino)-2-methylphenyl)-N-methylformimidamide;
- N-ethyl-N'-(5-fluoro-4-((4-methoxyphenyl)(methyl)amino)-2-methylphenyl)-N-
- 30 methylformimidamide;
- N-(5-chloro-4-(((ethyl(methyl)amino)methylene)amino)-2-methylphenyl)-N-(2-fluorophenyl)propionamide
- N'-(2-chloro-4-(N-(4-fluoro-3-(1,1,2,2-tetrafluoroethoxy)phenyl)methylsulfonamido)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- 35 N'-(2,5-dimethyl-4-((3-(1,1,2,2-tetrafluoroethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;

- N'-(2,5-dimethyl-4-(methyl(3-(1,1,2,2-tetrafluoroethoxy)phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N-ethyl-N'-(4-((2-fluoro-5-methylphenyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
- N-ethyl-N'-(5-fluoro-4-((2-fluorophenyl)amino)-2-methylphenyl)-N-methylformimidamide;
- 5 N-ethyl-N'-(4-((2-fluoro-5-methylphenyl)(methyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
- N'-(2-chloro-4-((2-fluoro-5-methylphenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N-ethyl-N'-(5-fluoro-2-methyl-4-(phenylamino)phenyl)-N-methylformimidamide;
- 10 N'-(4-((2-chlorophenyl)amino)-5-fluoro-2-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((4-(tert-butyl)phenyl)amino)-5-fluoro-2-methylphenyl)-N-ethyl-N-methylformimidamide;
- N-ethyl-N'-(5-fluoro-2-methyl-4-(m-tolylamino)phenyl)-N-methylformimidamide;
- N-(5-chloro-4-(((ethyl(methyl)amino)methylene)amino)-2-methylphenyl)-N-phenylpropionamide;
- N-(5-chloro-4-(((ethyl(methyl)amino)methylene)amino)-2-methylphenyl)-N-(3-
- 15 methoxyphenyl)acetamide;
- N'-(2-chloro-4-((4-fluoro-3-methoxyphenyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N-ethyl-N'-(4-((4-fluoro-3-methoxyphenyl)amino)-2,5-dimethylphenyl)-N-methylformimidamide;
- N-ethyl-N'-(4-((4-fluoro-3-methoxyphenyl)(methyl)amino)-2,5-dimethylphenyl)-N-
- 20 methylformimidamide;
- N'-(4-((2-((difluoromethyl)thio)phenyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(4-((2-((difluoromethyl)thio)phenyl)(methyl)amino)-2,5-dimethylphenyl)-N-ethyl-N-methylformimidamide;
- 25 N'-(2-chloro-4-((4-fluoro-3-methoxyphenyl)(methyl)amino)-5-methylphenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-bromo-6-fluoro-3-methyl-4-(phenylamino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-((5-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- 30 N'-(2-bromo-6-fluoro-3-methyl-4-(methyl(phenyl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2-chloro-5-methyl-4-((1-methylindolin-5-yl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N'-(2,5-dimethyl-4-((5-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)amino)phenyl)-N-ethyl-N-methylformimidamide;
- N-ethyl-N'-(5-fluoro-2-methyl-4-(methyl(phenyl)amino)phenyl)-N-methylformimidamide;
- 35 N'-(4-((4-(tert-butyl)phenyl)(methyl)amino)-5-fluoro-2-methylphenyl)-N-ethyl-N-methylformimidamide;

N-ethyl-N'-(5-fluoro-2-methyl-4-(methyl(m-tolyl)amino)phenyl)-N-methylformimidamide;
 N-ethyl-N'-(7-((2-methoxyphenyl)amino)-2,3-dihydro-1H-inden-4-yl)-N-methylformimidamide;
 N-ethyl-N-methyl-N'-(7-(p-tolylamino)-2,3-dihydro-1H-inden-4-yl)formimidamide;
 N'-(7-((4-chlorophenyl)amino)-2,3-dihydro-1H-inden-4-yl)-N-ethyl-N-methylformimidamide;
 5 N-ethyl-N-methyl-N'-(4-(phenylamino)naphthalen-1-yl)formimidamide;
 N'-(2,5-dimethyl-4-(pyridin-2-ylamino)phenyl)-N-ethyl-N-methylformimidamide;
 N'-(2,5-dimethyl-4-(methyl(pyridin-2-yl)amino)phenyl)-N-ethyl-N-methylformimidamide;
 N'-(2-chloro-5-methyl-4-(pyridin-2-ylamino)phenyl)-N-ethyl-N-methylformimidamide;

10 5) A composition for controlling or preventing against phytopathogenic microorganisms, comprising a compound of general formula (I) according to any of above claims and one or more inert carriers.

6) Compositions comprising compounds of general formula (I) according to any of above claims and or one or more active compatible compound selected from fungicides, insecticides, nematocides, acaricides, biopesticides, herbicides, plant growth regulators, antibiotics, fertilizers and or mixtures thereof.
 15

7) Compositions according to claim 5 or 6, wherein the concentration of compounds having general formula (I) ranges from 1 to 90% by weight with respect to the total weight of the composition, preferably from 5 to 50% by weight with respect to the total weight of the composition.

8) Use of compounds of general formula (I) according to any of above claims for the control of phytopathogenic fungi, bacteria, insects, nematodes, mites of agricultural crops and or horticultural crops.
 20

9) Use of compounds of general formula (I) according to claim 1 to 4, or compositions according to any of the claims 5 to 7, for controlling or preventing against phytopathogenic fungi of agricultural crops and or horticultural crops.
 25

10) Use of the compositions according to any of the claims 5 to 7 for controlling or preventing against phytopathogenic fungi, bacteria, insects, nematodes, mites of agricultural crops and or horticultural crops.

30 11) Use of the compounds of general formula (I) according to any of the claims 1 to 4 or compositions according to any of the claims 5 to 7, wherein the agricultural crops are cereals, corn, rice, soybean and other leguminous plants, fruits and fruit trees, nuts and nut trees, citrus and citrus trees, any horticultural plants, cucurbitaceae, oleaginous plants, tobacco, coffee, tea, cacao, sugar beet, sugar

cane, cotton, potato, tomato, onions, peppers and other vegetables, and ornamentals.

12) A method of controlling or preventing infestation of useful plants by phytopathogenic microorganisms in agricultural crops and or horticultural crops wherein a compound of general formula (I) according to any of the claim 1 to 4 or compositions according to any of the claims 5 to 7,
5 is applied to the plants, to parts thereof or the locus thereof.

13) A method of controlling or preventing infestation of useful plants by phytopathogenic microorganisms in agricultural crops and or horticultural crops wherein a compound of general formula (I) according to any of the claim 1 to 4 or compositions according to any of the claims 5 to 7,
is applied to the seeds of plants.

10 14) A method of controlling or preventing phytopathogenic microorganisms in agricultural crops and or horticultural crops using the compounds of general formula (I) according to any of the claims 1 to 4 or compositions according to any of the claims 5 to 7, which consists in applying effective dosages of compounds or compositions in amounts ranging from 1 g to 5 kg per hectare of agricultural or horticultural crops.

15

20

25

30

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2017/056277

A. CLASSIFICATION OF SUBJECT MATTER INV. A01N37/52 A01N43/40 A01N43/84 C07C257/12 C07D265/30 C07D211/12 A01P3/00 ADD.		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) A01N C07C C07D Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EPO-Internal, WPI Data, CHEM ABS Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00/46184 A1 (HOECHST SCHERING AGREVO GMBH [DE]; CHARLES MARK DAVID [GB]; FRANKE WIL) 10 August 2000 (2000-08-10)	1-3,5-14
Y	claim 19	1-14
X	----- Kenji Hagiwara ET AL: "Synthesis and Fungicidal Activity of 4-1, 2, 4-Thiadiazolines*", J. Pesticide Science, vol. 17 1 January 1992 (1992-01-01), pages 251-259, XP055439946, Retrieved from the Internet: URL:https://www.jstage.jst.go.jp/article/jpestics1975/17/4/17_4_251/_pdf/-char/ja page 256; table 1; compound 42 -----	1-14
Y	----- -/--	1-14
☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 12 January 2018		Date of mailing of the international search report 22/01/2018
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016		Authorized officer Panday, Narendra

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2017/056277

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	RODRIGUEZ F ET AL: "Guanidine and 2-aminoimidazoline Aromatic Derivatives as alpha2-Adrenoceptor Antagonists, 1:Toward New Antidepressants with Heteroatomic Linkers", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 50, 1 January 2007 (2007-01-01), pages 4516-4527, XP002534114, ISSN: 0022-2623, DOI: 10.1021/JM070229Q [retrieved on 2007-08-10] page 4518; table 1; compound 6a -----	1

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/IB2017/056277

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0046184	A1	10-08-2000	AT 247629 T 15-09-2003
		AU 768156 B2	04-12-2003
		BR 0009314 A	13-02-2002
		CA 2360943 A1	10-08-2000
		CN 1342137 A	27-03-2002
		CZ 20012842 A3	13-03-2002
		DE 60004637 D1	25-09-2003
		DE 60004637 T2	15-04-2004
		DK 1150944 T3	15-12-2003
		EP 1150944 A1	07-11-2001
		ES 2200816 T3	16-03-2004
		HK 1043358 A1	06-05-2005
		HU 0105098 A2	29-04-2002
		IL 144464 A	10-04-2006
		JP 2002536354 A	29-10-2002
		JP 2011057678 A	24-03-2011
		KR 20010101999 A	15-11-2001
		MX 222092 B	11-08-2004
		PT 1150944 E	31-12-2003
		RU 2234504 C2	20-08-2004
		TR 200102237 T2	21-12-2001
		US 6893650 B1	17-05-2005
		WO 0046184 A1	10-08-2000
		ZA 200105845 B	16-10-2002
